<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child - Bromley, R - 2014 | Cochrane Library</title> <meta content="Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child - Bromley, R - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010236.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child - Bromley, R - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010236.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010236.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child" name="citation_title"/> <meta content="Rebecca Bromley" name="citation_author"/> <meta content="University of Manchester" name="citation_author_institution"/> <meta content="rebecca.bromley@manchester.ac.uk" name="citation_author_email"/> <meta content="Jennifer Weston" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Naghme Adab" name="citation_author"/> <meta content="Walsgrave Hospital, University Hospitals Coventry and Warwickshire NHS Trust" name="citation_author_institution"/> <meta content="Janette Greenhalgh" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Anna Sanniti" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Andrew J McKay" name="citation_author"/> <meta content="Institute of Child Health, Alder Hey Hospital" name="citation_author_institution"/> <meta content="Catrin Tudur Smith" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD010236.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/10/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010236.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010236.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010236.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Age Factors; Anticonvulsants [*adverse effects]; Carbamazepine [adverse effects]; Developmental Disabilities [*chemically induced]; Epilepsy [*drug therapy]; Intelligence [*drug effects]; Pregnancy Complications [*drug therapy]; Prenatal Exposure Delayed Effects [*chemically induced]; Prospective Studies; Randomized Controlled Trials as Topic; Valproic Acid [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010236.pub2&amp;doi=10.1002/14651858.CD010236.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010236\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010236\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","pt","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010236.pub2",title:"Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child",firstPublishedDate:"Oct 30, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010236.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010236.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010236.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010236.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010236.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010236.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010236.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010236.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010236.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010236.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7110 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010236.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-sec-0176"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-sec-0008"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-sec-0013"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-sec-0014"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-sec-0162"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/appendices#CD010236-sec-0187"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/table_n/CD010236StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/table_n/CD010236StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#CD010236-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Rebecca Bromley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#CD010236-cr-0005">Jennifer Weston</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#CD010236-cr-0006">Naghme Adab</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#CD010236-cr-0007">Janette Greenhalgh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#CD010236-cr-0008">Anna Sanniti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#CD010236-cr-0009">Andrew J McKay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#CD010236-cr-0010">Catrin Tudur Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information#CD010236-cr-0011">Anthony G Marson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information/en#CD010236-sec-0207">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 October 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010236.pub2">https://doi.org/10.1002/14651858.CD010236.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010236-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010236-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010236-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010236-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010236-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010236-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010236-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010236-abs-0001" lang="en"> <section id="CD010236-sec-0001"> <h3 class="title" id="CD010236-sec-0001">Background</h3> <p>Accumulating evidence suggests an association between prenatal exposure to antiepileptic drugs (AEDs) and increased risk of both physical anomalies and neurodevelopmental impairment. Neurodevelopmental impairment is characterised by either a specific deficit or a constellation of deficits across cognitive, motor and social skills and can be transient or continuous into adulthood. It is of paramount importance that these potential risks are identified, minimised and communicated clearly to women with epilepsy. </p> </section> <section id="CD010236-sec-0002"> <h3 class="title" id="CD010236-sec-0002">Objectives</h3> <p>To assess the effects of prenatal exposure to commonly prescribed AEDs on neurodevelopmental outcomes in the child and to assess the methodological quality of the evidence. </p> </section> <section id="CD010236-sec-0003"> <h3 class="title" id="CD010236-sec-0003">Search methods</h3> <p>We searched the Cochrane Epilepsy Group Specialized Register (May 2014), Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2014, Issue 4), MEDLINE (via Ovid) (1946 to May 2014), EMBASE (May 2014), Pharmline (May 2014) and Reprotox (May 2014). No language restrictions were imposed. Conference abstracts from the last five years were reviewed along with reference lists from the included studies. </p> </section> <section id="CD010236-sec-0004"> <h3 class="title" id="CD010236-sec-0004">Selection criteria</h3> <p>Prospective cohort controlled studies, cohort studies set within pregnancy registers and randomised controlled trials were selected for inclusion. Participants were women with epilepsy taking AED treatment; the two control groups were women without epilepsy and women with epilepsy who were not taking AEDs during pregnancy. </p> </section> <section id="CD010236-sec-0005"> <h3 class="title" id="CD010236-sec-0005">Data collection and analysis</h3> <p>Three authors (RB, JW and JG) independently selected studies for inclusion. Data extraction and risk of bias assessments were completed by five authors (RB, JW, AS, NA, AJM). The primary outcome was global cognitive functioning. Secondary outcomes included deficits in specific cognitive domains or prevalence of neurodevelopmental disorders. Due to substantial variation in study design and outcome reporting only limited data synthesis was possible. </p> </section> <section id="CD010236-sec-0006"> <h3 class="title" id="CD010236-sec-0006">Main results</h3> <p>Twenty‐two prospective cohort studies were included and six registry based studies. Study quality varied. More recent studies tended to be larger and to report individual AED outcomes from blinded assessments, which indicate improved methodological quality.The developmental quotient (DQ) was lower in children exposed to carbamazepine (CBZ) (n = 50) than in children born to women without epilepsy (n = 79); mean difference (MD) of ‐5.58 (95% confidence interval (CI) ‐10.83 to ‐0.34, P = 0.04). The DQ of children exposed to CBZ (n = 163) was also lower compared to children of women with untreated epilepsy (n = 58) (MD ‐7.22, 95% CI ‐12.76 to ‐ 1.67, P = 0.01). Further analysis using a random‐effects model indicated that these results were due to variability within the studies and that there was no significant association with CBZ. The intelligence quotient (IQ) of older children exposed to CBZ (n = 150) was not lower than that of children born to women without epilepsy (n = 552) (MD ‐0.03, 95% CI ‐3.08 to 3.01, P = 0.98). Similarly, children exposed to CBZ (n = 163) were not poorer in terms of IQ in comparison to the children of women with untreated epilepsy (n = 87) (MD 1.84, 95% CI ‐2.13 to 5.80, P = 0.36). The DQ in children exposed to sodium valproate (VPA) (n = 123) was lower than the DQ in children of women with untreated epilepsy (n = 58) (MD ‐8.72, 95% ‐14.31 to ‐3.14, P = 0.002). The IQ of children exposed to VPA (n = 76) was lower than for children born to women without epilepsy (n = 552) (MD ‐8.94, 95% CI ‐11.96 to ‐5.92, P &lt; 0.00001). Children exposed to VPA (n = 89) also had lower IQ than children born to women with untreated epilepsy (n = 87) (MD ‐8.17, 95% CI ‐12.80 to ‐3.55, P = 0.0005). </p> <p>In terms of drug comparisons, in younger children there was no significant difference in the DQ of children exposed to CBZ (n = 210) versus VPA (n=160) (MD 4.16, 95% CI ‐0.21 to 8.54, P = 0.06). However, the IQ of children exposed to VPA (n = 112) was significantly lower than for those exposed to CBZ (n = 191) (MD 8.69, 95% CI 5.51 to 11.87, P &lt; 0.00001). The IQ of children exposed to CBZ (n = 78) versus lamotrigine (LTG) (n = 84) was not significantly different (MD ‐1.62, 95% CI ‐5.44 to 2.21, P = 0.41). There was no significant difference in the DQ of children exposed to CBZ (n = 172) versus phenytoin (PHT) (n = 87) (MD 3.02, 95% CI ‐2.41 to 8.46, P = 0.28). The IQ abilities of children exposed to CBZ (n = 75) were not different from the abilities of children exposed to PHT (n = 45) (MD ‐3.30, 95% CI ‐7.91 to 1.30, P = 0.16). IQ was significantly lower for children exposed to VPA (n = 74) versus LTG (n = 84) (MD ‐10.80, 95% CI ‐14.42 to ‐7.17, P &lt; 0.00001). DQ was higher in children exposed to PHT (n = 80) versus VPA (n = 108) (MD 7.04, 95% CI 0.44 to 13.65, P = 0.04). Similarly IQ was higher in children exposed to PHT (n = 45) versus VPA (n = 61) (MD 9.25, 95% CI 4.78 to 13.72, P &lt; 0.0001). A dose effect for VPA was reported in six studies, with higher doses (800 to 1000 mg daily or above) associated with a poorer cognitive outcome in the child. We identified no convincing evidence of a dose effect for CBZ, PHT or LTG. Studies not included in the meta‐analysis were reported narratively, the majority of which supported the findings of the meta‐analyses. </p> </section> <section id="CD010236-sec-0007"> <h3 class="title" id="CD010236-sec-0007">Authors' conclusions</h3> <p>The most important finding is the reduction in IQ in the VPA exposed group, which are sufficient to affect education and occupational outcomes in later life. However, for some women VPA is the most effective drug at controlling seizures. Informed treatment decisions require detailed counselling about these risks at treatment initiation and at pre‐conceptual counselling. We have insufficient data about newer AEDs, some of which are commonly prescribed, and further research is required. Most women with epilepsy should continue their medication during pregnancy as uncontrolled seizures also carries a maternal risk. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010236-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010236-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010236-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010236-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010236-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010236-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010236-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010236-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010236-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010236-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010236-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010236-abs-0002" lang="en"> <h3>Treatment for epilepsy in pregnant women and the development of the child</h3> <p><b>Background</b> </p> <p>For most women who have epilepsy it is important for their health that they continue their medication during pregnancy. Over the last 25 years research has shown that children exposed to these medications in the womb can be at a higher risk of having a birth defect or poorer level of development. </p> <p><b>Research question</b> </p> <p>This review aimed to understand whether exposure to antiepileptic drugs (AEDs) during pregnancy is linked to poorer levels of ability for skills such as IQ, language and memory (neurodevelopment). </p> <p><b>Characteristics of the studies</b> </p> <p>The review included 28 studies. Participants were women with epilepsy taking commonly used AEDs who were compared to either women without epilepsy or women who had epilepsy but who were not treated with AEDs. Comparisons were also made between children exposed to different AEDs in the womb. The evidence presented in this review was up to date to May 2014. </p> <p><b>Results</b> </p> <p>‐ The evidence for younger children exposed to carbamazepine (CBZ) in the womb was conflicting, however this was likely to be due to differences in the way that these studies were carried out. In older children those exposed to CBZ were not poorer in their IQ than children who were not exposed. No link was found between the dose of CBZ and child ability. </p> <p>‐ Both younger and older children exposed in the womb to sodium valproate (VPA) showed poorer cognitive development in comparison to children not exposed and children exposed to other AEDs. A link between dose of VPA and child ability was found in six studies; with higher doses of the drug linked to a lower IQ ability in the child. The level of this difference was likely to increase the risk of poorer educational levels. </p> <p>‐ Children exposed to CBZ in the womb did not differ in their skills from children exposed to lamotrigine (LTG), however very few studies investigated this. There were also no differences between children exposed to phenytoin (PHT) in the womb and those exposed to CBZ or those exposed to LTG. </p> <p>‐ There were very limited data on newer medications such as LTG, levetiracetam or topiramate. </p> <p><b>Quality of the studies</b> </p> <p>The quality of how studies were designed varied. The more recently completed studies tended to have higher quality ratings, which suggests more reliable evidence. </p> <p><b>Conclusions</b> </p> <p>This review found that children exposed to VPA in the womb were at an increased risk of poorer neurodevelopment scores both in infancy and when school aged. The majority of evidence indicates that exposure in the womb to CBZ is not associated with poorer neurodevelopment. Data were not available for all AEDs that are in use or for all aspects of child neurodevelopment. This means decision making for women and their doctors is difficult. Further research is needed so that women and their doctors can make decisions based on research evidence about which medication is right for them in their childbearing years. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010236-sec-0176" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010236-sec-0176"></div> <h3 class="title" id="CD010236-sec-0177">Implications for practice</h3> <section id="CD010236-sec-0177"> <p>There is converging evidence that prenatal exposure to VPA is associated with an increased risk of a range of neurodevelopmental deficits, including poorer early development, lower IQ in school aged children, and an increased risk of autistic spectrum disorders. In comparison to other treatments, VPA was associated with reduced IQ compared to CBZ, LTG and PHT. It remains to be seen, however, whether the levels of discrepancy between the children exposed to VPA and controls or other AED exposed groups increase or diminishe with time. Children exposed to CBZ were not found to have reduced global cognitive development in comparison to control children, but less is known about any potential impact of exposure on specific cognitive skills. There is a lack of evidence pertaining to the commonly prescribed treatments of LTG, LEV and TPM, amongst others, and therefore current practices are not underpinned by evidence of foetal safety. </p> <p>Women should be provided with information about the evidence on the risks and safety of particular AED treatments. Preconceptual counselling should be available and should cover both teratological risk and considerations of the efficacy of treatments for controlling seizures. A significant number of pregnancies are unplanned and health professionals should ensure that women are routinely informed about the risks and benefits of their medication, and prescribers should take the risk of unplanned pregnancy into account when prescribing AEDs. </p> <p>For those in paediatric services, poorer neurodevelopmental trajectories are in evidence for children below the age of two years that have been exposed to VPA. Routine monitoring should occur for these children to ensure that, if required, early intervention occurs to maximise child neurodevelopmental outcomes. </p> </section> <h3 class="title" id="CD010236-sec-0178">Implications for research</h3> <section id="CD010236-sec-0178"> <p>This area is complex and it is no wonder that knowledge about the risks associated with AED teratogenicity is low amongst prescribers (<a href="./references#CD010236-bbs2-0103" title="RobertsJI , MetcalfeA , AbdullaF , WiebeS , HansonA , FedericoP , JetteN . Neurologists' and neurology residents' knowledge of issues related to pregnancy for women with epilepsy. Epilepsy and Behavior2011;22(2):358-63.">Roberts 2011</a>) and women with epilepsy (<a href="./references#CD010236-bbs2-0097" title="MetcalfeA , RobertsJI , AbdullaF , WiebeS , HansonA , FedericoP , JetteN . Patient knowledge about issues related to pregnancy in epilepsy: a cross-sectional study. Epilepsy and Behavior2012;24(1):65-69.">Metcalfe 2012</a>). Historical methods of surveillance are obviously not suitable to detect neurodevelopmental impairment in a time‐efficient manner and therefore a different approach is required (<a href="./references#CD010236-bbs2-0080" title="FriedmanJM . ABCDXXX: The obscenity of postmarketing surveillance for teratogenic effects. Birth Defects Research A. Clinical and Molecular Teratology2012;94(8):670-6.">Friedman 2012</a>). There has been a proliferation in the application of electronic healthcare records in this area (for example <a href="./references#CD010236-bbs2-0074" title="ChristensenJ , GronborgTK , SorensenMJ , SchendelD , ParnerET , PedersenLH , VestergaardM . Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA2013;309(16):1696-703.">Christensen 2013</a>), which may provide some progress. This methodology is unlikely to offer a complete solution, however, as there is evidence that the records may under‐report malformation rates (<a href="./references#CD010236-bbs2-0072" title="CharltonRA , WeilJG , CunningtonMC , RayS , deVriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety 34;2:157-71.">Charlton 2011</a>) and in most cases they are unlikely to be suitable for IQ and other cognitive data. </p> <p>The neurodevelopmental risks reviewed here are likely to be lifelong and, as noted by <a href="./references#CD010236-bbs2-0080" title="FriedmanJM . ABCDXXX: The obscenity of postmarketing surveillance for teratogenic effects. Birth Defects Research A. Clinical and Molecular Teratology2012;94(8):670-6.">Friedman 2012</a>, signals of harm are important in this area and should not be dismissed due to poor methodologies but investigated with urgency. The prominence of these issues needs to be appraised and future work needs to ensure that research occurs in a more timely and almost automatic manner to ensure that the delays in establishing risk or safety data are reduced to optimise the health of both the mother and the child. No clear dominant method for investigation in this area has led to a variety of methodologies, cohorts, control groups, child assessment and reporting analysis methods being adopted. More coherence across investigations will help to make the risk‐benefit information more clear. Below are some suggested guidelines for methodologies. Whilst there are always differences in opinion about how to design a study these points aim to create more cohesion in this area. </p> <section id="CD010236-sec-0179"> <h5 class="title">Design</h5> <p>Both truly prospective and registry based neurodevelopmental studies have an important place. The dominance of pregnancy registers for the collection of data pertaining to major congenital malformations should not be ignored and their adaptation for the collection of neurodevelopment data offers a timely and cost‐effective method. However, the retrospective nature of recruitment into the neurodevelopmental follow up means that estimates may be seen as biased. Prospective studies where women enrol into the study prior to knowing the child's outcome offer less biased recruitment, however losses to follow up over the childhood years may mean that the biases for those who complete the final follow‐up assessment may not be that different from those who enrol into a registry follow up. In this review no differences were found between the outcomes of these methodologies and therefore both these methods have a place. </p> </section> <section id="CD010236-sec-0180"> <h5 class="title">Follow‐up age</h5> <p>Neurodevelopment is dynamic which presents a number of challenges. It has been argued that follow up to school age is required to understand the neurodevelopment of an exposed child (<a href="./references#CD010236-bbs2-0062" title="AdabN , KiniU , VintenJ , AyresJ , BakerG , Clayton-Smith J et al. The longer term outcome of children born to mothers with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry2004;75(11):1575-83.">Adab 2004b</a>), and the present findings pertaining to CBZ emphasise this point. This review demonstrates that whilst assessment at an early age may detect stable levels of impairment (that is in the case of VPA) it may also lead to premature conclusions about exposures to other AEDs as by school age improvements may have occurred. Follow up into the school age years is therefore required to ensure reliable conclusions. However, the development of the brain does not stop in the primary years and it could be argued that without follow up into adulthood we run the risk of failing to document reliable levels of risk to cognitive functioning. </p> </section> <section id="CD010236-sec-0181"> <h5 class="title">Control groups</h5> <p>The offspring of women with epilepsy who were not taking AEDs, or women without epilepsy whose children represent the general population are two common control groups in the studies reviewed here. The preference of one control group over the other has been debated (for example <a href="./references#CD010236-bbs2-0101" title="NicolaiJ , VlesJSH , AldenkampAP . Neurodevelopmental delay in children exposed to antiepileptic drugs in utero: A critical review directed at structural study-bias. Journal of the Neurological Sciences2008;271(1-2):1-14.">Nicolai 2008</a>). In this review no differences were found between the pattern of results across control group types, which is expected based on direct comparisons by other authors (for example <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0034" title="HolmesL , RosenbergerP , HarveyE , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61:196-202. ">Holmes 2000</a>). Decisions around control groups should also be based on additional considerations including recruitment sources. The offspring of women with untreated epilepsy might convey benefits in terms of reducing ascertainment bias as often pregnancy and epilepsy registers do not recruit women without epilepsy. </p> </section> <section id="CD010236-sec-0182"> <h5 class="title">Test selection</h5> <p>Over 15 different measurements were used to assess the different aspects of neurodevelopment in the studies included in this review. Whilst the manuals for these assessments will report correlations between measures it would be inappropriate to pool outcomes from all of these measures, and therefore direct comparisons across cohorts were not always possible. </p> <p>A measure of global cognitive ability (measured as IQ or DQ) was the most commonly assessed domain. Whilst this is a useful way to gauge cognitive development it may mask specific difficulties in one or more cognitive domains. For example, the full scale IQ score of a test comprises a number of subtests which measure a variety of skills from processing speed to verbal knowledge. The most common measure of neurodevelopment in younger children was Bayley Scales of Infant and Toddler Development, with the Wechsler IQ series being most commonly utilised for IQ measurement. Whilst the research question and author preference may dictate test selection, authors are urged to consider selecting measures which will allow direct comparisons across published cohorts. </p> </section> <section id="CD010236-sec-0183"> <h5 class="title">Outcome reporting</h5> <p>Across the papers reviewed here there were varied reporting practices with regards to the outcomes across the studies. The majority of studies report an overall mean and standard deviation or confidence intervals for all the exposed children together, however, as noted above this is likely to mask differences in outcomes across the groups. The reporting of outcomes of children exposed to monotherapy and polytherapy is also common but again carries a risk of masking effects which may be associated with an individual drug. Differences in prescribing practices across countries have been widely documented (<a href="./references#CD010236-bbs2-0095" title="MeadorKJ , PenovichP , BakerGA , PennellPB , BromfieldE , PackA . Antiepileptic drug use in women of childbearing age. Epilepsy and Behavior2009;15(3):339-43.">Meador 2009b</a>) and therefore one monotherapy or polytherapy group is unlikely to be directly comparable to another. Outcomes by specific AEDs should always be reported and studies should be powered to detect differences between different AED exposed groups. </p> <p>In addition to reporting at a group level there was considerable variation in how individual neurodevelopmental domains were reported. The reporting, at least in table form, of global and all individual domain standard (age adjusted) scores would assist with comparisons across cohorts and will aid future meta‐analysis. </p> <p>The reporting of numbers of children who fall below the average range may offer a more clinically meaningful representation of the data. However, reduction of global cognitive ability from the above average range to the average range should not be underestimated in terms of its importance to the individual, family and society. </p> </section> <section id="CD010236-sec-0184"> <h5 class="title">Dose</h5> <p>By their nature, dose is key to the effects of a teratogen (<a href="./references#CD010236-bbs2-0069" title="BrentR . Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics2004;13(4):957-68.">Brent 2004</a>), yet this is not considered by all studies. Just like treating all AEDs as a unified treatment group, treating all doses in the same manner may lead to the masking of effects on cognitive development. Doses should be investigated and reported. Dose exploration should at least undertake correlational analysis between the dose of AED and child score (for example IQ, DQ or specific language score). </p> </section> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010236-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010236-sec-0008"></div> <section id="CD010236-sec-0009"> <h3 class="title" id="CD010236-sec-0009">Description of the condition</h3> <p>Epilepsy is a common disorder affecting up to 1% of the population (<a href="./references#CD010236-bbs2-0084" title="HauserW , HesdorfferD . Epilepsy: Frequency, causes and consequences. New York: Demos Publications, 1990.">Hauser 1990</a>). Approximately one third of people receiving antiepileptic drugs (AEDs) are women of reproductive age (<a href="./references#CD010236-bbs2-0111" title="YerbyMS . Pregnancy, teratogenesis and epilepsy. Neurological Clinics1994;12:749-71.">Yerby 1994</a>), and approximately 1 in 250 pregnancies are exposed to AEDs (<a href="./references#CD010236-bbs2-0091" title="LindhoutD , MeinardiH , MeijerJ , NauH . Antiepileptic drugs and teratogenesis in two consecutive cohorts: Changes in prescription policy paralleled by changes in pattern of malformations. Neurology1992;42:94-110.">Lindhout 1992</a>). There is a growing body of evidence reporting an association between prenatal exposure to AEDs and negative physical and neurodevelopmental outcomes in the child (<a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0107" title="TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , Sabers A et al. Dose-dependent risk of malformation with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17.">Tomson 2011</a>). However, the latency between widespread use of an AED in women of childbearing age and knowledge of any teratological risk or safety concerns leads to uncertainty about the best course of action for both women and their treating physicians. </p> </section> <section id="CD010236-sec-0010"> <h3 class="title" id="CD010236-sec-0010">Description of the intervention</h3> <p>AEDs are the most common treatment for epilepsy and treatment continuation during pregnancy is a necessity for most women with epilepsy. AEDs readily cross the placenta from the mother into the foetus (<a href="./references#CD010236-bbs2-0068" title="BossiL . Neonatal period including drug disposition in new borns: Review of the literature. In: JanzD , DamM , RichensA , BossiL , HelgeH , SchmidtD , editors(s). Epilepsy, Pregnancy and the Child. New York: Ravens press, 1982:327-42.">Bossi 1982</a>) and are documented to pose different levels of teratogenic risk (<a href="./references#CD010236-bbs2-0107" title="TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , Sabers A et al. Dose-dependent risk of malformation with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17.">Tomson 2011</a>), which are dependent on the agent, its dose, timing of exposure and the genetic influences of both the mother and the foetus (<a href="./references#CD010236-bbs2-0069" title="BrentR . Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics2004;13(4):957-68.">Brent 2004</a>). </p> </section> <section id="CD010236-sec-0011"> <h3 class="title" id="CD010236-sec-0011">How the intervention might work</h3> <p>Exposure to AEDs during foetal development is noted to be associated with altered neuronal development in animal models. Reported alterations include disruption of neuronal birth, migrations and altered programmed cell death (<a href="./references#CD010236-bbs2-0067" title="BittigauP , SifringerM , IkonomidouC . Antiepileptic drugs and apoptosis in the developing brain. Annals of the New York Academy of Sciences2003;993:103-14.">Bittigau 2003</a>; <a href="./references#CD010236-bbs2-0098" title="MiyazakiK , NaritaN , NaritaM . Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: Implications for pathogenesis of autism. International Journal of Developmental Neuroscience2005;23:287-97.">Miyazaki 2005</a>). These are hypothesised to underpin the reported neurodevelopmental alterations noted in human infants and children (<a href="./references#CD010236-bbs2-0067" title="BittigauP , SifringerM , IkonomidouC . Antiepileptic drugs and apoptosis in the developing brain. Annals of the New York Academy of Sciences2003;993:103-14.">Bittigau 2003</a>). </p> <p>Early case reports have documented learning disabilities and difficulties, and low IQ or educational difficulties in children with major or minor congential malformations attributed to maternal AED use (<a href="./references#CD010236-bbs2-0063" title="ArdingerH , AtkinJ , BlackstonR , ElsasL , ClarrenS , Livingstone S et al. Verification of the fetal valproate syndrome phenotype. American Journal of Medical Genetics1988;29(1):171-85.">Ardinger 1988</a>; <a href="./references#CD010236-bbs2-0073" title="ChevallierB , NegreV , BidatE , LagardereB . Fetal valproate syndrome and somatic and psychomotor development. Archives Francaises Pediatrie1989;46:627-30.">Chevallier 1989</a>; <a href="./references#CD010236-bbs2-0076" title="Clayton-SmithJ , DonnaiD . Fetal valproate syndrome. Journal of Medical Genetics1995;32:724-7.">Clayton‐Smith 1995</a>; <a href="./references#CD010236-bbs2-0083" title="HansonJW , MyrianthopoulosNC , Sedgwick-HarveyMA , SmithDW . Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. The Journal of Pediatrics1976;89:662-8.">Hanson 1976</a>; <a href="./references#CD010236-bbs2-0110" title="WinterR , DonnaiD , BurnJ , TuckerS . Fetal valproate syndrome: Is there a recognisable phenotype?Journal of Medical Genetics1987;24:692-5.">Winter 1987</a>). A number of studies completed during the 1980s and 1990s aimed to investigate whether cognitive difficulties were associated with maternal use of AEDs during pregnancy but conflicting results were obtained due, at least in part, to methodological differences (<a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>; <a href="./references#CD010236-bbs2-0087" title="HillRM , VerniaudWM , RettigGM , TennysonLM , CraigJP . Relationship between antiepileptic drug exposure of the infant and developmental potential. In: JanzD , DamM , RichensA , BossiL , HelgeH , SchmidtD , editors(s). Epilepsy, Pregnancy and the Child. New York: Ravens Press, 1982:409-17.">Hill 1982</a>; <a href="./references#CD010236-bbs2-0088" title="HuthH , SteinhausenHC , HelgeH . Mental development in children of epileptic parents. In: JanzD , DamM , RichensA , BossiL , HelgeH , SchmidtD , editors(s). Epilepsy, Pregnancy and the Child. New York: Ravens Press, 1982:437-41.">Huth 1982</a>; <a href="./references#CD010236-bbs2-0104" title="SteinhausenHC , LoscheG , KochS , HelgeH . The psychological development of children of epileptic parents. I. Study design and comparative findings. Acta Paediatrica1994;83:955-60.">Steinhausen 1994</a>). Recent prospective studies report a significant association between prenatal exposure to sodium valproate and poorer cognitive functioning, often defined as intellectual quotient (IQ) or developmental quotient (DQ) (<a href="./references#CD010236-bbs2-0071" title="BromleyRL , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: A prospective report. Epilepsia2010;51(10):2058-65.">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0077" title="CummingsC , StewartM , StevensonM , MorrowJ , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:943-7.">Cummings 2011</a>; <a href="./references#CD010236-bbs2-0094" title="MeadorK , BakerGA , BrowningN , Clayton-SmithJ , Combs-CantrellD , Cohen M et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360:1597-605.">Meador 2009</a>; <a href="./references#CD010236-bbs2-0100" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of International Neuropsychological Society2011;17:1-10.">Nadebaum 2011</a>). The risks associated with other AEDs remain unclear with conflicting results reported for carbamazepine (CBZ) (<a href="./references#CD010236-bbs2-0077" title="CummingsC , StewartM , StevensonM , MorrowJ , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:943-7.">Cummings 2011</a>; <a href="./references#CD010236-bbs2-0081" title="GailyE , Kantola-SorsaE , HiilesmaaV , IsoahoM , MatilaR , KotilaM . Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32.">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0096" title="MeadorKJ , BakerGA , BrowningN , CohenM , Clayton-SmithJ , Kalayjian LA et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404.">Meador 2011</a>) and little evidence in relation to exposure in utero to lamotrigine (LTG) (<a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>), levetiracetam (LEV) (<a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>) or topiramate (TPM). </p> <p>In addition to adverse neurodevelopmental outcomes in relation to cognitive abilities, a link between maternal use of AEDs during pregnancy and an increased prevalence of neurodevelopmental disorders such as autistic spectrum disorders has been reported (<a href="./references#CD010236-bbs2-0070" title="BromleyRL , BakerGA , MeadorKJ . Cognitive abilities and behaviour of children exposed to antiepileptic drugs in utero. Current Opinion in Neurology2009;22:162-6.">Bromley 2009</a>; <a href="./references#CD010236-bbs2-0075" title="ChristiansonA , CheslerN , KrombergJ . Fetal valproate syndrome: Clinical and neurodevelopmental features in two sibling pairs. Developmental Medicine and Child Neurology1994;36:357-69.">Christianson 1994</a>; <a href="./references#CD010236-bbs2-0074" title="ChristensenJ , GronborgTK , SorensenMJ , SchendelD , ParnerET , PedersenLH , VestergaardM . Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA2013;309(16):1696-703.">Christensen 2013</a>; <a href="./references#CD010236-bbs2-0099" title="MooreSJ , Turnpenny, PD, QuinnA , GloverS , LloydDJ , Montgomery T et al. A clinical study of 57 children with fetal anticonvulsant syndromes. Journal of Medical Genetics2000;37:489-97.">Moore 2000</a>; <a href="./references#CD010236-bbs2-0102" title="RasalamAD , HaileyH , WilliamsJH , MooreSJ , TurnpennyPD , Lloyd DJ et al. Charateristics of fetal anticonvulsant syndrome associated autistic disorder. Developmental Medicine and Child Neurology2005;47(8):551-5.">Rasalam 2005</a>; <a href="./references#CD010236-bbs2-0109" title="WilliamsP , HershJ . A male with fetal valproate syndrome and autism. Developmental Medicine and Child Neurology1997;39:632-4.">Williams 1997</a>). </p> </section> <section id="CD010236-sec-0012"> <h3 class="title" id="CD010236-sec-0012">Why it is important to do this review</h3> <p>To continue AED treatment during pregnancy requires a risk‐benefit decision to be taken. On one side there is the risk prenatal exposure to AEDs poses to the physical and neurodevelopment of the child and the lifelong implications associated with such damage to the early developing brain (<a href="./references#CD010236-bbs2-0078" title="DeanJCS , HaileyH , MooreSJ , LloydDJ , TurnpennyPD , LitttleJ . Long term health and neurodevelopment in children with prenatal exposure to antiepileptic drugs before birth. Journal of Medical Genetics2002;39:251-9.">Dean 2002</a>). On the other side of this decision is the health and wellbeing of the mother who requires treatment for epilepsy. Careful consideration is required with regard to maximising treatment whilst limiting the risks to the foetus. </p> <p>Although a teratogenic role for certain AEDs is supported by a number of studies, results conflict with regard to the degree of risk, making it difficult to counsel women regarding their choice of treatment during pregnancy. Assessing neurodevelopmental outcomes is complex, long and expensive due to the numbers of patients required and the time required for follow up; resulting in a number of different methodologies being employed. There is, therefore, a clear need for a systematic review of the existing data to aid decision‐making. Although randomised controlled trials (RCTs) would be considered to provide the most reliable evidence about the effects of AEDs taken during pregnancy, RCTs are considered unethical in this area and even if undertaken would pose considerable difficulties in terms of design, recruitment and interpretation. In view of this we have decided to proceed with a systematic review of all available evidence including registry based data, prospective cohort studies and RCTs (if available). </p> <p>Evidence from this review can aid the decisions clinicians and women with epilepsy are required to make about the treatment of epilepsy in the childbearing years. The final review replaces a previously published Cochrane review entitled 'Common antiepileptic drugs in pregnancy in women with epilepsy' (<a href="./references#CD010236-bbs2-0061" title="AdabN , Tudur SmithC , VintenJ , WilliamsonPR , WinterbottomJB . Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004848]">Adab 2004</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010236-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010236-sec-0013"></div> <p>To assess the effects of prenatal exposure to commonly prescribed AEDs on neurodevelopmental outcomes in the child and to assess the methodological quality of the evidence. </p> <p>This review examined neurodevelopmental outcomes following exposure to AEDs during pregnancy compared to unexposed pregnancies in women representative of the general population or unexposed pregnancies in women with epilepsy. Comparisons were also made between specific monotherapy AED exposures. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010236-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010236-sec-0014"></div> <section id="CD010236-sec-0015"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010236-sec-0016"> <h4 class="title">Types of studies</h4> <p>The following types of study were considered.</p> <p> <ol id="CD010236-list-0001"> <li> <p>Randomised controlled trials (RCTs). These are studies which included women with epilepsy requiring treatment who were randomised to a particular AED prior to conception or to a control group. The intervention group were women with epilepsy taking an AED of interest as monotherapy. </p> </li> <li> <p>Prospective observational cohort studies. These included consecutive participants from single‐ or multi‐centre participating sites, where information regarding the pregnancy and history were collected prior to knowledge of the outcome. The intervention group were women with epilepsy taking an AED of interest as monotherapy. </p> </li> <li> <p>Registry studies. Registry studies involve the ascertainment of data from a wide region, country or number of countries and recruitment is often based on self referral or clinician referral leading to non‐sequential case ascertainment. Both independent and industry sponsored registry data were considered for inclusion. These included data from pregnant women ascertained retrospectively from prospective malformation registers. The intervention group were women with epilepsy taking an AED of interest as monotherapy. </p> </li> </ol> </p> </section> <section id="CD010236-sec-0017"> <h4 class="title">Types of participants</h4> <p>The following participants were eligible for the treatment group:</p> <p> <ul id="CD010236-list-0002"> <li> <p>pregnant women with epilepsy taking a single AED of interest.</p> </li> </ul> </p> <p>Participants eligible for the control groups were:</p> <p> <ul id="CD010236-list-0003"> <li> <p>pregnant women with epilepsy taking an AED; or</p> </li> <li> <p>pregnant women with epilepsy taking no AED; or</p> </li> <li> <p>pregnant women who did not have epilepsy.</p> </li> </ul> </p> <p>Studies reporting AED use solely in pregnant women with other conditions (for example mood disorders, pain etc) were excluded. </p> </section> <section id="CD010236-sec-0018"> <h4 class="title">Types of interventions</h4> <section id="CD010236-sec-0019"> <h5 class="title">Intervention group</h5> <p>Women with epilepsy receiving AED treatments including but not limited to:</p> <p>phenobarbitone, phenytoin (PHT), carbamazepine (CBZ), oxcarbazepine, sodium valproate (VPA), lamotrigine (LTG), topiramate (TPM), gabapentin, vigabatrin, tiagabine, zonisamide, levetiracetam (LEV), ethosuximide, clobazam, clonazepam, zonisamide, pregabalin, lacosamide, retigabine, rufinamide, and sulthiame. </p> <p>Comparisons of different AEDs were explored.</p> </section> <section id="CD010236-sec-0020"> <h5 class="title">Control groups</h5> <p>Women with a diagnosis of epilepsy who were not taking AEDs and women without epilepsy and who were not taking medication for a chronic condition during pregnancy. </p> <p>Women with epilepsy taking monotherapy treatment were employed as a 'comparator' group in analyses to enable AED treatment comparisons. </p> </section> </section> <section id="CD010236-sec-0021"> <h4 class="title">Types of outcome measures</h4> <section id="CD010236-sec-0022"> <h5 class="title">Primary outcomes</h5> <section id="CD010236-sec-0023"> <h6 class="title">Global cognitive functioning or ability</h6> <p>Global cognitive functioning or ability refers to a summary score of key cognitive processes such as reasoning, processing speed, mental flexibility and knowledge (<a href="./references#CD010236-bbs2-0066" title="BaronI . Neuropsychological Evaluation of the Child. Oxford: Oxford University Press, 2004.">Baron 2004</a>). The most frequently‐reported measure of global cognitive functioning is the intelligence quotient (IQ). Typically in younger children global ability assessments additionally include assessment of motor and social skills, due to their importance at this age, producing an outcome reported as the development quotient (DQ). Two dominant DQ assessments (the Griffith Mental Development Scales and the Bayley Scales of Infant and Toddler Development) differ in their approach to assessing overall cognitive ability. The Griffiths Mental Development Scales include child motor ability along with other cognitive skills to create the overall reported DQ score. In contrast, the Bayley Scales of Infant and Toddler Development explore motor ability separately and therefore data from these two measures could not be combined in a meta‐analysis. Global cognitive ability in school aged children is typically assessed as IQ. </p> <p>As well as a continuous variable, the primary outcome will be investigated and reported as the prevalence of children who fell below the average range. Typically, standardised measures of IQ and DQ have a mean of 100 and a standard deviation of 15, meaning that scores under 85 would be below the average range. </p> </section> </section> <section id="CD010236-sec-0024"> <h5 class="title">Secondary outcomes</h5> <section id="CD010236-sec-0025"> <h6 class="title">Neurodevelopmental disorders</h6> <p>The proportion of children who experience the following neurodevelopmental disorders:</p> <p> <ul id="CD010236-list-0004"> <li> <p>autistic spectrum disorders;</p> </li> <li> <p>attention deficit‐hyperactivity disorder (ADHD);</p> </li> <li> <p>dyspraxia.</p> </li> </ul> </p> <p>The above disorders were chosen as they are important neurodevelopmental disorders and have been associated with prenatal exposure to AEDs (<a href="./references#CD010236-bbs2-0061" title="AdabN , Tudur SmithC , VintenJ , WilliamsonPR , WinterbottomJB . Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004848]">Adab 2004</a>). These diagnoses were author‐defined but consistent with the Diagnostic and Statistical Manual of Mental (DSM‐IV) criteria for these conditions. </p> </section> <section id="CD010236-sec-0026"> <h6 class="title">Cognitive domains</h6> <p>The differences between specific cognitive domain scores including:</p> <p> <ul id="CD010236-list-0005"> <li> <p>attention;</p> </li> <li> <p>executive function;</p> </li> <li> <p>language;</p> </li> <li> <p>memory;</p> </li> <li> <p>visuospatial.</p> </li> </ul> </p> <p>In addition to a global cognitive ability score, neuropsychological assessment often examines more defined or specific cognitive skills which might contribute to lowered levels of global cognitive functioning. For example, the majority of IQ tests will report Verbal IQ (VIQ) (also known as Verbal Comprehension) and Performance IQ (PIQ) (also known as Non‐Verbal IQ). Attention, language and memory abilities are core cognitive skills that influence other cognitive functions and understanding the functioning of these systems following prenatal exposure is key. </p> </section> </section> </section> </section> <section id="CD010236-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010236-sec-0028"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases:</p> <p> <ol id="CD010236-list-0006"> <li> <p>Cochrane Epilepsy Review Group Specialized Register using the search terms pregnancy, pregnant, prenatal, teratogen, teratogenic, fetal, fetus, birth maternal and in utero (29 May 2014); </p> </li> <li> <p>Cochrane Central Register of Controlled trials (CENTRAL) in <i>The Cochrane Library</i> (2014, Issue 4) using the search strategy set out in <a href="./appendices#CD010236-sec-0188">Appendix 1</a>; </p> </li> <li> <p>MEDLINE (Ovid) using the search strategy set out in <a href="./appendices#CD010236-sec-0189">Appendix 2</a> (from 1946 to 29/05/2014); </p> </li> <li> <p>EMBASE (29 May 2014) using the search strategy set out in <a href="./appendices#CD010236-sec-0190">Appendix 3</a>; </p> </li> <li> <p>Pharmline (30 May 2014); and</p> </li> <li> <p>Reprotox (30 May 2014).</p> </li> </ol> </p> <p>The MEDLINE search strategy was adapted to meet the requirements of the EMBASE, Pharmline and Reprotox databases. </p> <p>No language restrictions were employed in the searches.</p> </section> <section id="CD010236-sec-0029"> <h4 class="title">Searching other resources</h4> <p>Conference abstracts were reviewed for the last seven years (2007 to 2014) from Neurology meetings, including the International League Against Epilepsy meetings (International Epilepsy Congress, European Congress on Epileptology, Asian and Oceanian Epilepsy Congress, and Latin American Congress on Epilepsy) and Teratology meetings (The Teratology Society and European Teratology Society). The Epilepsia Journal supplements from the past seven years (2007 to 2014) were searched for conference proceedings. Where possible, abstracts were linked to published data sets. Authors of abstracts which were not yet published were contacted for further information. When further information was unavailable the abstracts were listed in <a href="./references#CD010236-sec-0215" title="">Characteristics of studies awaiting classification</a>. </p> <p>Reference lists of original research and review articles were cross‐matched to the studies generated from the electronic searches. Reference lists of recent review articles were searched, and lead and corresponding authors in the area were contacted for any relevant unpublished material. </p> </section> </section> <section id="CD010236-sec-0030"> <h3 class="title" id="CD010236-sec-0030">Data collection and analysis</h3> <section id="CD010236-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Three authors (RB, JW, JG) reviewed the titles and abstracts of articles highlighted by the searches and removed studies that obviously did not meet the inclusion criteria. Full‐text reports were used by two authors (RB, JP) to determine eligibility. Disagreements were discussed and if not resolved the opinion of a third author (JG) was sought and all other authors were consulted if necessary. Multiple reports from single studies are common in this field and reports were linked where possible. </p> </section> <section id="CD010236-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Five authors (RB, JW, NA, AS, AJM) undertook data extraction from the included studies by splitting the number of studies into equal parts. Data extraction was cross‐checked. Data were extracted using pre‐standardised electronic data extraction forms. This was initially piloted by members of the review team and amendments were made where necessary (see <a href="./appendices#CD010236-sec-0191">Appendix 4</a> for the data extraction form). </p> </section> <section id="CD010236-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Five authors (RB, JW, NA, AS, AJM) assessed risk of bias in the included studies by splitting the number of studies equally. Risk of bias assessments were cross‐checked. Due to the observational design of some of the studies, we decided to utilise a version of the extended Cochrane Collaboration tool for assessing risk of bias, developed by the Cochrane Non‐Randomised Studies Methods Group. The tool examines selection bias (sequence generation, allocation concealment), performance bias (blinding), attrition bias (incomplete outcome data, blinding), detection bias (blinding, other potential threats to validity), reporting bias (selective outcome reporting), and the influence of confounding variables. The domains of blinding, incomplete outcome data, selective outcome reporting, confounding variables and other bias were rated on a five‐point scale, ranging from low in bias to high risk of bias, according to the risk on the outcome (See <a href="./appendices#CD010236-sec-0192">Appendix 5</a>; <a href="./appendices#CD010236-sec-0203">Appendix 6</a> for extended risk of bias tools). The parameters of this scale were determined by the review authors (see <a href="#CD010236-tbl-0001">Table 1</a> for the scale parameters). </p> <div class="table" id="CD010236-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias scale parameters</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>1</b> </p> <p><b>Low risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>4</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>5</b> </p> <p><b>High risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Confounding</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All important<sup>1</sup> confounders considered<sup>2</sup> and suitable method of adjustment<sup>3</sup> employed. Outcome unlikely to be affected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most important<sup>4</sup> confounders considered and suitable method of adjustment employed. Outcome unlikely to be affected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some confounders<sup>5</sup> considered and full or partial adjustment employed<sup>6</sup>. Possible implication on outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some confounders considered and no adjustment employed. Likely to affect outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No important confounders considered and no adjustment employed. Likely to affect outcome</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Blinding</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assessors blinded to participant’s drug regime and participants blinded to drug regime. Outcome unlikely to be affected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assessors blinded to participants drug regime. Outcome unlikely to be affected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Partial blinding<sup>7</sup> involved in study. Possible implication on outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Partial or no blinding involved in study. Outcome likely to be affected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No blinding involved in study.  Outcome likely to be affected</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Incomplete outcome data</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No missing data and/or</p> <p>appropriate analysis<sup>8</sup> used to deal with missing data. Unlikely to affect outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Smaller amount (&lt;25%) of missing data with reasons given, balanced across groups. Unlikely to affect outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Larger amount of missing data (&gt;25%) with or without reasons given, balanced across groups. Possible implication on outcome  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Larger amount (&gt;25%) of missing data, imbalance across groups. Outcome likely to be affected </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information provided regarding missing data. Likely to affect outcome</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Selective outcome reporting</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A priori outcomes measured, analysed and reported in main report. Protocol available. Unlikely to affect outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A priori outcomes measured, analysed and reported in main report<sup>9</sup>. Protocol not available. Unlikely to affect outcomes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited information regarding a priori outcomes and measures. Possible implication on outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes measured but not analysed or reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes measured  but not analysed or reported and clinical judgement infers the presence of an unreported measured outcome<sup>10</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other bias</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No bias identified  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bias identified. Unlikely to affect outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bias identified. Possible implication on outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bias identified. Likely to affect outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bias identified. Extremely likely to affect outcome</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Important confounders include maternal IQ, socio‐economic status, epilepsy type, seizure exposure, child age at assessment, child gender, child gestational age at birth or birth weight, polytherapy. </p> <p><sup>2</sup> Reported demographic information and other confounders. </p> <p><sup>3</sup> Matching scores, multiple regression, analysis of co‐variance, stratification. </p> <p><sup>4</sup> At least five out of eight important confounders including maternal IQ and socio‐economic status, gestational age at birth. </p> <p><sup>5</sup> At least two out of eight important confounders. </p> <p><sup>6</sup> Full adjustment of confounding variables e.g. see footnote 2 or partial adjustment such as researchers select limited number of variables to adjust for. </p> <p><sup>7</sup> Assessors of outcome are only blinded to certain groups e.g. blinded to intervention group but not controls. </p> <p><sup>8</sup> Intention‐to‐treat analysis. </p> <p><sup>9</sup> An a priori statement is made in methods section of main report regarding measurement and analysis of outcome. </p> <p><sup>10</sup> For example, failure to report full scale IQ when all other indices are reported. </p> </div> </div> </section> <section id="CD010236-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>The primary outcome of global cognitive ability (DQ and IQ) and secondary outcomes relating to cognitive domains were measured on a continuous scale and the measure of treatment effect was the mean difference (MD). Secondary outcomes relating to the presence of a neurodevelopmental disorder or an IQ below a specified range were categorical data and the measure of treatment effect was the risk ratio (RR). As data were sparse, with some studies reporting zero events in one or both groups, the risk difference (RD) was also calculated. </p> </section> <section id="CD010236-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>Repeated observations were common. This was dealt with through the analysis of separate time points, which limited the likelihood of more than one observation from a single cohort. As children age the complexity of their cognitive functioning improves, requiring different assessment techniques and considerations. The abilities of children under the age of three are typically assessed using a developmental scale where the outcome is reported as a DQ. For school aged children of five years plus, the typical assessment of global cognitive ability would take the form of an intelligence assessment which is reported as the IQ. However, assessments of DQ can extend up to eight years of age with IQ measures extending down to two years of age and authors varied in their selection of DQ or IQ to assess pre‐school aged children. </p> <p>Another unit of analysis issue in this review was the inclusion in studies of multiple children born to one mother. Studies varied in their inclusion of siblings, however data without the siblings included were rarely reported in full in the original papers and therefore at the review level it was not possible to address this issue. </p> </section> <section id="CD010236-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>Missing data were sought through contact with the study authors. Reasons for missing data were sought to determine if they were missing at random, or not, but analyses were undertaken using the available data. </p> </section> <section id="CD010236-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>Clinical heterogeneity was assessed by examining the differences in study characteristics in order to inform decisions regarding the combination of study data. An a priori hypothesis of sources of clinical heterogeneity would be: type of population (regional, national or international, single‐ or multi‐centre); loss to follow up; maternal factors including age, duration of AED treatment, IQ, lifestyle factors, monotherapy or polytherapy, socioeconomic status, type of epilepsy, use of other medications and years of education. Child factors included: age of assessment, gestational age at birth, gender, seizure exposure, time of follow up and outcome measurement. Where applicable, we also assessed statistical heterogeneity by examining the I<sup>2</sup> statistic and the Chi<sup>2</sup> test. In the event heterogeneity was significant, both fixed‐effect and random‐effects model analyses were presented enabling examination of the differences. </p> </section> <section id="CD010236-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>Outcome reporting bias was investigated using the ORBIT tool categories (<a href="./references#CD010236-bbs2-0090" title="KirkhamJ , DwanK , Altman D et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365.">Kirkham 2010</a>). All protocols were requested from study authors to enable comparison of the outcomes of interest. Only four protocols were provided. </p> <p>Publication bias was examined by identifying unpublished data, by carrying out a comprehensive search of multiple sources and requesting any unpublished data from authors. We looked for small‐study effects to establish the likelihood of publication bias. Funnel plots were intended to be examined in the event an appropriate number of studies could be combined, however this was unachievable. The Cochrane Collaboration recommends a minimum of 10 studies to be combined when examining funnel plots (<a href="./references#CD010236-bbs2-0086" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD010236-sec-0039"> <h4 class="title">Data synthesis</h4> <p>For each comparison with data available for at least two studies, we performed a meta‐analysis to provide overall estimates of treatment effect. A fixed‐effect model was utilised for the primary data analyses, with exploration of potential explanations for heterogeneity. Secondary analyses, adopting a random‐effects model to incorporate the assumption that the different studies were estimating different yet related treatment effects, was undertaken. Sources of variability between the studies were also investigated. For continuous outcomes the pooled MD was calculated with the 95% CI. For categorical outcomes the pooled RR was calculated with the 95% CI. As data were sparse for many studies a further analysis was undertaken to calculate the RD and 95% CI. As the method of synthesis that is used can impact on the estimate of pooled treatment effect for sparse data, sensitivity analysis was undertaken to explore the robustness of the results with different assumptions regarding the method of analysis. These analyses were not pre‐planned in the protocol as it was not clear at the planning stage that data would be so sparse. Several included studies provided data which were deemed appropriate to be incorporated into a meta‐analysis. Studies were not included in a meta‐analysis if there was only one study contributing to a comparison, the measure used was not a standardised measure (that is a test with published standard norms) or the assessment used to measure the outcome was fundamentally different to others (that is overall data from Griffiths Mental Development Scales assessment and data from assessments conducted with the Bayley Scales of Infant and Toddler Development). These studies were discussed narratively within the results and discussion sections. We also expected to find differences in the definitions of neurodevelopmental disorders as these were author defined. These differences were examined at the analysis stage to ensure the appropriate combination of data. </p> <p>Comparisons included:</p> <p> <ol id="CD010236-list-0007"> <li> <p>specific monotherapy group versus controls on global cognitive functioning;</p> </li> <li> <p>specific monotherapy group versus controls on neurodevelopmental disorders;</p> </li> <li> <p>specific monotherapy group versus controls on specific cognitive domains;</p> </li> <li> <p>specific monotherapy group versus specific monotherapy group on all above outcomes.</p> </li> </ol> </p> <p>Each comparison was stratified by control group, study design and measurement characteristics to ensure appropriate combination of study data. </p> </section> <section id="CD010236-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Heterogeneity across studies was explored by visual inspection of forest plots, interpretation of the I<sup>2</sup> statistic and the P value for the test of heterogeneity. If there was evidence of heterogeneity, subgroup analysis was carried out to explore the potential causes of heterogeneity using the factors listed previously. These subgroup analyses were stratified by drug, study design and type of control group. Random‐effects model analyses were carried out in addition to fixed‐effect model analyses to incorporate any unexplained heterogeneity in the calculation of the pooled effect. </p> </section> <section id="CD010236-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were carried out to explore the effects of the method of analysis for categorical data and to explore the effect of fixed‐effect and random‐effects models (see previous descriptions). See <a href="#CD010236-tbl-0002">Table 2</a> for the results of the sensitivity analysis. </p> <div class="table" id="CD010236-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis results for below average performance outcome</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AED</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control/Another AED</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main result: risk ratio</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity (i): risk difference (MH)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity (ii): OR (M‐H)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity (iii): OR (Peto)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ&lt;1SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Controls (women with epilepsy, no AED treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.33 (2.05, 52.01)</p> <p>P=0.0046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.20, 0.54)</p> <p>P&lt;0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.49 (2.86, 95.27)</p> <p>P=0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.68 (2.92, 25.80)</p> <p>P=0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ&gt;1SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.28 (0.63, 8.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (‐0.03, 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.43 (0.60, 9.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.35 (0.64, 8.56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ&gt;1SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.87 (1.50, 15.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16 (0.06, 0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.35 (1.73, 23.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.94 (1.79, 13.66)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ&gt;2SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26 (0.05, 1.19)</p> <p>P=0.083</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.04 (‐0.10, 0.01)</p> <p>P=0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.05, 1.21)</p> <p>P=0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19 (0.04, 0.96)</p> <p>P=0.04</p> </td> </tr> </tbody> </table> </div> <p>In cases where the number of events was 0 or 1, sensitivity analysis was performed using three alternative statistical methods including odds ratio (Mantel‐Haenszel (M‐H) method and Peto method) and risk difference (M‐H method). This was carried out for four comparisons only and the results are displayed in <a href="#CD010236-tbl-0002">Table 2</a>. The significance of the overall effect estimates was only altered in one comparison where the level of significance changed from non‐significant to significant. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010236-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010236-sec-0042"></div> <section id="CD010236-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD010236-sec-0044"> <h4 class="title">Results of the search</h4> <p>The search identified 10,769 records from the databases outlined in <a href="#CD010236-sec-0028">Electronic searches</a> and 55 records were found through handsearching. Following the removal of duplicates, 10,233 records remained; these were screened for inclusion in the review. Of these, 10,157 records were excluded due to irrelevance, leaving 83 full texts to be assessed for eligibility. Twenty‐six were excluded (see <a href="#CD010236-fig-0001">Figure 1</a> and <a href="./references#CD010236-sec-0214" title="">Characteristics of excluded studies</a> for reasons for exclusion). A total of 28 studies were included in the review, from 59 reports; 10 of these were included in the meta‐analyses. We identified one unpublished study (<a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>) and were provided with a draft publication and study data which we have included in the review and meta‐analysis. Unpublished data pertaining to the studies of <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> and <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> were provided. The 18 studies remaining were discussed in narrative form due to an inability to combine them with other data because of different methodological aspects or failure to report all required outcome data (that is number of included children, means along with standard deviations (SD), CIs or standard errors (SE). </p> <div class="figure" id="CD010236-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010236-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010236-sec-0045"> <h4 class="title">Included studies</h4> <p>From a total of 57 full texts, 28 independent studies were included in this review. No RCTs were found, 22 included studies were prospective cohort studies (<a href="./references#CD010236-bbs2-0001" title="ArulmozhiT , DhanarajM , RangarajR , VengatesanA . Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India2006;54(1):42-6. ">Arulmozhi 2006</a>; <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0005" title="D'SouzaS , RobertsonI , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1990;65:320-4. ">D'Souza 1991</a>; <a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>; <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0010" title="HansonJ , MyrianthopoulosN , HarveyM , SmithD . Risks to offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Journal of Pediatrics1976;89(4):662-8. ">Hanson 1976</a>; <a href="./references#CD010236-bbs2-0011" title="HillR , VerniaudW , HorningM , McCulleyL , MorganN . Infants exposed in utero to antiepileptic drugs: A prospective study. American Journal of Diseases in Childhood1974;127:645-53. HillR , VerniaudW , RettigG , TennysonL , CraigJ . Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz et al, editors(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:409-17. ">Hill 1974</a>; <a href="./references#CD010236-bbs2-0012" title="FujiokaK , KanekoS , Hirano T et al. A study of the psychomotor development of the offspring of epileptic mothers. 1984. HiranoT , FujiokaK , OkadaM , IwasaH , KanekoS . Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia2004;45 Suppl 8:53-7. NomuraY , TakebeY , NomuraY , ShinagawaS , KanekoS , SatoT . The physical and mental development of infants born to mothers treated with antiepileptic drugs. 1984. ">Hirano 2004</a>; <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0018" title="OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75:517-20. ">Ornoy 1996</a>; <a href="./references#CD010236-bbs2-0019" title="RegestaT . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana Epilessia1996;95(96):351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: An Itialian prospective controlled study. Neurology1992;42 Suppl 5:89-93. ">Regesta 1996</a>; <a href="./references#CD010236-bbs2-0020" title="RihtmanT , ParushS , OrnoyA . Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology2012;34(3):308-11. ">Rihtman 2012</a>; <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>; <a href="./references#CD010236-bbs2-0024" title="SobczykW , DowzenkoA , KrasickaJ . Investigation of children of mothers treated in pregnancy with anticonvulsants. Neurologia i Neurochirurgia Polska1977;11(1):59-63. ">Sobczyz 1977</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>; <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a>; <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a>) and six were registry studies (<a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0014" title="JonesK , LacroR , JohnsonK , AdamsJ . Patern of malformations in the children of women treated with carbamazepine during pregnancy. The New England Journal of Medicine1989;320(25):1661-6. ">Jones 1989</a>; <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>). See <a href="#CD010236-tbl-0003">Table 3</a> for a comparison of all study designs and methods. See <a href="./references#CD010236-sec-0213" title="">Characteristics of included studies</a> for details about each included study. </p> <div class="table" id="CD010236-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Matrix of study quality characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Representative Population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Controls From Same Community</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective/Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exposure Ascertainment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliable Diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recruitment Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different Interventions Compared</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes Investigated Over TIme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standardised Measure Used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data on Specific</p> <p>Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dose Investigated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Siblings Accounted</p> <p>For</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arulmozhi 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bromley 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bromley 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cummings 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D'Souza 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eriksson 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FINNISH Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hirano 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gaily 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GERMAN Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gladstone 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hanson 1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospectve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jones 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leavitt 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nadebaum 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NEAD Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ornoy 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regesta 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rihtman 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rihtman 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scolnik 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shallcross 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sobczyk 1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomas 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomas 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veiby 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wide 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> </tbody> </table> </div> <p>There were 29 linked papers, these full texts were related to an included study as they presented information on the same cohort of children. </p> </section> <section id="CD010236-sec-0046"> <h4 class="title">Excluded studies</h4> <p>Twenty‐six studies were excluded from the review (<a href="./references#CD010236-bbs2-0029" title="AnnegersJ , ElvebackL , HauserA , KurlandL . Do anticonvulsants have a teratogenic effect?Archives of Neurology1974;31:364-73. ">Annegers 1974</a>; <a href="./references#CD010236-bbs2-0030" title="AntigaE , MonettiV , Fallica E et al. Cognitive development in children born to mothers with epilepsy [Epilessia e gravidanza: valutazione dello sviluppo cognitivo nei bambini nati da donne con epilessia]. Bollettino Lega Italiana Epilessia2010;140:154-5. ">Antiga 2010</a>; <a href="./references#CD010236-bbs2-0031" title="DeanJ , HaileyH , MooreS , LloydD , TurnpennyP , LittleJ . Long term and health and neurodevelopment in children exposed to antiepileptic drugs before birth. Journal of Medical Genetics2002;36:251-9. ">Dean 2002</a>; <a href="./references#CD010236-bbs2-0032" title="DessensA , Cohen-KettenisP , MellenberghG , KoppeJ , vande PollN , BoerK . Association of prenatal phenobarbital and phenytoin exposure with small head size at birth with learning problems. Acta Paediatrica2000;89:533-41. ">Dessens 2000</a>; <a href="./references#CD010236-bbs2-0033" title="ForsbergL , WideK , KallenB . School performance at age 16 in children exposed to antiepileptic drugs in utero - A population-based study. Epilepsia2011;52(2):364-9. ">Forsberg 2011</a>; <a href="./references#CD010236-bbs2-0034" title="HolmesL , RosenbergerP , HarveyE , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61:196-202. ">Holmes 2000</a>; <a href="./references#CD010236-bbs2-0035" title="HolmesL , CoullB , DorfmanJ , RosenbergerP . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146:118-22. ">Holmes 2005</a>; <a href="./references#CD010236-bbs2-0036" title="JakubowskaT , KoziakM , Lipczynska-LojkowskaW , NiedzielskaK , Witkowska-OlearskaK , ZielinskiJ . Health status of children born to mothers with epilepsy [Ocena stanu zdrowia dzieci matek chorych na padaczke]. Neurologia i Neurochirurgia Polska1981;15(3):303-8. ">Jakubowska 1981</a>; <a href="./references#CD010236-bbs2-0037" title="KellyT , EdwardsP , ReinM , MillerJ , DreifussF . Teratogenicity of anticonvulsant drugs 2: a prospective study. American Journal of Medical Genetics1984;19:435-43. ">Kelly 1984</a>; <a href="./references#CD010236-bbs2-0038" title="KozhokaruA , KarlovV , ZhydkovaI , SerkinaA . Intellectual, psychomotor and speech development of children born to mothers with epilepsy. Zhurnal Nevropatologii i Psikhiatrii Imeni2010;110(2):25-30. ">Kozhokaru 2010</a>; <a href="./references#CD010236-bbs2-0039" title="LatisG , BattinoD , Boldi B et al. Preliminary data of a neuropediatric follow-up of infants born to epileptic mothers. In: Janz et al, editors(s). Epilepsy, Pregnancy and the Child. New York: Raven Press, 1982:419-23. ">Latis 1982</a>; <a href="./references#CD010236-bbs2-0040" title="LekwuwaG , AdewoleI , ThompsonM . Antiepileptic drugs and teratogenicity in Nigerians. Transanction of the Royal Society of Tropical Medicine and Hygiene1995;89:227. ">Lekwuwa 1995</a>; <a href="./references#CD010236-bbs2-0041" title="MajewskiF , StegerM , RichterB , GillJ , RabeF . The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in the children of epileptic parents. Biological Research in Pregnancy1981;2(1):94-102. ">Majewski 1981</a>; <a href="./references#CD010236-bbs2-0042" title="MeadorK , BakerG , Browning N et al. Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology2010;75:1954-60. ">Meador 2010</a>; <a href="./references#CD010236-bbs2-0043" title="MooreS , TurnpennyP , Quinn A et al. A clinical study of 57 children with fetal anticonvulsant syndromes. Journal of Medical Genetics2000;37:489-97. ">Moore 2000</a>; <a href="./references#CD010236-bbs2-0044" title="MortensenE , ReinischJ , SandersS , RubinD . Intelligensdefekter som senfølge af praenatal eksposition for phenobarbital fenemal. [Delayed effects of prenatal exposure to phenobarbital on intelligence Phenemal]. Ugeskrift for Laeger1996;158(46):6589-94. ReinischJ , SandersS , MortensenE , RubinD . In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA1995;274(19):1518-25. ">Mortensen 1996</a>; <a href="./references#CD010236-bbs2-0045" title="MortensenJ , OlsenJ , LarsenH , Bendsen, ObelC , SorensenH . Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. European Journal of Epidemiology2003;18:769-71. ">Mortensen 2003</a>; <a href="./references#CD010236-bbs2-0046" title="OyenN , VollsetS , EideM , BjerkedalT , SkjaervenR . Maternal epilepsy and offsprings' adult intelligence: A population-based study from Norway. Epilepsia2007;48(9):1731-8. ">Oyen 2007</a>; <a href="./references#CD010236-bbs2-0047" title="ParisiP , FranciaA , VanacoreN , FioreS , GillonardoA , ManfrediM . Psychomotor development and general movements in offspring of women with epilepsy and anticonvulsant therapy. Early Human Development2003;74:97-108. ">Parisi 2003</a>; <a href="./references#CD010236-bbs2-0048" title="PerinolaT , ButtiglioneM , MargariL . Antiepileptic drugs in pregnancy: late effects on the children's cognitive abilities. Acta Neurologia1992;14(4-6):543-6. ">Perinola 1992</a>; <a href="./references#CD010236-bbs2-0049" title="RasalamA , HaileyH , Williams J et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Developmental Medicine and Child Neurology2005;47:551-5. ">Rasalam 2005</a>; <a href="./references#CD010236-bbs2-0050" title="Sereno-ColoJ , DominguezF , GutierrezJ . Tratamiento de la gestante epileptica con carbamacepina. Ginecologia y Obstetricia de Mexico1984;52(329):231-5. ">Sereno‐Colo 1984</a>; <a href="./references#CD010236-bbs2-0051" title="SteinhausenHC , NestlerV , HuthH . Psychopathology and mental functions in the offspring of alcoholic and epileptic mothers. Journal of the American Academy of Child Psychiatry1982;21(3):268-73. ">Steinhausen 1982</a>; <a href="./references#CD010236-bbs2-0052" title="VanoverloopD , SchnellR , HarveyE , HolmesL . The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicology and Teratology1992;14:329-35. ">Vanoverloop 1992</a>; <a href="./references#CD010236-bbs2-0053" title="DeblayM , VertP , AndreM . Children of epileptic mothers [L'enfant de mere epileptique]. La Nouvelle Presse Mediciale1982;11(3):173-6. VertP , DeblayM , AndreM . Follow-up study on growth and neurologic development of children born to epileptic mothers. In: Janz et al, editors(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:433-6. ">Vert 1982</a>; <a href="./references#CD010236-bbs2-0054" title="YamatogiY , OkaE , SatohM , KobayashiK , YoshinagaH , OhtaharaS . A prospective follow-up of the offspring of epileptic patients. The Japanese Journal of Psychiatry and Neurology1993;47(2):309-11. ">Yamatogi 1993</a>). Several of these papers were not written in the English language and therefore were sent for translation and data extraction in order to determine the study design and methodology used. Twenty of the excluded studies employed a retrospective design or they were classed as a record linkage study or case series, not for inclusion within this review. Three studies did not examine the neurodevelopmental outcomes of interest to this review (<a href="./references#CD010236-bbs2-0040" title="LekwuwaG , AdewoleI , ThompsonM . Antiepileptic drugs and teratogenicity in Nigerians. Transanction of the Royal Society of Tropical Medicine and Hygiene1995;89:227. ">Lekwuwa 1995</a>; <a href="./references#CD010236-bbs2-0042" title="MeadorK , BakerG , Browning N et al. Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology2010;75:1954-60. ">Meador 2010</a>; <a href="./references#CD010236-bbs2-0054" title="YamatogiY , OkaE , SatohM , KobayashiK , YoshinagaH , OhtaharaS . A prospective follow-up of the offspring of epileptic patients. The Japanese Journal of Psychiatry and Neurology1993;47(2):309-11. ">Yamatogi 1993</a>), two studies had no control group data (<a href="./references#CD010236-bbs2-0048" title="PerinolaT , ButtiglioneM , MargariL . Antiepileptic drugs in pregnancy: late effects on the children's cognitive abilities. Acta Neurologia1992;14(4-6):543-6. ">Perinola 1992</a>; <a href="./references#CD010236-bbs2-0053" title="DeblayM , VertP , AndreM . Children of epileptic mothers [L'enfant de mere epileptique]. La Nouvelle Presse Mediciale1982;11(3):173-6. VertP , DeblayM , AndreM . Follow-up study on growth and neurologic development of children born to epileptic mothers. In: Janz et al, editors(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:433-6. ">Vert 1982</a>) and one study examined outcomes in a non‐epilepsy population (<a href="./references#CD010236-bbs2-0044" title="MortensenE , ReinischJ , SandersS , RubinD . Intelligensdefekter som senfølge af praenatal eksposition for phenobarbital fenemal. [Delayed effects of prenatal exposure to phenobarbital on intelligence Phenemal]. Ugeskrift for Laeger1996;158(46):6589-94. ReinischJ , SandersS , MortensenE , RubinD . In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA1995;274(19):1518-25. ">Mortensen 1996</a>). </p> </section> </section> <section id="CD010236-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>All domains of bias were rated on a scale of 1 to 5. The description of the scale parameters for each domain is presented in <a href="#CD010236-tbl-0001">Table 1</a>. </p> <section id="CD010236-sec-0048"> <h4 class="title">Allocation</h4> <p>For the domains of sequence generation and allocation concealment all included studies were rated as high risk of bias. Whether carried out prospectively or as a registry study the included studies did not employ rigorous methods (that is randomisation to treatment) as the research questions were not conducive to the design features of these types of study design. However, the non‐randomised risk of bias tool used in this review required the assessment of these two domains on a level playing field in comparison to RCTs. See <a href="#CD010236-fig-0002">Figure 2</a> for a summary of risk of bias judgements. </p> <div class="figure" id="CD010236-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD010236-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD010236-sec-0049"> <h4 class="title">Blinding</h4> <p>Overall, 17 studies were rated as 2 as the outcome assessors were blinded to the exposure status of the individuals (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0005" title="D'SouzaS , RobertsonI , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1990;65:320-4. ">D'Souza 1991</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0011" title="HillR , VerniaudW , HorningM , McCulleyL , MorganN . Infants exposed in utero to antiepileptic drugs: A prospective study. American Journal of Diseases in Childhood1974;127:645-53. HillR , VerniaudW , RettigG , TennysonL , CraigJ . Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz et al, editors(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:409-17. ">Hill 1974</a>; <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a>; <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0018" title="OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75:517-20. ">Ornoy 1996</a>; <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>; <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a>) and therefore the risk of bias was low in these studies. Five of the studies were rated as unclear due to the lack of details regarding methods of blinding (<a href="./references#CD010236-bbs2-0001" title="ArulmozhiT , DhanarajM , RangarajR , VengatesanA . Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India2006;54(1):42-6. ">Arulmozhi 2006</a>; <a href="./references#CD010236-bbs2-0010" title="HansonJ , MyrianthopoulosN , HarveyM , SmithD . Risks to offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Journal of Pediatrics1976;89(4):662-8. ">Hanson 1976</a>; <a href="./references#CD010236-bbs2-0012" title="FujiokaK , KanekoS , Hirano T et al. A study of the psychomotor development of the offspring of epileptic mothers. 1984. HiranoT , FujiokaK , OkadaM , IwasaH , KanekoS . Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia2004;45 Suppl 8:53-7. NomuraY , TakebeY , NomuraY , ShinagawaS , KanekoS , SatoT . The physical and mental development of infants born to mothers treated with antiepileptic drugs. 1984. ">Hirano 2004</a>; <a href="./references#CD010236-bbs2-0019" title="RegestaT . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana Epilessia1996;95(96):351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: An Itialian prospective controlled study. Neurology1992;42 Suppl 5:89-93. ">Regesta 1996</a>; <a href="./references#CD010236-bbs2-0020" title="RihtmanT , ParushS , OrnoyA . Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology2012;34(3):308-11. ">Rihtman 2012</a>).The remainder of the studies were rated as 4 or 5 meaning that few or no methods were used to blind the outcome assessors or other study team members leaving open the possibility that the outcomes were likely to be affected by knowledge of the outcome or treatment (<a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0014" title="JonesK , LacroR , JohnsonK , AdamsJ . Patern of malformations in the children of women treated with carbamazepine during pregnancy. The New England Journal of Medicine1989;320(25):1661-6. ">Jones 1989</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>; <a href="./references#CD010236-bbs2-0024" title="SobczykW , DowzenkoA , KrasickaJ . Investigation of children of mothers treated in pregnancy with anticonvulsants. Neurologia i Neurochirurgia Polska1977;11(1):59-63. ">Sobczyz 1977</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>; <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a>). </p> </section> <section id="CD010236-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>Only three studies (<a href="./references#CD010236-bbs2-0012" title="FujiokaK , KanekoS , Hirano T et al. A study of the psychomotor development of the offspring of epileptic mothers. 1984. HiranoT , FujiokaK , OkadaM , IwasaH , KanekoS . Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia2004;45 Suppl 8:53-7. NomuraY , TakebeY , NomuraY , ShinagawaS , KanekoS , SatoT . The physical and mental development of infants born to mothers treated with antiepileptic drugs. 1984. ">Hirano 2004</a>; <a href="./references#CD010236-bbs2-0020" title="RihtmanT , ParushS , OrnoyA . Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology2012;34(3):308-11. ">Rihtman 2012</a>); <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> were rated as 1 (low bias) as there were no missing data. The majority of studies (<a href="./references#CD010236-bbs2-0001" title="ArulmozhiT , DhanarajM , RangarajR , VengatesanA . Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India2006;54(1):42-6. ">Arulmozhi 2006</a>; <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0005" title="D'SouzaS , RobertsonI , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1990;65:320-4. ">D'Souza 1991</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0010" title="HansonJ , MyrianthopoulosN , HarveyM , SmithD . Risks to offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Journal of Pediatrics1976;89(4):662-8. ">Hanson 1976</a>; <a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a>; <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0018" title="OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75:517-20. ">Ornoy 1996</a>; <a href="./references#CD010236-bbs2-0019" title="RegestaT . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana Epilessia1996;95(96):351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: An Itialian prospective controlled study. Neurology1992;42 Suppl 5:89-93. ">Regesta 1996</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>) were rated 2 as there was only a small amount of missing data from the reports and this was balanced across the groups or appropriate reasons were reported. Three studies (<a href="./references#CD010236-bbs2-0011" title="HillR , VerniaudW , HorningM , McCulleyL , MorganN . Infants exposed in utero to antiepileptic drugs: A prospective study. American Journal of Diseases in Childhood1974;127:645-53. HillR , VerniaudW , RettigG , TennysonL , CraigJ . Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz et al, editors(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:409-17. ">Hill 1974</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>; <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a>) were rated as 3 suggesting a possible implication on the outcomes due to a larger amount of missing data. Two studies (<a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0014" title="JonesK , LacroR , JohnsonK , AdamsJ . Patern of malformations in the children of women treated with carbamazepine during pregnancy. The New England Journal of Medicine1989;320(25):1661-6. ">Jones 1989</a>) were rated as 4 as there was a large amount of missing data which was imbalanced across the groups suggesting the outcomes were likely to be affected. Two studies (<a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a>) were rated 5 suggesting a high risk of bias due to the lack of information provided about a large amount of missing data. One study (<a href="./references#CD010236-bbs2-0024" title="SobczykW , DowzenkoA , KrasickaJ . Investigation of children of mothers treated in pregnancy with anticonvulsants. Neurologia i Neurochirurgia Polska1977;11(1):59-63. ">Sobczyz 1977</a>) was rated unclear due to the lack of detail regarding missing data. </p> </section> <section id="CD010236-sec-0051"> <h4 class="title">Selective reporting</h4> <p>Selective outcome reporting was rated on a 1 to 5 scale, one demonstrating low risk of bias and five demonstrating high risk of bias. The majority of studies (<a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0010" title="HansonJ , MyrianthopoulosN , HarveyM , SmithD . Risks to offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Journal of Pediatrics1976;89(4):662-8. ">Hanson 1976</a>; <a href="./references#CD010236-bbs2-0012" title="FujiokaK , KanekoS , Hirano T et al. A study of the psychomotor development of the offspring of epileptic mothers. 1984. HiranoT , FujiokaK , OkadaM , IwasaH , KanekoS . Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia2004;45 Suppl 8:53-7. NomuraY , TakebeY , NomuraY , ShinagawaS , KanekoS , SatoT . The physical and mental development of infants born to mothers treated with antiepileptic drugs. 1984. ">Hirano 2004</a>; <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>; <a href="./references#CD010236-bbs2-0018" title="OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75:517-20. ">Ornoy 1996</a>; <a href="./references#CD010236-bbs2-0019" title="RegestaT . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana Epilessia1996;95(96):351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: An Itialian prospective controlled study. Neurology1992;42 Suppl 5:89-93. ">Regesta 1996</a>; <a href="./references#CD010236-bbs2-0020" title="RihtmanT , ParushS , OrnoyA . Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology2012;34(3):308-11. ">Rihtman 2012</a>; <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>; <a href="./references#CD010236-bbs2-0024" title="SobczykW , DowzenkoA , KrasickaJ . Investigation of children of mothers treated in pregnancy with anticonvulsants. Neurologia i Neurochirurgia Polska1977;11(1):59-63. ">Sobczyz 1977</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>; <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a>; <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a>) were rated 2 as there was no evidence of selective outcome reporting within the publications; however this could not be tested against the protocols for the studies as they were not provided. Three studies were rated 3 as the risk of bias was unclear due to a small amount of non‐reporting (<a href="./references#CD010236-bbs2-0001" title="ArulmozhiT , DhanarajM , RangarajR , VengatesanA . Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India2006;54(1):42-6. ">Arulmozhi 2006</a>; <a href="./references#CD010236-bbs2-0005" title="D'SouzaS , RobertsonI , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1990;65:320-4. ">D'Souza 1991</a>; <a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>). Four studies were rated 4 due to selective reporting (<a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0011" title="HillR , VerniaudW , HorningM , McCulleyL , MorganN . Infants exposed in utero to antiepileptic drugs: A prospective study. American Journal of Diseases in Childhood1974;127:645-53. HillR , VerniaudW , RettigG , TennysonL , CraigJ . Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz et al, editors(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:409-17. ">Hill 1974</a>; <a href="./references#CD010236-bbs2-0014" title="JonesK , LacroR , JohnsonK , AdamsJ . Patern of malformations in the children of women treated with carbamazepine during pregnancy. The New England Journal of Medicine1989;320(25):1661-6. ">Jones 1989</a>; <a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a>). </p> <p>Study protocols were requested from authors who had contact details available. Only five responses were received with protocols being provided (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>). The protocol for <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a> was unavailable. No other responses were received. </p> <p>For the four studies where the protocol was made available a rating of 1 for low risk of bias was allocated as there was no evidence of selective outcome reporting following protocol review. </p> </section> <section id="CD010236-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>Any other biases were examined and this domain was rated on a scale of 1 to 5. The main other sources of bias that were identified included data for different AEDs being combined and the use of inappropriate measures for year of recruitment or for age of children at assessment. Taking all studies into account, nine were rated as low risk of bias (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>; <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a>), nine were unclear (<a href="./references#CD010236-bbs2-0001" title="ArulmozhiT , DhanarajM , RangarajR , VengatesanA . Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India2006;54(1):42-6. ">Arulmozhi 2006</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a>; <a href="./references#CD010236-bbs2-0018" title="OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75:517-20. ">Ornoy 1996</a>; <a href="./references#CD010236-bbs2-0019" title="RegestaT . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana Epilessia1996;95(96):351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: An Itialian prospective controlled study. Neurology1992;42 Suppl 5:89-93. ">Regesta 1996</a>; <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a>) and 10 were rated as at high risk of bias (<a href="./references#CD010236-bbs2-0005" title="D'SouzaS , RobertsonI , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1990;65:320-4. ">D'Souza 1991</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>; <a href="./references#CD010236-bbs2-0010" title="HansonJ , MyrianthopoulosN , HarveyM , SmithD . Risks to offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Journal of Pediatrics1976;89(4):662-8. ">Hanson 1976</a>; <a href="./references#CD010236-bbs2-0011" title="HillR , VerniaudW , HorningM , McCulleyL , MorganN . Infants exposed in utero to antiepileptic drugs: A prospective study. American Journal of Diseases in Childhood1974;127:645-53. HillR , VerniaudW , RettigG , TennysonL , CraigJ . Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz et al, editors(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:409-17. ">Hill 1974</a>; <a href="./references#CD010236-bbs2-0012" title="FujiokaK , KanekoS , Hirano T et al. A study of the psychomotor development of the offspring of epileptic mothers. 1984. HiranoT , FujiokaK , OkadaM , IwasaH , KanekoS . Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia2004;45 Suppl 8:53-7. NomuraY , TakebeY , NomuraY , ShinagawaS , KanekoS , SatoT . The physical and mental development of infants born to mothers treated with antiepileptic drugs. 1984. ">Hirano 2004</a>; <a href="./references#CD010236-bbs2-0014" title="JonesK , LacroR , JohnsonK , AdamsJ . Patern of malformations in the children of women treated with carbamazepine during pregnancy. The New England Journal of Medicine1989;320(25):1661-6. ">Jones 1989</a>; <a href="./references#CD010236-bbs2-0020" title="RihtmanT , ParushS , OrnoyA . Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology2012;34(3):308-11. ">Rihtman 2012</a>; <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a>; <a href="./references#CD010236-bbs2-0024" title="SobczykW , DowzenkoA , KrasickaJ . Investigation of children of mothers treated in pregnancy with anticonvulsants. Neurologia i Neurochirurgia Polska1977;11(1):59-63. ">Sobczyz 1977</a>). See the risk of bias tables for the individual studies in the <a href="./references#CD010236-sec-0213" title="">Characteristics of included studies</a>. </p> </section> <section id="CD010236-sec-0053"> <h4 class="title">Confounding variables</h4> <p>A pre‐specified list of confounding variables was compiled prior to carrying out the review as described in <a href="#CD010236-sec-0033">Assessment of risk of bias in included studies</a>. Overall, six studies were rated as at low risk of bias and scored either a 1 or 2 (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>) as they examined relevant variables and used an appropriate method of analysis to deal with them. Eleven studies were rated 3 (unclear risk of bias) as they showed evidence of investigating some important confounders but not all that were relevant to the area (<a href="./references#CD010236-bbs2-0001" title="ArulmozhiT , DhanarajM , RangarajR , VengatesanA . Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India2006;54(1):42-6. ">Arulmozhi 2006</a>; <a href="./references#CD010236-bbs2-0005" title="D'SouzaS , RobertsonI , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1990;65:320-4. ">D'Souza 1991</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0010" title="HansonJ , MyrianthopoulosN , HarveyM , SmithD . Risks to offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Journal of Pediatrics1976;89(4):662-8. ">Hanson 1976</a>; <a href="./references#CD010236-bbs2-0012" title="FujiokaK , KanekoS , Hirano T et al. A study of the psychomotor development of the offspring of epileptic mothers. 1984. HiranoT , FujiokaK , OkadaM , IwasaH , KanekoS . Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia2004;45 Suppl 8:53-7. NomuraY , TakebeY , NomuraY , ShinagawaS , KanekoS , SatoT . The physical and mental development of infants born to mothers treated with antiepileptic drugs. 1984. ">Hirano 2004</a>; <a href="./references#CD010236-bbs2-0019" title="RegestaT . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana Epilessia1996;95(96):351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: An Itialian prospective controlled study. Neurology1992;42 Suppl 5:89-93. ">Regesta 1996</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>; <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a>; Wide 2002). Eleven studies were rated as high risk of bias and scored either a 4 or a 5 (<a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>; <a href="./references#CD010236-bbs2-0011" title="HillR , VerniaudW , HorningM , McCulleyL , MorganN . Infants exposed in utero to antiepileptic drugs: A prospective study. American Journal of Diseases in Childhood1974;127:645-53. HillR , VerniaudW , RettigG , TennysonL , CraigJ . Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz et al, editors(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:409-17. ">Hill 1974</a>; <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0014" title="JonesK , LacroR , JohnsonK , AdamsJ . Patern of malformations in the children of women treated with carbamazepine during pregnancy. The New England Journal of Medicine1989;320(25):1661-6. ">Jones 1989</a>; <a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a>; <a href="./references#CD010236-bbs2-0018" title="OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75:517-20. ">Ornoy 1996</a>; <a href="./references#CD010236-bbs2-0020" title="RihtmanT , ParushS , OrnoyA . Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology2012;34(3):308-11. ">Rihtman 2012</a>; <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a>; <a href="./references#CD010236-bbs2-0024" title="SobczykW , DowzenkoA , KrasickaJ . Investigation of children of mothers treated in pregnancy with anticonvulsants. Neurologia i Neurochirurgia Polska1977;11(1):59-63. ">Sobczyz 1977</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>). These studies either did not examine the influence of key confounding variables or they did not employ appropriate methods to account for them, or included women taking AEDs for other indications. </p> </section> </section> <section id="CD010236-sec-0054"> <h3 class="title" id="CD010236-sec-0054">Effects of interventions</h3> <section id="CD010236-sec-0055"> <h4 class="title">Neurodevelopmental outcomes of children exposed to carbamazepine (CBZ) in comparison to control children </h4> <p>Eight studies investigated the cognitive abilities of children exposed to CBZ in comparison to a control group where the outcome was measured as DQ with four studies reporting child IQ. </p> <section id="CD010236-sec-0056"> <h5 class="title">Developmental quotient (DQ)</h5> <section id="CD010236-sec-0057"> <h6 class="title">CBZ versus controls (women without epilepsy)</h6> <p>Pooled results from three studies (<a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0018" title="OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75:517-20. ">Ornoy 1996</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>) using the Bayley Scales of Infant Development reported a significant MD of ‐5.58 (95% CI ‐10.83 to ‐0.34, P = 0.04, I<sup>2</sup> = 60%) with the children exposed to CBZ (n = 50) exhibiting poorer earlier performance than control children (n = 79). Due to high heterogeneity a random‐effects model analysis was undertaken and gave an MD of ‐4.35 (95% CI ‐14.04 to 5.34, P = 0.38), which changed the overall estimate to non‐significant (<a href="./references#CD010236-fig-0004" title="">Analysis 1.2</a>). </p> <p><a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a> reported that the group means on the Bayley Scale of Infant and Toddler Development were not significantly different for children exposed to CBZ (mean 122, SD not reported, P = 0.571) in comparison to general population control children (mean 119, SD not reported); however, the specific number of children exposed to CBZ monotherapy was not reported in the paper and this study could not contribute to the meta‐analysis. </p> <p>Two studies were identified to have investigated the neurodevelopment of children exposed to CBZ in comparison to control children using the Griffith Mental Development Scales (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a>). <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> found that the overall DQ of children exposed to CBZ (n = 48) did not differ significantly from control children (n = 230) (CBZ mean 98, 95% CI 94.0 to 102.5 versus control mean 100, 95% CI 98.9 to 102.1, P = 0.342). Consistently, <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a> also failed to find a significant difference between the DQ of the children exposed to CBZ either at nine months of age (n = 35) and control children (n = 81) (CBZ mean (unstandardised) 350, range 324 to 435 versus control mean (unstandardised) 335, range 307 to 396, P = 0.4). Similarly, reassessment at four years of age also found that the children exposed to CBZ (n = 35) were not significantly different in comparison to control children (n = 66) (CBZ mean (unstandardised) 641, 95% CI unclear, P value not reported versus control mean (unstandardised) 641, 95% CI unclear, P value not reported). Meta‐analysis was not possible as data were not provided in one of the publications (<a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a>) in a format that allowed calculation of mean difference (<a href="./references#CD010236-fig-0003" title="">Analysis 1.1</a>). Finally, <a href="./references#CD010236-bbs2-0018" title="OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75:517-20. ">Ornoy 1996</a> found a significant difference in the abilities of children exposed to CBZ (n = 19) (mean 99.4, SD 21) in comparison to controls (n = 12) (mean 113, SD 15, P &lt; 0.05) when measured using the McCarthy Scales of Children's Abilities. </p> </section> <section id="CD010236-sec-0058"> <h6 class="title">CBZ versus controls (women with epilepsy not taking AEDs)</h6> <p>The pooled results from two studies (<a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>) measuring neurodevelopment with the Bayley Scales of Infant and Toddler Development and comparing children exposed to CBZ (n = 163) to the offspring of women with untreated epilepsy (n = 58), found a significant MD of ‐7.22 (95% CI ‐12.76 to ‐1.67, P = 0.01, I<sup>2</sup> = 56%) indicating poorer developmental abilities for children exposed to CBZ. Due to high heterogeneity a random‐effects model analysis was undertaken and gave an MD of ‐5.60 (95% CI ‐15.40 to 4.20, P = 0.26) changing the result to non‐significant (<a href="./references#CD010236-fig-0010" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD010236-sec-0059"> <h5 class="title">Intellectual quotient (IQ)</h5> <section id="CD010236-sec-0060"> <h6 class="title">CBZ versus controls (women without epilepsy)</h6> <p>The pooled MD comparing IQ levels of 150 CBZ exposed children to 552 control children across three studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>) was not statistically significant (MD ‐0.03, 95% CI ‐3.08 to 3.01, P = 0.98, I<sup>2</sup> = 0%) (<a href="./references#CD010236-fig-0005" title="">Analysis 1.3</a>). </p> </section> <section id="CD010236-sec-0061"> <h6 class="title">CBZ versus controls (women with epilepsy not taking AEDs)</h6> <p>Four studies, two prospective (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>) and two register studies (<a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>), were pooled in a meta‐analysis. The MD for 163 CBZ exposed children in comparison to 87 control children was non‐significant (MD 1.84, 95% CI ‐2.13 to 5.80, P = 0.36, I<sup>2</sup> = 0%) (<a href="./references#CD010236-fig-0011" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD010236-sec-0062"> <h5 class="title">Autistic spectrum disorder</h5> <p>Three studies investigated whether children exposed to CBZ were at greater risk of being diagnosed with an autistic spectrum disorder. Two studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>), using a prospective and register methodology respectively, identified and investigated rates of autistic spectrum disorder in children exposed to CBZ in comparison to a control group. <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a> found that in comparison to general population control children there was no increased risk of autistic spectrum disorder (2% versus 1.8%, P value not reported). In the small study by <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a> no cases were identified for either the control group (n = 13) or the CBZ exposure group (n = 13) (P value not reported), probably due to small group size. Unpublished data provided in relation to the <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> study reported a 6% prevalence within the group exposed to CBZ but control data were not available. Meta‐analysis would not have been reliable due to the difference in methods used to collect the data across these three studies. </p> <p>Parental reporting regarding infants at the age of 18 months did not find the children exposed to CBZ (n = 41) to be at an increased risk on an autism checklist (CBZ 8.8% versus control 10.0%, OR 1.1, 95% CI 0.3 to 3.6, P &gt; 0.05) or on a questionnaire of autistic traits (CBZ 2.9% versus control 0.5%, OR 3.3, 95% CI 0.5 to 24.8, P &gt; 0.05) in comparison to children born to women without epilepsy (n = 225) (<a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a>). In this study, at 36 months, parents were asked to re‐rate their child in terms of autistic traits and the CBZ exposed children (n = 31) again were not found to differ significantly from control children (n = 154) (CBZ 3.4% versus 0.7%, OR 2.5, 95% 0.3 to 19.1, P &gt; 0.05). </p> </section> <section id="CD010236-sec-0063"> <h5 class="title">Specific cognitive abilities</h5> <p>The pooled estimates for VIQ resulted in an MD of ‐1.81 (95% CI ‐4.94 to 1.33, P = 0.26, I<sup>2</sup> = 74%), from 136 CBZ exposed children compared to 351 general population controls (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>). Due to the high statistical heterogeneity a random‐effects model analysis was undertaken and produced an MD of ‐1.84 (95% CI ‐8.01 to 4.34, P = 0.56) resulting in no change to the level of significance (<a href="./references#CD010236-fig-0007" title="">Analysis 1.5</a>). </p> <p>The pooled estimates for PIQ (MD 1.27, 95% CI ‐1.55 to 4.09, P = 0.38, I<sup>2</sup> = 0%), calculated from 136 CBZ children compared to 351 general population controls from two studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>), were not statistically significant (<a href="./references#CD010236-fig-0008" title="">Analysis 1.6</a>). Consistently, non‐significant MDs were also found for children exposed to CBZ (n = 149) in comparison to no medication controls (n = 83) for VIQ (MD 0.13, 95% CI ‐3.98, 4.23, P = 0.95, I<sup>2</sup> = 0%) and PIQ (MD 3.65, 95% CI ‐0.60 to 7.90, P = 0.09, I<sup>2</sup> = 0%) based on three studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>) (<a href="./references#CD010236-fig-0014" title="">Analysis 2.6</a>; <a href="./references#CD010236-fig-0015" title="">Analysis 2.7</a>). </p> <p>In children aged between seven and 85 months of age, the registry study by <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a> reported that the language development of children exposed to CBZ (n = 28) did not differ significantly from matched controls (n = 28) for either language comprehension or language expression (mean scores unavailable from the paper). <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>, also measured early language development and failed to find a significant difference between the abilities of children exposed to CBZ (n = 48) under two years of age and control children (both standard (n = 230) and no‐medication (n = 27)). No significant difference was found between the children exposed to CBZ or general population controls (CBZ mean 103, 95% CI 98 to 108 versus control mean 105, 95% CI 103 to 106, P = 0.684) or to children born to women with untreated epilepsy (mean 109, 95% CI 105 to 114, P = 0.307). In an older aged cohort, the language abilities of 14 CBZ (mean 74.9, SD 21, P = 0.87) exposed children did not differ from controls (mean not reported) in the registry study of <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a> when assessed at school age. Meta‐analysis was a not carried out due to the variation in language measures used and the different language outcomes targeted. </p> <p>In terms of motor abilities, <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a> found comparable motor development between children exposed to CBZ (n = 101) (mean 95, 95% CI 90 to 100, P value not reported) and no‐medication control children (n = 32) (mean 94.7, 95% CI 85 to 105). This was consistent with the findings of <a href="./references#CD010236-bbs2-0018" title="OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75:517-20. ">Ornoy 1996</a> (CBZ (n = 20) mean 97.5, SD 18 versus controls (n = 34) mean 101, SD 12, P &gt; 0.05), <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> (CBZ (n = 48) mean 94, 95% CI 89 to 99 versus controls (n = 230) mean 98, 95% CI 97 to 100, P = 0.059) and also the small study by <a href="./references#CD010236-bbs2-0001" title="ArulmozhiT , DhanarajM , RangarajR , VengatesanA . Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India2006;54(1):42-6. ">Arulmozhi 2006</a> (CBZ (n = 7) mean 101, SD 4 versus controls (n = 30) mean 102, SD 4.7, P value not reported). </p> </section> <section id="CD010236-sec-0064"> <h5 class="title">CBZ versus controls: prevalence of below average performance</h5> <p>For CBZ there were too few studies with similar methodologies to allow for meta‐analysis in comparison to control children. <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> reported a significantly increased prevalence of performance 1 SD below the normative mean based on 49 CBZ exposed children in comparison to 44 controls (10% versus 4.5% respectively, OR 7.7, 95% CI 1.4 to 43.1, P &lt; 0.01), assessed with either the Grifftihs Mental Development Scales or the Bayley Scales of Infant and Toddler Development. With the prevalence of children performing at a level 2 SDs below the mean only the data by <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> reported this, and noted that 2% of children exposed to CBZ and only 1% of control children fell below 2 SDs from the mean; a difference which was not significant. </p> <p>In the study by <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a> parents completed the Ages and Stages Questionniare for their child at 6, 18 and 36 months of age. No significant level of difference in the prevalence of performance 2 SD from the mean was reported for the children exposed to CBZ (n = 48) in comparison to children born to women without epilepsy (n = 276) for gross motor development (CBZ 12.8% versus control 12.0%, OR 1.3, 95% CI 0.5 to 3.0, P &gt; 0.05), fine motor development (CBZ 10.9% versus control 6.9%, OR 2.3, 95% CI 0.9 to 6.0, P &gt; 0.05) or early social development (CBZ 12.8% versus control 13.4%, OR 1.4, 95% CI 0.6 to 3.3, P &gt; 0.05). At 18 months of age the children exposed to CBZ (n = 41) scored significantly at risk for their fine motor development (CBZ 10.0% versus control 5.1%, OR 3.3, 95% CI 1.1 to 9.2, P &lt; 0.05) and their personal and social skill development (CBZ 12.2% versus control 3.7%, OR 3.2, 95% CI 1.3 to 8.3, P &lt; 0.05) but not for gross motor skills (CBZ 0% versus control 3.2%, OR calculation not possible) in comparison to the control children (n = 221). Reassessment again at 36 months of age failed to find any significant differences between the children exposed to CBZ (n = 31) and control children (n = 154) for gross motor skills (CBZ 6.5% versus control 6.0%, OR 2.3, 95% CI 0.5 to 9.9, P &gt; 0.05), fine motor skills (CBZ 3.3% versus control 5.6%, OR 1.0, 95% CI 0.1 to 7.5, P &gt; 0.05), communication skills (CBZ 0% versus control 1.3%, OR could not be calculated), or sentence skills (CBZ 6.5% versus control 3.9%, OR 1.2, 95% CI 0.3 to 5.1, P &gt; 0.05) (<a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a>). Consistently, <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> using the Griffiths Mental Development Scales found no significant difference in the prevalence of below average performance for children exposed to CBZ (n = 48, 16%) in comparison to general population control children (n = 230, 8%) or children born to women with an untreated epilepsy (n = 27, 7%) in children aged two years. It was likely that these conflicting results were due to methodological differences. </p> </section> <section id="CD010236-sec-0065"> <h5 class="title">Dose of CBZ</h5> <p>No relationship between dose of CBZ and neurodevelopmental outcome was reported in five (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0018" title="OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75:517-20. ">Ornoy 1996</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>) of the six identified studies that had investigated this issue. The sixth study (<a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>) failed to find an association between CBZ dose and general cognitive ability (DQ and IQ); however, the study reported a relationship between CBZ dose and verbal abilities when the cohort were three years of age. It was of note, however, that this association was not replicated in this cohort when they were six years of age (<a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>). </p> </section> </section> <section id="CD010236-sec-0066"> <h4 class="title">Neurodevelopmental outcomes of children exposed to lamotrigine (LTG) in comparison to control children </h4> <p>Despite its widespread use in women of childbearing age, only three identified studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a>) investigated the cognitive abilities of children exposed to LTG in comparison to a control group. Due to differences in methodologies and data reporting meta‐analysis was not possible. </p> <section id="CD010236-sec-0067"> <h5 class="title">Developmental quotient (DQ)</h5> <section id="CD010236-sec-0068"> <h6 class="title">LTG versus controls (women without epilepsy)</h6> <p>Using the Griffiths Mental Development Scales, <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> investigated the cognitive abilities of children exposed to LTG (n = 34) (mean 99, 95% CI 94 to 103, P = 0.21) in comparison to control children (n = 230) (mean 100, 95% CI 99 to 102); no significant differences were found. </p> </section> <section id="CD010236-sec-0069"> <h6 class="title">LTG versus controls (women with epilepsy not taking AEDs)</h6> <p>In the study by <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>, the mean DQ for children exposed to LTG (n = 34) (mean 99, 95% CI 94 to 103, P = 0.470) was not significantly different from that of children born to women with untreated epilepsy (n = 27) (mean 104, 95% CI 101 to 108). </p> </section> </section> <section id="CD010236-sec-0070"> <h5 class="title">Intellectual quotient (IQ)</h5> <section id="CD010236-sec-0071"> <h6 class="title">LTG versus controls (women without epilepsy)</h6> <p>Consistent with the assessment at the earlier age, <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> failed to find a significant difference between the children exposed to LTG (n = 29) (mean 103, SD 11, P = 0.22) in comparison to control children of women without epilepsy (n = 210) (mean 107, SD 12) in their prospective cohort at six years. </p> <p><a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> compared 41 LTG exposed children to 52 control children. These data could not be combined with that of <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> due to the inclusion of children born to women with psychiatric indications who were exposed to LTG (10%). <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> found a non‐significant difference between the children exposed to LTG and control children (LTG mean 105.56, SD 12.49 versus control mean 108.71, SD 10.20, P &gt; 0.05). </p> </section> <section id="CD010236-sec-0072"> <h6 class="title">LTG versus controls (women with epilepsy not taking AEDs)</h6> <p>Only a single identified study investigated this comparison. <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> found comparable mean IQs for children exposed to LTG (n = 29) (mean 103, SD 11, P value not reported) and children born to women with untreated epilepsy (n = 25) (mean 104, SD 13). </p> </section> </section> <section id="CD010236-sec-0073"> <h5 class="title">Autistic spectrum disorder</h5> <p>The rate of diagnosis of autistic spectrum disorder in children exposed to LTG was only reported in one published study (<a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>). In comparison to a rate of 1.8% in the general population controls (n = 210) the prevalence of 3.3% for the LTG group (n = 30) was not significantly higher in children at six years of age. In unpublished data (linked to <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>) a 0% prevalence of autistic spectrum disorder in 35 LTG exposed children was reported; no control data were available however. </p> <p>Investigation of autistic symptomatology was undertaken in one study. <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a> found that, based on parental ratings, children aged 18 months were not at increased risk based on an autism checklist (LTG 15.6% versus controls 10.0%, OR 1.8, 95% CI 0.9 to 3.8, P &gt; 0.05) or on a questionnaire regarding autistic traits (LTG 3.1% versus 0.5%, OR 1.5, 95% CI 0.2 to 11.0, P &gt; 0.05). At 36 months, however, parental ratings indicated an increased risk in the LTG group (n = 44) of autistic traits (LTG 9.3% versus control 3.4%, OR 5.0, 95% CI 1.7 to 14.4, P &lt; 0.05) in comparison to controls (n = 154) (<a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a>). </p> </section> <section id="CD010236-sec-0074"> <h5 class="title">Specific cognitive abilities</h5> <p>The VIQ (mean 99, SD 13, P = 0.23) and PIQ (mean 103, SD 12, P = 0.34) of children exposed to LTG (n = 29) did not differ significantly in comparison to general population controls (n = 210) (VIQ mean 103, SD 12; PIQ mean 106, SD 13) or untreated epilepsy controls (n = 29) (VIQ mean 99, SD 12, P value not reported; PIQ mean 104, SD 14, P value not reported) in the one identified study to investigate such abilities in school aged children (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>). From the same cohort but at a younger age time point (under two years of age) children exposed to LTG were also not found to significantly differ from control children for their early development across language (LTG mean 104, 95% CI 98 to 100 versus control mean 105, 95% CI 103 to 106, P = 0.476), motor (LTG mean 100, 95% CI 94 to 105 versus control mean 98, 95% CI, 97 to 100, P = 0.733), social (LTG mean 100, 95% CI 95 to 106 versus control mean 97, 95% CI 95 to 98, P = 0.379) and non‐verbal skills (LTG mean 97, 95% CI 91 to 103 versus control mean 102, 95% CI 100 to 104, P=0.104). The younger aged LTG exposed children were found to be significantly poorer in their hand and eye co‐ordination (LTG mean 90, 95% CI 84 to 97, P = 0.104) in comparison to general population controls (mean 101, 95% CI 98 to 103); however this difference disappeared when confounders (that is maternal IQ and socioeconomic status) were adjusted for (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>). <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> reported poorer fine motor skills for children exposed to LTG (n = 42) in comparison to control children (n = 52) (LTG mean 30.57, SD 22.90 versus control mean 43.08, SD 21.17, P &lt; 0.05) as well as poorer gross motor skills (LTG mean 34.78, SD 24.47 versus control mean 49.92, SD 28.29). Visual perception abilities were also noted to be poorer in the <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> study for the children exposed to LTG (n = 42) in comparison to control children (n = 51) (LTG mean 42.76, SD 31.85 versus control mean 60.46, SD 28.68, P &lt; 0.05) as were motor co‐ordination abilities (LTG mean 31.18, SD 28.62 versus control mean 51.53, SD 25.26, P &lt; 0.05) but not their visual‐motor integration abilities (LTG mean 53.86, SD 25.24 versus control mean 63.90, SD 23.78, P &lt; 0.05). </p> </section> <section id="CD010236-sec-0075"> <h5 class="title">LTG versus controls: prevalence of below average performance</h5> <p>Two studies compared the prevalence of child DQ performance 1 SD below the mean, but meta‐analysis was not possible. The study by <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> found that 2.9% of children exposed to LTG (n = 35) and 4.5% of control children fell 1 SD below the mean, a difference that was not significant. Consistently, <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> also found comparable levels of below average performance in 34 LTG exposed children (15%) and 230 control children (8%). </p> <p>At 6 months of age <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a> did not find children exposed to LTG (n = 71) to be at an increased risk of 2 SDs below the mean on parental completed measures of gross motor skills (LTG 15.7 versus controls 12%, OR 1.5, 95% CI 0.8 to 2.9, P &gt; 0.05), fine motor skills (LTG 10.1 versus control 6.9, OR 1.8, 95% CI 0.8 to 3.9, P &gt; 0.05) or early social development (LTG 12.7% versus control 13.4%, OR 1.2, 95% CI 0.6 to 2.5, P &gt; 0.05). At 18 months, parents provided further ratings of their child's development and reported no significant levels of difference between the children exposed to LTG (n = 65) and control children (n = 221) for gross motor skills (LTG 7.8% versus control 3.2%, OR 1.7, 95% CI 0.6 to 5.1, P &gt; 0.05), fine motor skills (LTG 3.1% versus control 5.1%, OR 0.9, 95% CI 0.2 to 3.7, P &gt; 0.05) or personal and social skills (LTG 3.1% versus control 3.7%, OR 0.6, 95% CI 0.2 to 2.7, P &gt; 0.05). Reassessment of this group at 36 months found that, based on parent ratings, children exposed to LTG were at an increased risk of poorer sentence skills (LTG 14.3% versus control 3.9%, OR 2.8, 95% CI 1.2 to 6.9, P &lt; 0.05) but not gross motor skills (LTG 9.8% versus control 3.3%, OR 2.4, 95% CI 0.8 to 7.0, P &gt; 0.05), fine motor skills (LTG 7.7% versus control 5.6%, OR 2.1, 95% CI 0.7 to 7.0, P &gt; 0.05) or communication skills (LTG 7.1% versus controls 1.3%, OR 2.0, 95% CI 0.6 to 6.7, P &gt; 0.05). </p> </section> <section id="CD010236-sec-0076"> <h5 class="title">Dose of LTG</h5> <p>No relationship between dose and child DQ or IQ was found (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>); this was not investigated in the study by <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>. <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> found a relationship between dose of LTG on fine motor ability and non‐verbal IQ but not for the other cognitive measures. </p> </section> </section> <section id="CD010236-sec-0077"> <h4 class="title">Neurodevelopmental outcomes of children exposed to levetiracetam (LEV) in comparison to control children </h4> <p>Only one study was identified by the searches to have investigated the neurodevelopment of children exposed to LEV in utero (<a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>). </p> <section id="CD010236-sec-0078"> <h5 class="title">Developmental quotient (DQ)</h5> <p><b>LEV versus controls (women without epilepsy)</b> </p> <p>One study investigated the neurodevelopment of children exposed to LEV in comparison to children born to women without epilepsy (<a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>) who were under two years of age. Data collected using the Griffiths Mental Development Scales found that children exposed to LEV (n = 51) (mean 99.9, 95% CI 97 to 103, P = 0.62) did not differ significantly in comparison to general population control children (n = 97) (mean 98.8, 95% CI 96 to 102). </p> <section id="CD010236-sec-0079"> <h6 class="title">LEV versus controls (women with epilepsy not taking AEDs)</h6> <p>No comparisons comparing the DQ of children exposed to LEV to children born to women with untreated epilepsy were identified. </p> </section> </section> <section id="CD010236-sec-0080"> <h5 class="title">Intellectual quotient (IQ)</h5> <p>No studies measured this aspect of neurodevelopment in comparison to either control type. </p> </section> <section id="CD010236-sec-0081"> <h5 class="title">Autistic spectrum disorder</h5> <p>No studies were identified.</p> </section> <section id="CD010236-sec-0082"> <h5 class="title">Specific cognitive abilities</h5> <p>In the study by <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>, children exposed to LEV (n = 51) did not differ from control children on tasks of language (LEV mean 100.5, 95% CI 97 to 104 versus control mean 101.2. 95% CI 98 to 104, P=0.79), hand and eye coordination (LEV mean 101.8, 95% CI 97 to 106 versus control mean 97.4, 95% CI 94 to 101, P = 0.14), non‐verbal reasoning (LEV mean 101.7, 95% CI 98 to 105 versus control mean 101.4, 95% CI 98 to 105, P = 0.92) or social development (LEV mean 98.0, 95% CI 94 to 102 versus control mean 98, 95% CI 95 to 101, P = 0.99). </p> <p>In a later paper linked to the <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> paper, the research group reported on global cognitive ability of 53 LEV exposed children at between three and four years of age in comparison to children born to women without epilepsy (n = 131); 32% of this LEV group had been assessed under the age of two years and were reported in the <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> publication. Consistent with the outcome at the younger age assessments the children exposed to LEV did not differ in their performance on tasks of motor development (LEV mean 110.4, SD17.2 versus control mean 110.9, SD 20.1, P=0.9), social development (LEV mean 116.5, SD 19.1 versus control mean 119.9, SD 16.3, P = 0.1), hand and eye co‐ordination tasks (LEV mean 104.8, SD 13.9 versus control mean 103.3, SD 15.6, P = 0.8), non‐verbal skills (LEV mean 109.9, SD 15.4 versus control mean 110.5, SD 16.3, P = 0.6) and practical developmental skills (LEV mean 113.4, SD 16.6 versus control mean 113.9, SD 17.0, P = 0.5). The authors also completed the Reynell Scales of Infant and Toddler Development to assess language development in the pre‐school aged LEV exposed children in comparison to the control children. No significant differences were found in terms of language comprehension (LEV mean 49.6, SD 10.3 versus control mean 52.2, SD 9.6, P = 0.2); for language expression skills the children exposed to LEV scored significantly higher than the control children (LEV mean 52.0, SD 13.4 versus control mean 46.6, SD 10.2, P = 0.01). </p> </section> <section id="CD010236-sec-0083"> <h5 class="title">Dose of LEV</h5> <p>In the study by <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> a linear relationship between daily dose of LEV and the Griffiths Mental Development score was noted to be significant, but it was a weak relationship (r = 0.25). </p> </section> </section> <section id="CD010236-sec-0084"> <h4 class="title">Neurodevelopmental outcomes of children exposed to phenytoin (PHT) in comparison to control children </h4> <p>Despite its many years of use only five studies investigated the cognitive abilities of children exposed to PHT in isolation from other AEDs. Variance across methodologies limited our ability to perform meta‐analysis. </p> <section id="CD010236-sec-0085"> <h5 class="title">Developmental quotient</h5> <section id="CD010236-sec-0086"> <h6 class="title">PHT versus controls (women without epilepsy)</h6> <p>The pooled MD estimate from 20 children exposed to PHT in comparison to 44 controls (<a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>) was not statistically significant (MD ‐0.12, 95% CI ‐7.54 to 7.30, P = 0.98, I<sup>2</sup> = 55%) using the Bayley Scales of Infant and Toddler Development (<a href="./references#CD010236-fig-0030" title="">Analysis 5.1</a>). <a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a> reported that the mean scores on the Bayley Scales of Infant and Toddler Development were not significantly different for children exposed to PHT in comparison to general population control children (PHT mean 113, SD not reported versus control mean 119, SD not reported, P = 0.173); however, the specific number of PHT monotherapy exposed children was not reported in the paper. <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a> noted no significant difference at nine months of age for 21 children exposed to PHT (mean 635, 95% CI unclear versus control mean 641, 95% CI unclear, P value not reported) in terms of global neurodevelopment on the Griffiths Mental Development Scales. This finding was consistent with later follow up of this cohort at four years (PHT n = 15 mean (unstandarised) 635, 95% CI unclear, P value not reported). </p> </section> <section id="CD010236-sec-0087"> <h6 class="title">PHT versus controls (women with epilepsy not taking AEDs)</h6> <p><a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a> failed to find a significant difference between children exposed to PHT (n = 29) (PHT mean 90.3, 95% CI 77 to 103, P value not reported) and controls (n = 32) (mean 92.3, 95% CI 81 to 103) when children were assessed with an adapted version of the Bayley Scales of Infant and Toddler Development. </p> </section> </section> <section id="CD010236-sec-0088"> <h5 class="title">Intellectual quotient (IQ)</h5> <p>Two studies investigated the IQ abilities of children exposed to PHT in comparison to control children (<a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>), however neither compared PHT monotherapy outcomes to controls in isolation and therefore the data could not be reported for PHT. </p> </section> <section id="CD010236-sec-0089"> <h5 class="title">Autistic spectrum disorder</h5> <p>No studies were identified.</p> </section> <section id="CD010236-sec-0090"> <h5 class="title">Specific cognitive abilities</h5> <p><a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a> demonstrated significantly poorer language abilities in children exposed to PHT compared to controls as measured by the Reynell Language Scales across both comprehension and expressive language (means not reported). <a href="./references#CD010236-bbs2-0001" title="ArulmozhiT , DhanarajM , RangarajR , VengatesanA . Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India2006;54(1):42-6. ">Arulmozhi 2006</a>, reported delayed sitting abilities in 18 infants exposed to PHT when compared to 30 control children (means not reported). <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a> also found delayed motor development in 15 PHT exposed children aged between four and five years of age (PHT mean 98, 95% CI unclear versus control mean 106, 95% CI unclear). Finally, a non‐significant OR for PHT (n=12) (OR 1.37, 95% CI 0.38 to 5.0, P value not reported) in comparison to controls was noted for specific cognitive dysfunction in the early <a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>. </p> </section> <section id="CD010236-sec-0091"> <h5 class="title">Dose of PHT</h5> <p>The studies of <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a> and <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> investigated but failed to demonstrate a dose effect with PHT. </p> </section> </section> <section id="CD010236-sec-0092"> <h4 class="title">Neurodevelopmental outcomes of children exposed to phenobarbital (PB) in comparison to control children </h4> <p>Despite its historical use the majority of investigations into children exposed to PB reported outcomes as part of a single AED exposed group rather than as a group in its own right. Therefore, limited data was available on PB exposure and child neurodevelopmental outcomes. </p> <section id="CD010236-sec-0093"> <h5 class="title">Developmental quotient</h5> <section id="CD010236-sec-0094"> <h6 class="title">PB versus controls (women without epilepsy)</h6> <p><a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a> reported that the mean Bayley scores were not significantly different for children exposed to PB (mean 115, SD not reported, P = 0.372) compared to general population control children (mean 119, SD not reported); however the specific number of women with PB monotherapy was not reported in the paper. </p> </section> <section id="CD010236-sec-0095"> <h6 class="title">PB versus controls (women with epilepsy not taking AEDs)</h6> <p><a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a> failed to find a significant difference between children exposed to PB (n = 41) (mean 90.3, 95% CI 94 to 97, P value not reported) and control children (n = 32) (mean 92.3, 95% CI 81 to 103). </p> </section> </section> <section id="CD010236-sec-0096"> <h5 class="title">Intellectual quotient (IQ)</h5> <p><b>PB versus controls (women without epilepsy)</b> </p> <p><a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a> collected IQ data in children exposed to PB (n=14) mean 86.2, SD 11, P value not reported) however they did not make a direct statistical comparison to control children (n= 201) (mean 93, SD 14.4). </p> </section> <section id="CD010236-sec-0097"> <h5 class="title">Autistic spectrum disorder</h5> <p>No studies were identified.</p> </section> <section id="CD010236-sec-0098"> <h5 class="title">Specific cognitive abilities</h5> <p><a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a> reported on the language abilities of 14 children exposed to PB (mean 70.6, SD 9, P = 0.146) however they did not make a direct comparison to control children, whose overall language mean was not reported. </p> </section> <section id="CD010236-sec-0099"> <h5 class="title">Dose of PB</h5> <p>No studies reported on dose of PB and child DQ or IQ.</p> </section> </section> <section id="CD010236-sec-0100"> <h4 class="title">Neurodevelopmental outcomes of children exposed to primidone (PRM) in comparison to control children </h4> <p>Few studies reported on exposure to primidone in isolation from other treatments and only one included study assessed cognitive outcomes in children exposed to monotherapy primidone (<a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>). </p> <section id="CD010236-sec-0101"> <h5 class="title">Developmental quotient (DQ)</h5> <p>Only one study investigated DQ in PRM exposed infants in comparison to controls. The <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a> reported a non‐significant difference between 15 PRM exposed infants (mean 105.7, SD 13, P value not reported) and 15 matched controls (mean 110.1, SD 10). </p> </section> <section id="CD010236-sec-0102"> <h5 class="title">Intellectual quotient (IQ)</h5> <section id="CD010236-sec-0103"> <h6 class="title">PRM versus controls (women without epilepsy)</h6> <p>In the <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>, 15 cases exposed to PRM (mean 92.6, SD 2, P = 0.033) did not differ from control children representative of the general population (mean 105.4, SD 11). </p> </section> </section> <section id="CD010236-sec-0104"> <h5 class="title">Autistic spectrum Disorder</h5> <p>No studies were identified.</p> </section> <section id="CD010236-sec-0105"> <h5 class="title">Specific cognitive abilities</h5> <p>No studies were identified.</p> </section> <section id="CD010236-sec-0106"> <h5 class="title">Dose of PRM</h5> <p>No studies investigated dose of PRM and child neurodevelopment.</p> </section> </section> <section id="CD010236-sec-0107"> <h4 class="title">Neurodevelopmental outcomes of children exposed to topiramate (TPM) in comparison to control children </h4> <p>Only a single article was identified which assessed the neurodevelopment of children exposed to topiramate (<a href="./references#CD010236-bbs2-0020" title="RihtmanT , ParushS , OrnoyA . Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology2012;34(3):308-11. ">Rihtman 2012</a>). </p> <section id="CD010236-sec-0108"> <h5 class="title">Developmental quotient (DQ)</h5> <p>No studies were identified.</p> </section> <section id="CD010236-sec-0109"> <h5 class="title">Intellectual quotient (IQ)</h5> <section id="CD010236-sec-0110"> <h6 class="title">TPM versus controls (women without epilepsy)</h6> <p>The article by <a href="./references#CD010236-bbs2-0020" title="RihtmanT , ParushS , OrnoyA . Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology2012;34(3):308-11. ">Rihtman 2012</a> included just nine TPM exposed children of which only six were offsprings of mothers with epilepsy. Global cognitive ability was assessed using the Stanford‐Binet fifth edition and the authors reported a significant difference between the nine TPM exposed children and 18 control children in terms of global cognitive ability (TPM mean 96.33, SD 10.37 versus control mean 111.39, SD 12.20, P = 0.005). </p> </section> </section> <section id="CD010236-sec-0111"> <h5 class="title">Autistic spectrum disorder</h5> <p>No studies were identified.</p> </section> <section id="CD010236-sec-0112"> <h5 class="title">Specific cognitive abilities</h5> <p>In the article by <a href="./references#CD010236-bbs2-0020" title="RihtmanT , ParushS , OrnoyA . Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology2012;34(3):308-11. ">Rihtman 2012</a> a large number of specific cognitive abilities were assessed. The children exposed to TPM (n = 9) were found to differ significantly from control children (n = 18) on a task of visual perception (TPM mean 92.00, SD 13.73 versus control mean 110.41, SD 15.88, P = 0.010), tasks of motor control (TPM mean 78.56, SD 17.36 versus control mean 101.47, 16.82, P = 0.005), general co‐ordination (TPM mean 20.71, SD 4.15 versus control mean 23.57, SD 2.47, P = 0.035), fine motor performance (TPM mean 6.78, SD 1.86 versus control mean 9.00, SD 2.14, P = 0.016) and also on gross motor performance (TPM mean 7.78, SD 2.44 versus 10.72, SD 3.49, P = 0.043). No significant differences were found on tasks of visual motor integration (TPM mean 95.56, SD 9.79 versus control mean 106.83, SD 16.94, P = 0.067), control during motor movement (TPM 20.14, SD 5.27 versus control mean 22.28, SD 3.56, P = 0.380) or on fine motor perceptual abilities (TPM mean 22.86, SD 2.79 versus control mean 23.86, SD 1.96, P = 0.300). </p> </section> </section> <section id="CD010236-sec-0113"> <h4 class="title">Neurodevelopmental outcomes of children exposed to sodium valproate (VPA) in comparison to control children </h4> <p>Ten studies investigated the cognitive abilities of children exposed to VPA in comparison to a control group (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>). </p> <section id="CD010236-sec-0114"> <h5 class="title">Developmental quotient (DQ)</h5> <section id="CD010236-sec-0115"> <h6 class="title">VPA versus controls (women without epilepsy)</h6> <p>Three studies made comparisons between children exposed to VPA and children born to women who did not have epilepsy (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>). The <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a> measured neurodevelopment with the Bayley Scales of Infant and Toddler Development and found a significant difference between nine VPA exposed (mean 103.5, SD 11, P = 0.01) and nine matched control children (mean 116.8, SD 11). In a larger sample, <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> demonstrated a significant difference between the VPA exposed (n = 42) (mean 92, 95% CI 87 to 96, P &lt; 0.001) and control children (n = 230) (mean 100, 95% CI 99 to 102) for early development measured by the Griffiths Mental Development Scales. </p> </section> <section id="CD010236-sec-0116"> <h6 class="title">VPA versus controls (women with epilepsy not taking AEDs)</h6> <p>The pooled results from two studies measuring neurodevelopment with the Bayley Scales of Infant and Toddler Neurodevelopment (<a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>) found VPA exposed children (n = 123) to have a significantly lower development in comparison to children born to mothers with epilepsy not taking AEDs (n = 58) with a MD of ‐8.72 (95% CI ‐14.31 to ‐3.31, P = 0.002, I<sup>2</sup> = 0%) (<a href="./references#CD010236-fig-0024" title="">Analysis 4.2</a>). </p> <p>Using the Griffiths Mental Development Scales, children exposed to VPA (mean 92, 95% CI 87 to 96, P value not reported) had significantly poorer DQ than children born to women with epilepsy untreated (mean 104, 95% CI 101 to 108) (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>). </p> <p><a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>, demonstrated significantly poorer neurodevelopment in a VPA (n = 44) (mean 82.2, SE 2.5, P &lt; 0.001) group recruited from the UK Epilepsy and Pregnancy Register in comparison to control children (n = 97) (mean 99.0, SE 1.4). However, this control group overlapped with that of <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> and therefore was not included in the meta‐analysis. </p> </section> </section> <section id="CD010236-sec-0117"> <h5 class="title">Intellectual quotient (IQ)</h5> <section id="CD010236-sec-0118"> <h6 class="title">VPA versus controls (women without epilepsy)</h6> <p>The pooled estimate from three studies, one prospective study (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>) and two register studies (<a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>), found a significant MD of ‐8.94 (‐11.96 to ‐5.92, P &lt; 0.00001, I<sup>2</sup> = 88%) finding VPA exposed children (n = 76) to have poorer levels of neurodevelopment in comparison to control children (n = 552) (<a href="./references#CD010236-fig-0018" title="">Analysis 3.3</a>). Variance was high between the studies included in this meta‐analysis (I<sup>2</sup> = 88%) and visual inspection of the plot indicated that this was due to the small study of <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a> where the results, based on only 12 cases, were in the opposite direction to those of the other included studies, reporting a higher mean for the small VPA group in comparison to the controls. A random‐effects model analysis was undertaken and gave an MD of ‐5.28 (95% CI ‐15.54 to 4.97, P = 0.31), which altered the significance of the results. However, the forest plot clearly indicated that the <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a> study was in contradiction to the other four studies and therefore a sensitivity analysis without this study showed a significant MD of ‐11.42 (‐14.68 to 8.15, P &lt; 0.00001), altering the I<sup>2</sup> statistic to 2% and indicating little variance between the other studies. </p> <p><a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> also compared VPA exposed children to control children using the Standford Binet, fifth Edition, however 21% were not born to women with epilepsy and therefore this data could not be combined in a meta‐analysis. It was of note that the mean dose of VPA was low (546.3 mg daily), probably reflecting its use for a non‐epilepsy indication in this paper. In the comparison of the 30 VPA exposed children to 52 control children <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> reported no significant differences in terms of global IQ (VPA mean 103.93, SD 10.00 versus control mean 108.71, SD 10.20, P &gt; 0.05). </p> </section> <section id="CD010236-sec-0119"> <h6 class="title">VPA versus controls (women with epilepsy not taking AEDs)</h6> <p>Four studies contributed to the pooled estimates for child IQ in those exposed to VPA compared to the offspring of women with untreated epilepsy (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>). Meta‐analysis found a significant MD of ‐8.17 (95% CI ‐12.80 to ‐3.55, P = 0.0005, I<sup>2</sup> = 27%) with VPA (n = 89) exposed children having a lower IQ than controls (n = 87) (<a href="./references#CD010236-fig-0025" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD010236-sec-0120"> <h5 class="title">Autistic spectrum disorder</h5> <p>Three studies reported on the prevalence of autistic spectrum diagnosis in groups of children exposed to VPA (<a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>). In the largest study, the prevalence of autistic spectrum diagnosis was 8% in the VPA exposed group compared to 1.8% in the general population controls (n = 210) (<a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>) in six year olds. <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> noted a 12% prevalence of autistic spectrum disorder in the group exposed to VPA. Finally, <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a> reported two cases from 15 (15.4%) who had autistic and regressive behavioural features suggestive of low intelligence in children aged 6 to 13 years. Meta‐analysis was not possible due to the variance in the way these data were collected. <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a> analysed parental reports of autistic symptomology at 18 and 36 months of age. At 18 months the children exposed to VPA (n = 25) were not reported to be at a significantly higher risk based on an autism checklist (VPA 8.3% versus 10.0%, OR 1.0, 95% CI 0.2 to 4.5, P &gt; 0.05) or on a measure of autistic traits (VPA 0% versus 0.5%, OR could not be calculated) in comparison to control children (n = 221). Consistently, at 36 months parents did not report the children exposed to VPA (n = 19) to be at an increased risk of autistic traits (VPA 5.6% versus 0.7%, OR 3.7, 95% CI 0.5 to 28.4, P &gt; 0.05) in comparison to control children (n = 154). </p> </section> <section id="CD010236-sec-0121"> <h5 class="title">Specific cognitive abilities</h5> <p>The VIQ abilities of VPA exposed children (n = 64) were significantly poorer than general population control children (n = 351) in the pooled estimates from two studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>) with a MD of ‐11.39 (95% CI ‐14.68 to ‐8.10, P &lt; 0.00001, I<sup>2</sup> = 0%) (<a href="./references#CD010236-fig-0021" title="">Analysis 3.6</a>). Consistently, in comparison to no treatment controls (n = 83) the VIQ was demonstrated to be significantly lower for children exposed to VPA (n = 77) (MD ‐8.81 95% CI ‐13.32 to ‐4.30, P = 0.0001, I<sup>2</sup> = 0%) (<a href="./references#CD010236-fig-0028" title="">Analysis 4.6</a>). For PIQ, children exposed to VPA (n = 64) had significantly poorer abilities (MD ‐10.48, 95% CI ‐13.94 to ‐7.02, P &lt; 0.00001, I<sup>2</sup> = 68%) compared to general population controls (n = 392) based on the pooled estimates from these two studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>) (<a href="./references#CD010236-fig-0022" title="">Analysis 3.7</a>). This was consistent with the pooled estimates for PIQ for children exposed to VPA (n = 77) in comparison to no treatment controls (n = 83) (MD ‐7.20, 95% CI ‐12.44 to ‐1.96, P = 0.007, I<sup>2</sup> = 12%) based on three studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>) (<a href="./references#CD010236-fig-0029" title="">Analysis 4.7</a>). Due to high heterogeneity a random‐effects model analysis was performed for women on VPA versus women without epilepsy for the PIQ results and gave a significant MD of ‐12.11 (95% CI ‐19.66 to ‐4.55, P = 0.002), which did not alter the significance of the overall estimate. The data from <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> were not included in the meta‐analysis (due to inclusion of psychiatric indications) but the VIQ and PIQ were assessed and reported and were not in agreement with the meta‐analysis results. In the <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> study no significant difference was reported for VIQ (VPA mean 101.38, SD 11.73 versus 105.27, SD 11.76, P &lt; 0.05) or PIQ (VPA mean 106.59, SD 10.32 versus 112.06, SD 11.02, P &lt; 0.05) for the children exposed to VPA (n = 29) in comparison to children born to women without epilepsy (n = 52). </p> <p>To date few studies have consistently investigated specific cognitive ability types in comparison to a control group or shared a control group (in the case of <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> and <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>) and therefore meta‐analysis was not possible. </p> <p>In terms of early gross motor development, <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> found that the children exposed to VPA were significantly poorer on motor abilities than general population control children (VPA mean 91, 95% CI 86 to 96 versus control mean 98, 95% CI 97 to 100, P = 0.015). VPA exposed infants taking part in the Kerala Pregnancy Register had high rates of motor delay (38%); however no statistical comparison to the no medication control group was reported (<a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>). At the later assessment of the <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> cohort, children exposed to VPA (n = 45) performed significantly less well on tasks of motor development (VPA mean 96.6, SD 22.1 versus control mean 110.9, SD 20.1, P = 0.001). In school aged children, <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> reported poorer gross motor function (VPA mean 31.30, SD 24.18 versus control mean 49.92, SD 28.29, P &lt; 0.05) and poorer motor control (VPA mean 25.54, SD 26.54 versus control mean 51.53, SD 25.26, P &lt; 0.05) in VPA exposed children (n = 29) in comparison to children born to women without epilepsy (n = 30). </p> <p>Early language development was assessed by a number of studies in comparison to control children. <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> found the language skills of VPA exposed children to be poorer than control children born to women without epilepsy (VPA mean 97, 95% CI 92 to 103 versus control mean 105, 95% CI 103 to 106, P=0.008) and in comparison to children born to women with untreated epilepsy (control mean 109, 95% CI 105 to 114, P value not reported). Consistently, <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> used the same measure and also found poorer language development in children exposed to VPA (VPA 84.9, SE 2.7 versus control mean 101.3, SE 1.6, P ≤ 0.001). When children in the <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> cohort were assessed later at between three and four years of age, the children exposed to VPA were still significantly poorer in terms of language comprehension abilities (VPA mean 44.0, SD 16.1 versus control mean 52.2, SD 9.6, P = 0.003) but did not differ from control children on expressive language abilities (VPA mean 43.1, SD 15.9 versus control mean 46.6, SD 10.2, P = 0.9), although we noted that the language assessment measure was different at this reassessment (Reynell Language Scales). <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a> investigated the language development of children exposed to VPA in comparison to control children; however, no direct statistical comparison was reported between these groups. Finally, verbal dysfunction was present in three of 15 cases (23%) in the small cohort of <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a> in comparison to a single case in the control group (7.7%). </p> <p>The social abilities of infants were assessed in two studies. <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> found that young children exposed to VPA had poorer social abilities (VPA mean 90, 95% CI 85 to 95 versus control mean 97, 95% CI 95 to 98, P = 0.003); with <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> also reporting this association in children under the age of two years (VPA mean 87.9, SE 2.9 versus control mean 98.2, SE 1.6, P = 0.001). Reassessment of the <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> cohort at between three and four years of age showed continuing poorer early social development (VPA mean 108.4, SD 21.4 versus control mean 119.9, SD 16.3, P = 0.002). </p> <p>One study reported significantly poorer hand and eye co‐ordination in children exposed to VPA (n = 42) (VPA mean 89, 95% CI 84 to 95 versus control mean 101, 95% CI 98 to 103, P &lt; 0.001) (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>), which was consistent with the report of increased fine motor difficulties reported by <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> in 30 VPA exposed children (VPA mean 24.57, SD 18.74 versus control mean 43.08, SD 21.17, P &lt; 0.05). However, assessment of the <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> cohort failed to find a significant difference between VPA exposed children (n = 40) and control children (n = 96) for hand and eye co‐ordination at the younger age assessment (under two years of age) (VPA mean 95.4, SE 2.9 versus control mean 97.6, SE 1.9, P = 1.00) or at the older age assessment (VPA mean 102.1, SD 17.7 versus control mean 103.3, SD 15.6, P = 0.9). </p> <p>Finally, two studies investigated non‐verbal reasoning in children under the age of two years using the Griffths Mental Development Scales (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>), with both finding a poorer level of performance for the children exposed to VPA (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>: VPA mean 92, 95% CI 87 to 97 versus control mean 102, 95% CI 100 to 104, P &lt; 0.001; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>: VPA mean 93.5, SE 3.3 versus control mean 101.6 SE 1.8, P=0.040). At the reassessment of the <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> cohort later in childhood, however, the non‐verbal abilities of the children exposed to VPA were comparable to the control children (VPA mean 111.4, SD 23.1 versus control mean 110.5, SD 16.3, P = 0.6). </p> </section> <section id="CD010236-sec-0122"> <h5 class="title">VPA versus controls: prevalence of below average performance</h5> <p>For VPA in comparison to controls, although a number of studies reported the prevalence of DQ performance below the average range, meta‐analysis was limited due to heterogeneity across methodologies. Based on two studies the meta‐analysis demonstrated a significantly increased risk of below average performance (RR 10.33, 95% CI 2.05‐52.01, P = 0.005, I<sup>2</sup> = 0%) (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>, <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>). The study by <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> also reported a significant increase in the number of children with below average performance (1 SD) among the 58 valproate exposed children (39.6%) in comparison to 44 controls (4.5%) with a significant OR of 26.1 (95% CI 4.9 to 139; P &lt; 0.001). Consistently, <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> demonstrated a significantly increased risk of performance 1 SD below the mean for children exposed to VPA (n = 42, 29%) in comparison to general population controls (n = 230, 8%) and control children born to women with and untreated epilepsy (n = 27, 7%). Using parent completed questionnaires to rate child development at six months, <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a> reported no significant difference between the children exposed to VPA (n = 27) and control children (n = 276) for the prevalence of below average performance on gross motor development (VPA 7.4% versus control 9.8%, OR 0.7, 95% CI 0.2 to 2.8, P &gt; 0.05), fine motor development (VPA 11.5% versus control 6.9%, OR 2.1, 95% CI 0.6 to 7.3, P &gt; 0.05) or early social development (VPA 3.7% versus control, OR 0.3, 95% CI 0.1 to 2.4, P &gt; 0.05). At 18 months, <a href="./references#CD010236-bbs2-0027" title="VeibyG , DaltveitA , SchjolbergS , StoltenbergC , Oyen A-S, Vollset S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia2013;54(8):1462-72. ">Veiby 2013</a> reported significant differences for the VPA exposed children (n = 25) in comparison to control children (n = 221) with regards to rates of impairment in gross motor skills (VPA 16% versus control 3.2%, OR 7.0, 95% CI 2.4 to 21.0, P &lt; 0.05) but not on measures of fine motor skills (VPA 4.0% versus control 5.1%, OR 1.3, 95% CI 0.2 to 9.7, P &gt; 0.05) or personal or social skills (VPA 0% versus control 0.9%, OR could not be calculated). Parents were asked to rate their child again at 36 months when the children exposed to VPA were rated to be at risk of poor sentence skills (VPA 15.8% versus 3.9%, OR 3.4, 95% CI 1.0 to 12.0, P &lt; 0.05) but not for difficulties with gross motor development (VPA 10.5% versus 3.3%, OR 3.4, 95% CI 0.8 to 14.9, P &gt; 0.05), fine motor development (VPA 5.6% versus control 5.6%, OR 1.7, 95% CI 1.7 0.2 to 13.1, P &gt; 0.05) or communication skills (VPA 10.5% versus 1.3%, OR 3.5, 95% CI 0.8 to 15.4, P &gt; 0.05). </p> </section> <section id="CD010236-sec-0123"> <h5 class="title">Dose of VPA</h5> <p>It was consistently reported that higher levels of VPA were associated with poorer levels of global neurodevelopment (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>). Most commonly, doses of 800 to 1000 mg daily were reportedly associated with increasing levels of risk. It was of note that the mean dose of VPA in the <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> study (mean dose 546.3 mg daily) was considerably below this level and may have accounted for the differences in findings between this study and the majority of other included studies. In addition to a relationship between dose and global cognitive abilities, the studies of <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a> and the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> group also demonstrated a dose relationship between higher VPA doses and poorer language skills. <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a> reported a relationship between dose of VPA and infant motor ability. However, not all studies replicated this association between dose and ability (<a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>). </p> </section> </section> <section id="CD010236-sec-0124"> <h4 class="title">AED versus AED comparisons across neurodevelopmental outcomes</h4> </section> <section id="CD010236-sec-0125"> <h4 class="title">CBZ versus VPA</h4> <p>A total of nine studies investigated the abilities of children exposed to CBZ and VPA (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>). </p> <section id="CD010236-sec-0126"> <h5 class="title">Developmental quotient (DQ)</h5> <p>Four studies were prospective and used the Bayley Scales of Infant and Toddler Development (<a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>). The pooled estimates suggested a higher mean score for CBZ (n = 210) compared to VPA (n = 160) but this was not statistically significant (MD 4.16, 95% CI ‐0.21 to 8.54, P = 0.06, I<sup>2</sup> = 5%) (<a href="./references#CD010236-fig-0055" title="">Analysis 17.1</a>). Only one identified study used the Griffiths Mental Development Scales (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>) and found a significantly poorer outcome for children exposed to VPA (n = 42) (mean 92, 95% CI 87 to 96, P = 0.028) in comparison to those exposed to CBZ (n = 48) (mean 98, 95% CI 94 to 103). </p> </section> <section id="CD010236-sec-0127"> <h5 class="title">Intellectual quotient (IQ)</h5> <p>Two prospective studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>) and three registry studies (<a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>) assessed IQ in children exposed to CBZ or VPA. The pooled estimate found a higher mean score for children exposed to CBZ (n = 191) in comparison to VPA exposed children (n = 112) (MD 8.69, 95% CI 5.51 to 11.87, P &lt; 0.00001, I<sup>2</sup> = 43%) (<a href="./references#CD010236-fig-0056" title="">Analysis 17.2</a>). </p> </section> <section id="CD010236-sec-0128"> <h5 class="title">Autistic spectrum disorders</h5> <p>Three studies investigated the prevalence of autistic spectrum disorder in children exposed to either CBZ or VPA (<a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>). In one study the presence of autistic and regressive behavioural features were reported for 2/13 (15.4%) of children exposed to VPA, with no such cases in the CBZ exposed children (<a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>). <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a> reported an increased prevalence of autistic spectrum disorders with VPA (4/50, 8%) in comparison to CBZ (0/50, 0%). In this study the diagnoses were made independent of the study team, through routine clinical services. An unpublished data set was provided (<a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>), which reported consistent data in the two studies above (VPA 8/58, 13.7% and CBZ 3/49, 6.1%, P value not available). Meta‐analysis was not carried out due to variations in the methodologies of these studies. </p> </section> <section id="CD010236-sec-0129"> <h5 class="title">Specific cognitive abilities</h5> <p>The meta‐analysis of VIQ was based on three studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>) as the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> did not report VIQ isolated from other language measures (<a href="./references#CD010236-fig-0057" title="">Analysis 17.3</a>). A significant MD of 8.44 (95% CI 4.21 to 12.66, P &lt; 0.00001, I<sup>2</sup> = 0%) was found favouring the VIQ outcome for children exposed to CBZ (n = 149) in comparison to those exposed to VPA (n = 77). Meta‐analysis using the same studies but regarding the PIQ abilities of children exposed to CBZ (n = 149) and VPA (n = 77) also found a significant MD of 10.48 (95% CI 6.02 to 14.94, P &lt; 0.00001, I<sup>2</sup> = 0%) with children exposed to CBZ performing better (<a href="./references#CD010236-fig-0058" title="">Analysis 17.4</a>). </p> <p>Due to heterogeneity in the investigation of specific cognitive abilities a meta‐analysis was not possible. </p> <p>At three years of age, the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> reported the specific cognitive abilities of children exposed to CBZ in comparison to children exposed to VPA on a verbal and non‐verbal index. The verbal index included a naming vocabulary task, a verbal comprehension task, an expressive communication task, an auditory comprehension task and a picture naming task. The children exposed to VPA (n = 43) were reported to have a significantly poorer verbal index than the children exposed to CBZ (n = 59) (CBZ mean 93.0, 95% CI 88.6 to 97.3 versus VPA mean 83.9, 95% CI 78.8 to 89.0, P value not reported). On the non‐verbal index, no significant difference was found between the CBZ exposed children and the VPA exposed children (CBZ mean 99.6, 95% CI 95.0 to 104.2 versus VPA mean 98.5, 95% CI 93.1 to 103.8, P value not reported). At six years of age, the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> noted significant differences between the memory (CBZ (n = 61) mean 104, 95% CI 100 to 108 versus VPA (n = 49) mean 92, 95% CI 87 to 98, P = 0.0010) and language (CBZ mean 104, 95% CI 102 to 107 versus VPA mean 97, 95% CI 94 to 100, P = 0.005) abilities of the children exposed to VPA, with non‐significant differences for CBZ exposed children in comparison to VPA exposed children for non‐verbal abilities (CBZ mean 104, 95% CI 102 to 107 versus VPA mean 101, 95% CI 98 to 104, P = 0.08) and executive abilities (CBZ mean 105, 95% CI 103 to 108 versus VPA mean 101, 95% CI 98 to 104, P = 0.11). </p> <p><a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>, assessed global language development in 23 VPA exposed children in comparison to 34 children exposed to CBZ. The number of children considered to have language delay varied (30.4% VPA exposed children versus 17.6% in the CBZ exposed children) but a significant difference was not found between the group means. </p> </section> <section id="CD010236-sec-0130"> <h5 class="title">CBZ versus VPA: prevalence of below average performance</h5> <p>A comparison of below average performance for children exposed to VPA and children exposed to CBZ, from three studies using the Bayley Scales of Infant and Toddler Development (DQ) (<a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>), found a non‐significant RR of 0.83 (95% CI 0.62 to 1.12, P = 0.22, I<sup>2</sup> = 0%). This was based on 152 VPA exposed children and 211 CBZ exposed children for performance 1 SD below the mean (<a href="./references#CD010236-fig-0059" title="">Analysis 17.5</a>). The pooled estimate for performance 2 SDs below the mean gave a non‐significant RR of 0.77 (95% CI 0.38 to 1.58, P = 0.47, I<sup>2</sup> = 17%) based on 81 VPA exposed children and 110 CBZ exposed children (<a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>) (<a href="./references#CD010236-fig-0060" title="">Analysis 17.6</a>). </p> <p>In older children whose abilities were measured by IQ the pooled estimate from three studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>) provided a statistically significant RR of 0.40 (95% CI 0.19 to 0.83, P = 0.01, I<sup>2</sup> = 0%) based on 91 CBZ exposed children and 87 VPA exposed children for prevalence of performance 1 SD from the mean, showing that VPA exposed children had a higher rate of below average performance (<a href="./references#CD010236-fig-0062" title="">Analysis 17.8</a>). The more severe level of IQ impairment (2 SDs from the mean) was reported by four studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>) with a non‐significant RR of 0.26 (95% CI 0.05 to 1.19, P = 0.08, I<sup>2</sup> = 0%) based on 177 CBZ exposed children and 100 VPA exposed children (<a href="./references#CD010236-fig-0061" title="">Analysis 17.7</a>). </p> </section> </section> <section id="CD010236-sec-0131"> <h4 class="title">CBZ versus LTG</h4> <p>Four studies investigated the abilities of both children exposed to CBZ and to LTG (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>). </p> <section id="CD010236-sec-0132"> <h5 class="title">Developmental quotient (DQ)</h5> <p>Two studies assessed the neurodevelopment of children exposed to either CBZ or LTG using the Bayley Scales of Infant and Toddler Development (<a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>). <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> reported child neurodevelopment scores on the Bayley Scales of Infant and Toddler Development in conjunction with scores collected on the Griffiths Mental Development Scales and therefore meta‐analysis was not possible. The <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> reported that the neurodevelopment of children exposed to CBZ (n = 43, mean 94, SD 15) was not significantly different from those exposed to LTG at two years of age (n = 57, mean 97, SD 17, P value not reported). </p> <p>Two studies measured infant neurodevelopment with the Griffiths Mental Development Scales (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>). <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> noted no significant difference between the children exposed to CBZ (n = 48, mean 98, 95% CI 94 to 103) and those exposed to LTG (n = 34, mean 99, 95% CI 94 to 103), however these data overlapped in part with the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>. </p> </section> <section id="CD010236-sec-0133"> <h5 class="title">Intellectual quotient (IQ)</h5> <p>Two studies assessed the IQ of children exposed to CBZ and LTG (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>). These studies overlapped in part and meta‐analysis was conducted utilising only the additional UK children who had not been reported as part of the NEAD study. Pooled estimates gave a non‐significant MD of ‐1.62 (95% CI ‐5.44 to 2.21, P = 0.41, I<sup>2</sup> = 0%) when comparing 78 children exposed to CBZ and 84 LTG exposed children from two studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>) (<a href="./references#CD010236-fig-0043" title="">Analysis 12.2</a>). </p> </section> <section id="CD010236-sec-0134"> <h5 class="title">Autistic spectrum disorders</h5> <p>No significant differences between the rates of autistic spectrum disorder were reported in the study by <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>. No cases (0%) were found in this study from 50 CBZ exposed children and 30 LTG exposed children at six years of age. Unpublished data provided by <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> reported a 6.1% prevalence (3/49) for CBZ in comparison to 0% prevalence for those exposed to LTG (0/35). </p> </section> <section id="CD010236-sec-0135"> <h5 class="title">Specific cognitive abilities</h5> <p>Only the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> assessed and reported on specific cognitive abilities of children exposed to CBZ and children exposed to LTG. A verbal index was created by the authors and included a naming vocabulary task, a verbal comprehension task, an expressive communication tasks, an auditory comprehension task and a picture naming task. At three years of age the children exposed to CBZ (n = 59) did not differ significantly from the children exposed to LTG (n = 70) on this verbal index (CBZ mean 93.0, 95% CI 88.6 to 97.3, P value not reported). A non‐verbal index was also created based on a block design task and a task of visual‐motor integration. The children exposed to CBZ did not differ from the children exposed to LTG on this non‐verbal index (CBZ mean 99.6, 95% CI 95.0 to 104.2 versus LTG mean 106.3, 95% CI 101.7 to 110.9, P value not reported). At six years of age a comprehensive assessment of a range of cognitive abilities was undertaken. No differences were found between the CBZ exposed children (n = 61) and the LTG exposed children (n = 74) on tasks of memory (CBZ (n = 61) mean 104, 95% CI 100 to 108 versus LTG (n = 74) mean 106, 95% CI 102 to 110, P value not reported), language (CBZ mean 104, 95% CI 102 to 107 versus LTG mean 105, 95% CI 102 to 107, P value not reported) and executive functioning (CBZ mean 105, 95% CI 103 to 108 versus LTG mean 107, 95% CI 104 to 109, P value not reported). </p> <p>Rates of language impairment were higher for children exposed to CBZ (n = 34, 17.6%) but were not significantly different from the rates in children exposed to LTG (n = 9, 0%); the numbers were small and the difference was not statistically significant in the study by <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>. </p> </section> <section id="CD010236-sec-0136"> <h5 class="title">CBZ versus LTG: prevalence of below average performance</h5> <p>The pooled estimate for DQ performance 1 SD below the mean demonstrated no significant difference in the frequency of performance in this range for children exposed to CBZ (n = 76) in comparison to children exposed to LTG (n = 83) (RR 2.28, 0.63 to 8.22, P = 0.21, I<sup>2</sup> = 0%) from two studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>) (<a href="./references#CD010236-fig-0044" title="">Analysis 12.3</a>). </p> </section> </section> <section id="CD010236-sec-0137"> <h4 class="title">CBZ versus PHT</h4> <section id="CD010236-sec-0138"> <h5 class="title">Developmental quotient (DQ)</h5> <p>Pooled results from four identified studies (<a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>) using the Bayley Scales of Infant and Toddler Development found a non‐significant MD of 3.02 (95% CI ‐2.41 to 8.46, P = 0.28, I<sup>2</sup> = 0%) for 172 CBZ exposed children in comparison to 87 PHT exposed children (<a href="./references#CD010236-fig-0045" title="">Analysis 13.1</a>). <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a> compared the development of 35 children exposed to CBZ (mean 618, 95% CI unclear) to 15 children exposed to PHT (mean 635, 95% CI unclear) and failed to find a significant difference for overall cognitive ability. </p> </section> <section id="CD010236-sec-0139"> <h5 class="title">Intellectual quotient (IQ)</h5> <p>A non‐significant MD was noted for CBZ (n = 75) in comparison to PHT (n = 45), with an MD of ‐3.30 (95% CI ‐7.91 to 1.30, P = 0.16, I<sup>2</sup> = 0%), with data coming from two studies (<a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>) (<a href="./references#CD010236-fig-0046" title="">Analysis 13.2</a>). </p> </section> <section id="CD010236-sec-0140"> <h5 class="title">Autistic spectrum disorders</h5> <p>No studies reported rates of autistic spectrum disorder in these two AED groups simultaneously.</p> </section> <section id="CD010236-sec-0141"> <h5 class="title">Specific cognitive abilities</h5> <p>The <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> assessed the verbal and non‐verbal cognitive abilities of children exposed to CBZ in comparison to those exposed to PHT. A verbal index was created by the authors which included a number of language tasks. At three years of age the tasks included in this index were a naming vocabulary task, a verbal comprehension task, an expressive communication tasks, an auditory comprehension task and a picture naming task. The children exposed to CBZ (n = 59) were not significantly different from the children exposed to PHT (n = 39) on this verbal index (CBZ mean 93.0, 95% CI 88.6 to 97.3 versus PHT mean 95.9, 95% CI 91.0 to 100.8, P value not reported). A non‐verbal index was created and included a block design task and a task of visuomotor integration. Consistently, the children exposed to CBZ did not differ from the PHT exposed children on the non‐verbal index (CBZ mean 99.6, 95% CI 95.0 to 104.2 versus PHT mean 102.0, 95% CI 96.9 to 107.2, P value not reported). Reassessment of this cohort at six years of age also found no significant differences between children exposed to CBZ and those exposed to PHT on measures of verbal, (CBZ (n = 61) mean 104, 95% CI 102 to 107 versus PHT (n = 40) mean 106, 95% CI 102 to 109), non‐verbal (CBZ mean 104, 95% CI 102 to 107 versus PHT mean 106, 95% CI 103 to 109), memory (CBZ mean 104, 95% CI 100 to 108 versus PHT mean 101, 95% CI 96 to 107) and executive functioning skills (CBZ mean 105, 95% CI 103 to 108 versus PHT 103, 95% CI 100 to 106) at six years of age. </p> <p>In a linked paper to <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>, increased rates of expressive language dysfunction in the children exposed to PHT (n = 26, 23%) were reported in comparison to CBZ exposed children (n = 28, 6.7%). <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a> found no significant differences between children exposed to CBZ (n = 35) and children exposed to PHT (n = 15) on tasks of motor (CBZ mean 104, 95% CI unclear versus PHT mean 98, 95% CI unclear, P &gt; 0.05), social (CBZ mean 107, 95% CI unclear versus PHT mean 105, 95% CI unclear, P &gt; 0.05), language (CBZ mean 105, 95% CI unclear versus PHT mean 111, 95% CI unclear, P &gt; 0.05), hand and eye co‐ordination (CBZ mean 100 95% CI unclear versus PHT mean 101, 95% CI unclear, P &gt; 0.05) and practical reasoning ability (CBZ mean 101, 95% CI unclear versus PHT mean 110, 95% CI unclear, P &gt; 0.05). </p> </section> <section id="CD010236-sec-0142"> <h5 class="title">CBZ versus PHT: prevalence of below average performance</h5> <p>The prevalence of children exposed to CBZ falling below 1 SD from the mean was not significantly increased compared to PHT exposed infants (RR 0.78, 95% CI 0.52 to 1.15, P = 0.21, I<sup>2</sup> = 0%) based on 149 CBZ and 149 PHT exposed children (<a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>) (<a href="./references#CD010236-fig-0047" title="">Analysis 13.3</a>). </p> </section> </section> <section id="CD010236-sec-0143"> <h4 class="title">VPA versus LTG</h4> <p>Four studies were identified that made comparisons between children exposed to VPA and LTG (<a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a>). </p> <section id="CD010236-sec-0144"> <h5 class="title">Developmental quotient (DQ)</h5> <p>The <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> reported a significant difference between children exposed to VPA (n = 28, mean 85, SD 19) and those exposed to LTG (n = 57, mean 97, SD 17) when neurodevelopment was assessed using the Bayley Scales of Infant and Toddler Development. </p> <p><a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>, used both the Bayley and Griffiths Scales and found differing levels of below average performance for those exposed to VPA (39.6%) and those exposed to LTG (2.9%); however, the data were not in a format in which they could be utilised in a meta‐analysis. </p> </section> <section id="CD010236-sec-0145"> <h5 class="title">Intellectual quotient (IQ)</h5> <p>At six years of age, the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> found that children exposed to VPA (n = 49, mean 98, SD 10) had significantly poorer scores compared to children exposed to LTG (n = 74, mean 108, SD 13). The pooled estimate from the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> and <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>, in six year old children, produced a significant MD of ‐10.79 (95% CI ‐14.41 to ‐7.17, P &lt; 0.00001, I<sup>2</sup> = 0%) for 74 VPA exposed children in comparison to 84 LTG exposed children (<a href="./references#CD010236-fig-0049" title="">Analysis 14.2</a>). </p> <p><a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> also assessed the IQ of children exposed to VPA and children exposed to LTG, however their study included women taking these medications for indications other than epilepsy and therefore this data was not included in the meta‐analysis. In contrast to the data reported from the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>, <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> and the meta‐analysis, <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> failed to find a significant difference between the IQ of children exposed to VPA (n = 29) and those exposed to LTG (n = 41). </p> </section> <section id="CD010236-sec-0146"> <h5 class="title">Autistic spectrum disorders</h5> <p>Two identified studies, one published (<a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>) and one with unpublished data (<a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>), reported rates of community diagnoses of autistic spectrum disorders for children exposed to VPA or LTG. In the study by <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a> no diagnoses of autistic spectrum disorder were reported for the LTG exposed group (n = 30) whilst the prevalence in the VPA exposed group was 8% (4/50). Consistently, there were no cases of autistic spectrum disorder in the group exposed to LTG (n = 35) with the VPA group prevalence at 13.7% (8/58) in the study of <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>. </p> </section> <section id="CD010236-sec-0147"> <h5 class="title">Specific cognitive abilities</h5> <p>The <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> undertook a comprehensive assessment of specific cognitive abilities at both three and six years of age. A verbal index was created by the authors which included a number of language tasks. At three years of age the tasks included in this index were a naming vocabulary task, a verbal comprehension task, an expressive communication task, an auditory comprehension task and a picture naming task. The children exposed to VPA (n = 43) had significantly poorer scores on the verbal index (VPA mean 83.9, 95% CI 78.8 to 89.0 versus LTG mean 96.6, 95% CI 92.3 to 100.9, P &lt; 0.0001) in comparison to the children exposed to LTG (n = 70). The non‐verbal index included a block building task and a visuomotor integration task and the children exposed to VPA again had poorer scores than the children exposed to LTG (VPA mean 98.5, 95% CI 93.1 to 103.8 versus LTG mean 106.3, 95% CI 101.7 to 110.9, P value not reported). At this age the magnitude of the difference in verbal abilities (MD 12.7) of the VPA exposed children was more than the non‐verbal abilities (MD 7.8 points) when compared to the LTG group. In <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>, the verbal, non‐verbal, memory and executive functioning abilities of children exposed to VPA or LTG were analysed at six years of age. Children exposed to VPA (n = 49) had significantly poorer scores than children exposed to LTG (n = 74) on verbal (VPA mean 97, 95% CI 94 to 100 versus LTG mean 105, 95% CI 102 to 107, P = 0.003), non‐verbal (VPA mean 101, 95% CI 98 to 104 versus LTG mean 108, 95% CI 105 to 110, P = 0.0015), memory (VPA mean 92, 95% CI 87 to 98 versus LTG mean 106, 95% CI 102 to 110, P = 0.003) and executive functioning (VPA 101, 95% CI 98 to 104 versus LTG mean 107, 95% CI 104 to 109, P = 0.0078) skills. </p> <p><a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a> reported significantly poorer language abilities in children exposed to VPA (n = 23) in comparison to LTG (n = 9) (VPA 30.4% versus LTG 0%, P = 0.025). </p> <p><a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> failed to find a significant difference between the children exposed to VPA (n = 29) and those exposed to LTG (n = 42) on tasks of visuomotor integration (VPA mean 42.55, SD 27.68 versus LTG mean 53.86, SD 25.54, P &gt; 0.05), visual perception (VPA mean 49.03, SD 31.42 versus LTG mean 42.76, SD 31.85, P &gt; 0.05), motor co‐ordination (VPA mean 25.54, SD 26.54 versus LTG mean 31.18, SD 28.62, P &gt; 0.05), fine motor abilities (VPA mean 24.57, SD 18.74 versus LTG mean 30.57, SD 22.90, P &gt; 0.05) or gross motor ability (VPA mean 31.30, SD 24.18 versus LTG mean 34.78, SD 24.47, P &gt; 0.05) but did not assess language development. </p> </section> <section id="CD010236-sec-0148"> <h5 class="title">VPA versus LTG: prevalence of below average performance</h5> <p>The pooled estimate based on two studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>) gave a significant RR of 4.87 (95% CI 1.50, 15.78, P = 0.008, I<sup>2</sup> = 0%) for performance below 1 SD of the mean based on 74 VPA exposed children and 83 LTG exposed children (<a href="./references#CD010236-fig-0050" title="">Analysis 14.3</a>). Children exposed to VPA were therefore found to be at a higher risk of below average performance. </p> </section> </section> <section id="CD010236-sec-0149"> <h4 class="title">VPA versus LEV</h4> <p>Only a single study was identified comparing the neurodevelopment of children exposed to VPA in comparison to LEV (<a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>). Comparisons were made at under two years of age and again at between three and four years of age. However, only 32% of the LEV exposed children and 11% of the VPA exposed children were reassessed at the older age and the remaining proportion of the cohort were newly recruited. </p> <section id="CD010236-sec-0150"> <h5 class="title">Developmental quotient (DQ)</h5> <p>Using the Griffiths Mental Development Scales, <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> found that children exposed to VPA (n = 44) (mean 87.9, 95% CI 83 to 93, P &lt; 0.001) had a significantly poorer level of global cognitive development in comparison to those exposed to LEV (n = 51) (mean 99.9, 95% CI 97 to 103). </p> </section> <section id="CD010236-sec-0151"> <h5 class="title">Intellectual quotient (IQ)</h5> <p>No studies were identified.</p> </section> <section id="CD010236-sec-0152"> <h5 class="title">Autistic spectrum disorders</h5> <p>No studies were identified.</p> </section> <section id="CD010236-sec-0153"> <h5 class="title">Specific cognitive abilities</h5> <p>In the paper by <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> children exposed to VPA had significantly poorer scores in comparison to LEV exposed children under the age of two years on motor tasks (VPA (n = 44) mean 84.6, 95% CI 79 to 91 versus LEV (n = 51) mean 97.3, 95% CI 94 to 98, P &lt; 0.001), hand and eye co‐ordination (VPA mean 88.2, 95% CI 82 to 94 versus LEV mean 101.8, 95% CI 97 to 106, P = 0.01), non‐verbal skills (VPA mean 88.8, 95% CI 83 to 94 versus LEV mean 101.7, 95% CI 98 to 105, P &lt; 0.001), language (VPA mean 90.4, 95% CI 84 to 97 versus LEV mean 100.5, 95% CI 96 to 104, P = 0.01) and social skills (VPA mean 98.8, 95% CI 84 to 96 versus LEV 98, 95% CI 94 to 102, P = 0.03). Following assessment at between three and four years of age the children exposed to LEV performed significantly better than the children exposed to VPA on tasks of motor development (LEV mean 110.4, SD 17.2 versus VPA mean 96.8, SD 22.1, P = 0.002) and expressive language development (LEV mean 52.0, SD 13.4 versus VPA mean 43.1, SD 15, P = 0.005). No significant differences were found between the LEV exposed and VPA exposed children on social development (LEV mean 116.5, SD 19.1 versus VPA mean 108.4, SD 21.4, P = 0.2), hand and eye co‐ordination skills (LEV mean 104.8, SD 13.9 versus VPA mean 102.1, SD 17.7, P = 0.8), non‐verbal performance skills (LEV mean 109.9, SD 15.4 versus VPA mean 11.4, SD 23.1, P = 0.6), practical reasoning (LEV mean 113.4, SD 16.6 versus VPA mean 108.9, SD 18.8, P = 0.2) and language comprehension ability (LEV mean 49.6, SD 10.3 versus VPA mean 44.0, SD 16.1, P = 0.2) at this older age point. </p> </section> </section> <section id="CD010236-sec-0154"> <h4 class="title">PHT versus VPA</h4> <p>Four studies investigated the cognitive abilities of children exposed to VPA and PHT (<a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>). </p> <section id="CD010236-sec-0155"> <h5 class="title">Developmental quotient (DQ)</h5> <p>Pooled estimates from the three studies using the Bayley Scales of Infant and Toddler Development (<a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>) found a significant MD of 7.04 (95% CI 0.44 to 13.65, P = 0.04, I<sup>2</sup> = 0%), when 80 children exposed to PHT were compared to 108 VPA exposed children. VPA exposed children were found to have significantly poorer early development (<a href="./references#CD010236-fig-0052" title="">Analysis 16.1</a>). </p> </section> <section id="CD010236-sec-0156"> <h5 class="title">Intellectual quotient (IQ)</h5> <p>In school aged children, pooled estimates from two studies (<a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>) measuring IQ demonstrated a significant MD of 9.25 (95% CI 4.78 to 13.72, P &lt; 0.0001, I<sup>2</sup> = 70%), with children exposed to PHT (n = 45) having significantly higher scores than children exposed to VPA (n = 61) (<a href="./references#CD010236-fig-0053" title="">Analysis 16.2</a>). A random‐effects model analysis was carried out for this comparison, due to high heterogeneity, which gave an MD of 6.38 (95% CI ‐4.84 to 17.58, P = 0.27) and the overall estimate became non‐significant. </p> </section> <section id="CD010236-sec-0157"> <h5 class="title">Autistic spectrum disorders</h5> <p>No studies investigated this outcome.</p> </section> <section id="CD010236-sec-0158"> <h5 class="title">Specific cognitive abilities</h5> <p>In children aged three years of age the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> reported a significantly poorer verbal ability (as measured by a composite index including a range of language based tasks) for the children exposed to VPA (n = 43) in comparison to those exposed to PHT (n = 39) (VPA mean 83.9, 95% CI 78.8 to 89.0 versus PHT mean 95.9, 95% CI 91.0 to 100.8, P value not reported). In comparison, no significant difference was found between the children exposed to VPA versus those exposed to PHT for their non‐verbal ability (as measured by a non‐verbal index created by the authors) (VPA mean 98.5, 95% CI 93.1 to 103.8 versus PHT mean 102.0, 95% CI 101.7 to 110.9, P value not reported). In the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>, at six years of age the abilities of children exposed to PHT were found to be superior to those of children exposed to VPA on verbal (PHT (n = 40) mean 106, 95% CI 102 to 109 versus VPA (n = 49) mean 97, 95% CI 94 to 100, P = 0.0005) and memory ability (PHT mean 101, 95% CI 96 to 107 versus VPA mean 92, 95% CI 87 to 98, P = 0.0260) at six years of age. There was no significant difference however in non‐verbal abilities (PHT mean 106, 95% CI 103 to 109 versus VPA mean 101, 95% CI 98 to 104, P = 0.0514) and executive functioning skills (PHT mean 103, 95% CI 100 to 106 versus VPA mean 101, 95% CI 98 to 104, P = 0.28) (<a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>). </p> </section> <section id="CD010236-sec-0159"> <h5 class="title">VPA versus PHT: prevalence of below average performance</h5> <p>A non‐significant RR was demonstrated for VPA exposed children (n = 120) in comparison to PHT exposed children (n = 71) (RR 1.40, 95% CI 0.91 to 2.15, P = 0.12, I<sup>2</sup> = 78%) for the prevalence of performance 1 SD below the mean (<a href="./references#CD010236-fig-0054" title="">Analysis 16.3</a>) (<a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>). Caution is required however, as the findings of these two studies were in the opposite direction, which led to the high I<sup>2</sup> statistic. </p> </section> </section> <section id="CD010236-sec-0160"> <h4 class="title"><i>Sensitivity analysis</i> </h4> <p>There were 44 meta‐analyses that included two or more studies for which heterogeneity could be assessed. There were 34 meta‐analyses containing continuous data measured as the MD. Of these, the I<sup>2</sup> was less than 25% in 23 analyses, and 0% in 19 of the analyses. There were three meta‐analyses with an I<sup>2</sup> statistic in the range 25% to 50%, seven between 50% and 75%, and one over 75%. Nine meta‐analyses were undertaken on binary data using the RR to investigate the prevalence of below average DQ or IQ. Of these, eight had an I<sup>2</sup> statistic less than 25%, all eight were 0%. The remaining I<sup>2</sup> statistic was high at 78%. The percentage of DQ and IQ meta‐analyses with I<sup>2</sup> statistics under 25% were roughly comparable (63% for DQ and 69% for IQ). Due to the limited data it was not possible to fully explore the heterogeneity. However, the plots were visually inspected and random‐effects model analyses were undertaken, which provided similar results and conclusions in all but three cases (see <a href="#CD010236-tbl-0004">Table 4</a>). </p> <div class="table" id="CD010236-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Fixed and random effects analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No. studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Effect measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fixed‐effect result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Heterogeneity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Random‐effects result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Conclusion change?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AED</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control/Another AED</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi<sup>2*</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women without epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bayley</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.58 (‐10.83 to ‐0.34), P=0.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.35 (‐14.04 to 5.34), P=0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Changed to non‐significant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women without epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VIQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.81 (‐4.94 to 1.33) P=0.026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.84 (‐8.01 to 4.34), P=0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No change</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women with epilepsy, no AED treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bayley</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7.22 (‐12.76 to ‐1.67), P=0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.60 (‐15.40 to 4.20), P=0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Changed to non‐significant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women without epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.94 (‐11.96 to ‐5.92), P&lt;0.00001</p> <p>‐11.42 (‐14.68 to ‐8.15), P&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88%</p> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.003</p> <p>P=0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.28 (‐15.54 to 4.97), P=0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Changed to non‐significant</p> <p>Changed to significant with the removal of Thomas 2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women without epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PIQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10.48 (‐13.94 to ‐7.02), P&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.11 (‐19.66 to ‐4.55), P=0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No change</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.25 (4.78 to 13.72), P&lt;0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.38 (‐4.84 to 17.58), P=0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Changed to non‐significant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA mono</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA polytherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.96 (‐2.68 to 6.61), P=0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.67 (‐5.46 to 12.80), P=0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No change</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Chi<sup>2</sup> is significant at 0.1 </p> </div> </div> </section> <section id="CD010236-sec-0161"> <h4 class="title">Studies which met inclusion criteria, results not reported</h4> <p>A number of studies met the inclusion criteria for the review but due to one or more issues with reporting they were not included in the results section (<a href="./references#CD010236-bbs2-0005" title="D'SouzaS , RobertsonI , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1990;65:320-4. ">D'Souza 1991</a>; <a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>; <a href="./references#CD010236-bbs2-0010" title="HansonJ , MyrianthopoulosN , HarveyM , SmithD . Risks to offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Journal of Pediatrics1976;89(4):662-8. ">Hanson 1976</a>; <a href="./references#CD010236-bbs2-0011" title="HillR , VerniaudW , HorningM , McCulleyL , MorganN . Infants exposed in utero to antiepileptic drugs: A prospective study. American Journal of Diseases in Childhood1974;127:645-53. HillR , VerniaudW , RettigG , TennysonL , CraigJ . Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz et al, editors(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:409-17. ">Hill 1974</a>; <a href="./references#CD010236-bbs2-0012" title="FujiokaK , KanekoS , Hirano T et al. A study of the psychomotor development of the offspring of epileptic mothers. 1984. HiranoT , FujiokaK , OkadaM , IwasaH , KanekoS . Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia2004;45 Suppl 8:53-7. NomuraY , TakebeY , NomuraY , ShinagawaS , KanekoS , SatoT . The physical and mental development of infants born to mothers treated with antiepileptic drugs. 1984. ">Hirano 2004</a>; <a href="./references#CD010236-bbs2-0014" title="JonesK , LacroR , JohnsonK , AdamsJ . Patern of malformations in the children of women treated with carbamazepine during pregnancy. The New England Journal of Medicine1989;320(25):1661-6. ">Jones 1989</a>; <a href="./references#CD010236-bbs2-0019" title="RegestaT . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana Epilessia1996;95(96):351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: An Itialian prospective controlled study. Neurology1992;42 Suppl 5:89-93. ">Regesta 1996</a>; <a href="./references#CD010236-bbs2-0024" title="SobczykW , DowzenkoA , KrasickaJ . Investigation of children of mothers treated in pregnancy with anticonvulsants. Neurologia i Neurochirurgia Polska1977;11(1):59-63. ">Sobczyz 1977</a>). The failure to report mean scores or percentages below average scores occurred in two studies (<a href="./references#CD010236-bbs2-0005" title="D'SouzaS , RobertsonI , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1990;65:320-4. ">D'Souza 1991</a>; <a href="./references#CD010236-bbs2-0024" title="SobczykW , DowzenkoA , KrasickaJ . Investigation of children of mothers treated in pregnancy with anticonvulsants. Neurologia i Neurochirurgia Polska1977;11(1):59-63. ">Sobczyz 1977</a>) with the others not reporting exposure types separately (<a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>; <a href="./references#CD010236-bbs2-0011" title="HillR , VerniaudW , HorningM , McCulleyL , MorganN . Infants exposed in utero to antiepileptic drugs: A prospective study. American Journal of Diseases in Childhood1974;127:645-53. HillR , VerniaudW , RettigG , TennysonL , CraigJ . Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz et al, editors(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:409-17. ">Hill 1974</a>; <a href="./references#CD010236-bbs2-0012" title="FujiokaK , KanekoS , Hirano T et al. A study of the psychomotor development of the offspring of epileptic mothers. 1984. HiranoT , FujiokaK , OkadaM , IwasaH , KanekoS . Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia2004;45 Suppl 8:53-7. NomuraY , TakebeY , NomuraY , ShinagawaS , KanekoS , SatoT . The physical and mental development of infants born to mothers treated with antiepileptic drugs. 1984. ">Hirano 2004</a>; <a href="./references#CD010236-bbs2-0019" title="RegestaT . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana Epilessia1996;95(96):351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: An Itialian prospective controlled study. Neurology1992;42 Suppl 5:89-93. ">Regesta 1996</a>). Some studies did not differentiate between exposure types even at the monotherapy versus polytherapy level (<a href="./references#CD010236-bbs2-0001" title="ArulmozhiT , DhanarajM , RangarajR , VengatesanA . Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India2006;54(1):42-6. ">Arulmozhi 2006</a>; <a href="./references#CD010236-bbs2-0007" title="GailyE , Kantola-SorsaE , GranstromM . Intelligence of children of epileptic mothers. The Journal of Pediatrics1988;113(4):677-84. GailyE , Kantola-SorsaE , GranstromM . Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology1990;32:403-14. GranstromM . In: Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982 edition. New York: Raven Press. ">FINNISH Study</a>; <a href="./references#CD010236-bbs2-0010" title="HansonJ , MyrianthopoulosN , HarveyM , SmithD . Risks to offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Journal of Pediatrics1976;89(4):662-8. ">Hanson 1976</a>; <a href="./references#CD010236-bbs2-0014" title="JonesK , LacroR , JohnsonK , AdamsJ . Patern of malformations in the children of women treated with carbamazepine during pregnancy. The New England Journal of Medicine1989;320(25):1661-6. ">Jones 1989</a>; <a href="./references#CD010236-bbs2-0019" title="RegestaT . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana Epilessia1996;95(96):351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: An Itialian prospective controlled study. Neurology1992;42 Suppl 5:89-93. ">Regesta 1996</a>; <a href="./references#CD010236-bbs2-0024" title="SobczykW , DowzenkoA , KrasickaJ . Investigation of children of mothers treated in pregnancy with anticonvulsants. Neurologia i Neurochirurgia Polska1977;11(1):59-63. ">Sobczyz 1977</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010236-sec-0162" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010236-sec-0162"></div> <section id="CD010236-sec-0163"> <h3 class="title" id="CD010236-sec-0163">Summary of main results</h3> <section id="CD010236-sec-0164"> <h4 class="title">Carbamazepine (CBZ)</h4> <p>The most commonly investigated AED was CBZ, both in terms of the frequency of investigations and the total number of children. The pooled estimates from meta‐analyses found that the DQ was poorer for young children exposed to CBZ in comparison to both control group types. However, there were high levels of heterogeneity for both comparisons and sensitivity analysis using a random‐effects model altered the effect estimates so that they became non‐significant, suggesting that the significant finding was linked to the variability within study methodologies. Two relatively large observational studies with better quality ratings also consistently failed to find a significant difference between children exposed to CBZ and control children when they were assessed using the Griffiths Mental Development Scales (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; Wide 2002). In contrast, the data from <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> were not included in the meta‐analysis but reported poorer early neurodevelopment for children exposed to CBZ. </p> <p>Data from school aged children that was collected with IQ measures failed to find a significant difference between children exposed to CBZ and control children. Children exposed to CBZ were not found to differ from control children in terms of either their VIQ or PIQ. Limited evidence was available for specific cognitive abilities, however two studies of pre‐school children and one with school aged children failed to find a significant association between language development and exposure to CBZ. There was little evidence from the studies reviewed here that children exposed to CBZ may be at an increased risk for autistic spectrum disorders; although there is not an adequate level of evidence to refute this. However, the large record linkage study by <a href="./references#CD010236-bbs2-0074" title="ChristensenJ , GronborgTK , SorensenMJ , SchendelD , ParnerET , PedersenLH , VestergaardM . Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA2013;309(16):1696-703.">Christensen 2013</a> failed to find an association between exposure to CBZ and an increased rate of diagnoses of autistic spectrum disorder. </p> <p>When compared to children exposed to other AEDs, younger children exposed to CBZ did not perform significantly differently from children exposed to VPA, LTG or PHT. When older children were assessed with an IQ measure, children exposed to CBZ had significantly higher IQ scores than children exposed to VPA and comparable levels to children exposed to PHT and LTG. </p> <p>Increased dose of CBZ is reportedly associated with an elevated risk of major congential malformation (<a href="./references#CD010236-bbs2-0107" title="TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , Sabers A et al. Dose-dependent risk of malformation with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17.">Tomson 2011</a>). Six studies investigated the relationship between dose of CBZ and child cognitive outcome and all failed to demonstrate a significant association between increasing doses and reduced child global cognitive ability. </p> <p>It should be noted that the findings of this meta‐analyses are in contradiction to those reported in the review by <a href="./references#CD010236-bbs2-0065" title="BanachR , BoskovicR , EinarsonT , KorenG . Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs. A meta-analysis of cohort studies. Drug Safety2010;33(1):73-9.">Banach 2010</a>, who reported, based on more heterogeneous data, that children exposed to CBZ are at an increased risk of poorer PIQ. Our review differed from that of Banach and colleagues due to the inclusion of only prospectively ascertained cohorts and including data from cohorts which uniformly were children born to women with epilepsy. </p> </section> <section id="CD010236-sec-0165"> <h4 class="title">Valproate (VPA)</h4> <p>Since the early case reports pertaining to prenatal exposure to VPA there have been frequent reports of neurodevelopmental deficits (for example <a href="./references#CD010236-bbs2-0061" title="AdabN , Tudur SmithC , VintenJ , WilliamsonPR , WinterbottomJB . Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004848]">Adab 2004</a>; <a href="./references#CD010236-bbs2-0063" title="ArdingerH , AtkinJ , BlackstonR , ElsasL , ClarrenS , Livingstone S et al. Verification of the fetal valproate syndrome phenotype. American Journal of Medical Genetics1988;29(1):171-85.">Ardinger 1988</a>; <a href="./references#CD010236-bbs2-0073" title="ChevallierB , NegreV , BidatE , LagardereB . Fetal valproate syndrome and somatic and psychomotor development. Archives Francaises Pediatrie1989;46:627-30.">Chevallier 1989</a>; <a href="./references#CD010236-bbs2-0031" title="DeanJ , HaileyH , MooreS , LloydD , TurnpennyP , LittleJ . Long term and health and neurodevelopment in children exposed to antiepileptic drugs before birth. Journal of Medical Genetics2002;36:251-9. ">Dean 2002</a>; <a href="./references#CD010236-bbs2-0099" title="MooreSJ , Turnpenny, PD, QuinnA , GloverS , LloydDJ , Montgomery T et al. A clinical study of 57 children with fetal anticonvulsant syndromes. Journal of Medical Genetics2000;37:489-97.">Moore 2000</a>). Consistent with this, poorer cognitive abilities for children exposed to VPA were reported by all included studies with just three exceptions (<a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>; <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a>). The outcome of the meta‐analyses reported here are consistent with that of <a href="./references#CD010236-bbs2-0065" title="BanachR , BoskovicR , EinarsonT , KorenG . Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs. A meta-analysis of cohort studies. Drug Safety2010;33(1):73-9.">Banach 2010</a> and suggest an increasing body of evidence reporting an association between VPA exposure and poorer child neurodevelopment. Of note, in one of the meta‐analyses including VPA (VPA versus women without epilepsy on IQ) the I<sup>2</sup> statistic was above 75%. This was due to the inclusion of the data (n = 12) from <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a>, which was in contrast to the other larger included studies. Removal of these data reduced the I<sup>2</sup> statistic to 2% and the significance remained unchanged, therefore this comparison remains consistent with other evidence. </p> <p>In our meta‐analyses VPA exposure was associated with significantly lower DQs and IQs in comparison with control children, with the MD ranging from eight to nine DQ or IQ points lower. The DQ and IQ are continuously measured skills with a normal distribution and therefore a mean group reduction of eight to nine points would cause a shift to the left in the normal distribution curve. This would lead to a decrease in the number of children falling within the above average range and an increase in the rate of children falling below the average range. Interestingly, the prevalence of below average performance at 1 SD level was significantly increased in comparison with children born to women with untreated epilepsy, with an RR of 10.33. Meta‐analysis for the prevalence of below average performance compared with general population control children was not possible, however the studies of <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> and <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> demonstrated an increased rate of below average performance for the VPA exposed children in comparison to this control group population. Data on the number of children falling 2 SD below the mean did not reach significance, which may be accounted for by a lack of power to detect such a rare outcome. </p> <p>In comparisons with children exposed to other AEDs, children exposed to VPA did not have significantly poorer scores for global cognitive ability than those exposed to CBZ when the outcome was measured in younger children as the DQ. However, a significant difference in IQ ability is reported by the individual studies included here with the pooled estimate from the meta‐analysis demonstrating an eight point lower mean for children exposed to VPA, a figure which was comparable to the poorer outcome for VPA exposed children compared to control children. In a comparison with children exposed to LTG, more limited data suggest that children exposed to VPA have a group mean 10 points lower than for children exposed to LTG, and between seven and nine points lower for DQ and IQ respectively in comparison to children exposed to PHT. It is of note, however, that the pooled estimate for VPA versus PHT was not significant in the random‐effects model analysis which was undertaken due to high levels of heterogeneity. </p> <p>A consistent finding across comparisons with control groups and other AED exposed groups is a poorer neurodevelopmental outcome for children exposed to VPA. In context, a mean reduction of 8 to 10 IQ points is a substantial decrease when it is considered that the standard deviation for the normative sample is 15 points. Research in typically developing children links IQ test performance to educational outcome. A longitudinal study of 70,000 pupils in the UK demonstrated that 58% of children falling within the average range for their IQ obtained five or more General Certificate of General Education subjects (GCSEs) at A* to C level in comparison to just 16% of children whose IQ was within the below average range (<a href="./references#CD010236-bbs2-0079" title="DearyIJ , StranS , SmithP , FernandesC . Intelligence and educational achievement. Intelligence2007;35:13-21.">Deary 2007</a>). The poorer levels of IQ observed for groups of children exposed to VPA is therefore likely to convey real life implications for educational attainment. Interestingly, poorer educational abilities have been reported for children exposed to VPA in retrospective cohorts (<a href="./references#CD010236-bbs2-0060" title="AdabN , JacobyA , SmithD , ChadwickD . Additional educational needs in children born to mothers with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry2001;70(1):15-21.">Adab 2001</a>; <a href="./references#CD010236-bbs2-0062" title="AdabN , KiniU , VintenJ , AyresJ , BakerG , Clayton-Smith J et al. The longer term outcome of children born to mothers with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry2004;75(11):1575-83.">Adab 2004b</a>) strengthening this conclusion regarding real life implications. </p> <p>Investigations into the abilities of children in specific cognitive domains was more limited. In younger children there was evidence of poorer motor and language development (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>). Previous research has suggested a particular vulnerability of verbal skills in comparison to non‐verbal skills (<a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>), but our meta‐analysis demonstrated that VIQ and PIQ were significantly lower than in both control groups, with comparable MDs, and therefore does not support a specific vulnerability limited to the verbal domain. </p> <p>An increased prevalence of autistic spectrum disorders has been reported in three studies, with prevalence estimates ranging from 8% to 15% (<a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>). Cases were limited within the population, due to the relatively rarity of this condition. However, a recent large study utilising electronic healthcare data has also found a significant risk of autistic spectrum disorder associated with VPA (absolute risk of 4.42%, 95% CI, 2.59 to 7.46) based on 508 children exposed to VPA (<a href="./references#CD010236-bbs2-0074" title="ChristensenJ , GronborgTK , SorensenMJ , SchendelD , ParnerET , PedersenLH , VestergaardM . Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA2013;309(16):1696-703.">Christensen 2013</a>). Retrospective data sets not included in this review have also found increased prevalence rates for autistic spectrum diagnoses, ranging from 3% to 9% (<a href="./references#CD010236-bbs2-0062" title="AdabN , KiniU , VintenJ , AyresJ , BakerG , Clayton-Smith J et al. The longer term outcome of children born to mothers with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry2004;75(11):1575-83.">Adab 2004b</a>; <a href="./references#CD010236-bbs2-0102" title="RasalamAD , HaileyH , WilliamsJH , MooreSJ , TurnpennyPD , Lloyd DJ et al. Charateristics of fetal anticonvulsant syndrome associated autistic disorder. Developmental Medicine and Child Neurology2005;47(8):551-5.">Rasalam 2005</a>). Finally, there is evidence from animal models that early exposure to VPA is associated with autistic type behavioural presentations (<a href="./references#CD010236-bbs2-0064" title="ArndtTL , StodgellCJ , RodierPM . The teratology of autism. International Journal of Developmental Neuroscience2005;23(2-3):189-99.">Ardnt 2005</a>). </p> <p>The majority of studies investigating the relevance of the dose of VPA reported a significant correlation between dose and child IQ, with the majority of studies reporting an increase in risk at doses above 800 to 1000 mg, which is consistent with earlier reports from a large retrospective study (<a href="./references#CD010236-bbs2-0062" title="AdabN , KiniU , VintenJ , AyresJ , BakerG , Clayton-Smith J et al. The longer term outcome of children born to mothers with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry2004;75(11):1575-83.">Adab 2004b</a>). The study by <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> used a substantially lower mean daily dose (546.3 mg daily) than the other included studies, which at least in part is likely to be due to the inclusion of women taking VPA for indications other than epilepsy. It is likely that this lower dose accounts for the patchy level of association between the different cognitive outcomes and VPA exposure that were seen in this paper. In addition to a reported relationship between dose of VPA and IQ, <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a> and the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> group reported a significant association between the dose of VPA and language abilities, with higher doses associated with lower language functioning scores. </p> <p>In meta‐analysis the influence of other variables is not taken into consideration. For the data included in the meta‐analyses in this review, the studies of <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> and <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> were rated as having a low risk of bias because of their statistical control over the a priori identified important confounding factors; the studies by <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a> and <a href="./references#CD010236-bbs2-0009" title="HattigH , HelgeH , SteinhausenHC . Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16. New York: Raven Press, 1987. HattigH , SteinhausenHC . Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987. Jager RomanS , FatingD , Koch et al. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32. KochS , Jager-RomanE , LoscheG , NauH , RatingD , HelgeH . Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica1996;84:739-46. KochS , TitzeK , ZimmermanR , SchroderM , LehmkuhlU , RauhH . Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia1999;40(9):1237-43. LoscheG , SteinhausenHC , KochS , HelgeH . The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica1994;83:961-6. RatingD , NauH , Jager-RomanE , Gopfert-GeyerI , KockS , Beck-Mannagetta G et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica1982;71(2):301-11. SteinhausenHC , LoscheG , KockS , HelgeH . The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica1994;83:955-60. TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , SteinhausenHC . Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50:117-22. ">GERMAN Study</a> adjusted for certain but not all identified key confounding variables. The studies by <a href="./references#CD010236-bbs2-0006" title="ErikssonK , ViinikainenK , MonkkonenA , AikiaM , NieminenP , Heinonen et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research2005;65:189-200. ViinikainenK . The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior2006;9:636-40. ">Eriksson 2005</a>, <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a>, <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a> and <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a> were given high bias ratings due to their failure to measure and adjust for maternal and paternal IQs. For the studies reviewed in relation to VPA outcomes but not entered into the meta‐analysis, four out of six studies were rated as having a low risk of bias in relation to dealing with potential confounding variables (<a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a>; <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>). Therefore, the majority of evidence provided in this review in relation to VPA made important adjustments to limit the impact of potential confounding variables. There is, however, a frequently raised concern pertaining to confounding by indication in that VPA is most frequently prescribed for idiopathic generalised epilepsies. Therefore, a possible drug association is never looked for outside of the potential influence of the presence of maternal idiopathic generalised epilepsy. Whilst this is the case, certain studies have made attempts to analyse the neurodevelopmental outcomes of children born to women with idiopathic generalised epilepsy in isolation, comparing VPA treated and non‐VPA treated groups. The most prominent example is the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>. This study demonstrates that within the group of children born to mothers with idiopathic generalised epilepsy, the mean IQ at six years was 12 points lower than for those children exposed to other AEDs, a level comparable to the discrepancies reported for the VPA group as a whole in comparison to the other AEDs. A further consideration is the wealth of data from animal models, which requires caution but highlights that in the absence of any form of maternal epilepsy VPA is associated with altered neuronal development and functional outcomes (<a href="./references#CD010236-bbs2-0067" title="BittigauP , SifringerM , IkonomidouC . Antiepileptic drugs and apoptosis in the developing brain. Annals of the New York Academy of Sciences2003;993:103-14.">Bittigau 2003</a>; <a href="./references#CD010236-bbs2-0098" title="MiyazakiK , NaritaN , NaritaM . Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: Implications for pathogenesis of autism. International Journal of Developmental Neuroscience2005;23:287-97.">Miyazaki 2005</a>). Research into the outcomes of children born to women taking VPA for other indications will assist to definitively answer this point in the future. Currently, however, the present evidence should be explained to women and their families along with its strengths and limitations. </p> <p>The risks associated with VPA treatment need to be communicated to women and their families. Cognitive and behavioural functioning is complex and the risk to the individual woman and her child will be dependent on the dose and genetic factors. Therefore, a single risk figure to apply to all women would not be accurate. The differences between VPA and other treatment groups reported here range from eight to 10 points for DQ and IQ, with the poorer developmental trajectory observed from infancy and present at least into the school aged years and possibly beyond (<a href="./references#CD010236-bbs2-0105" title="TitzeK , KochS , HelgeH , LehmkuhlU , RauhH , Steinhausen H-C. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology2008;50(2):117-22.">Titze 2008</a>). However, such figures do not take account of the dose of VPA. Data pertaining to dose would suggest that the risk for a women on a lower dose of VPA would be less than the figures reported here, whilst a higher dose would convey an even higher level of risk. The included studies of <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>, <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>, <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>, <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>, <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> and <a href="./references#CD010236-bbs2-0013" title="JamesF , WalshawD , KellyT , LynchS , JacksonM . Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England. ">Jackson 2013</a> report that an increased risk occurs from approximately 800 to 1000 mg daily, but currently there are not enough data to determine risk level at specific dose ranges. Future work needs to address this lack of information. </p> </section> <section id="CD010236-sec-0166"> <h4 class="title">Lamotrigine (LTG)</h4> <p>Despite its prevalent use in women of childbearing age (<a href="./references#CD010236-bbs2-0059" title="AckersR , BesagFM , WadeA , MurrayML , WongIC . Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Archive of Disease in Childhood2009;94(6):443-7.">Ackers 2009</a>; <a href="./references#CD010236-bbs2-0095" title="MeadorKJ , PenovichP , BakerGA , PennellPB , BromfieldE , PackA . Antiepileptic drug use in women of childbearing age. Epilepsy and Behavior2009;15(3):339-43.">Meador 2009b</a>), there is limited evidence pertaining to prenatal LTG exposure in terms of neurodevelopmental outcome. Only four identified studies investigated the neurodevelopmental abilities of children exposed to LTG in comparison to control children, and meta‐analysis was not possible. Despite methodological differences, both <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> and <a href="./references#CD010236-bbs2-0004" title="CummingsC , StewartM , StevensonM , MorrowM , NelsonJ . Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood2011;96:643-7. CummingsC . Personal communication with C Cummings. 2013. ">Cummings 2011/2013</a> failed to find a significant difference in neurodevelopmental outcome for younger children exposed to LTG compared to control children. In the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a> children exposed to LTG had significantly higher IQs and other cognitive abilities than children exposed to VPA, and these measures were similar to those in children exposed to CBZ and PHT. The pooled estimates reported here incorporated the data from the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>, with a small number of additional cases from the Liverpool and Manchester Neurodevelopment Group (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>), to give a non‐significant MD in comparison to CBZ but a significantly higher mean IQ in comparison to VPA exposed children. </p> <p>The study by <a href="./references#CD010236-bbs2-0021" title="RihtmanT , ParushS , OrnoyA . Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology2013;41:115-25. ">Rihtman 2013</a> was not included in the meta‐analysis due to the inclusion of women taking LTG for indications other than epilepsy. This study found a significantly poorer level of development on certain aspects of perceptual and motor development for the LTG exposed children in comparison to control children; however, confounding variables were not adjusted for that have been noted to alter the significance levels in relation to LTG exposure and the hand and eye co‐ordination outcome in other studies (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>). </p> <p>No relationship with dose was found by the <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>. Consistent with other AEDs, increasing the dose of LTG has been associated with an increase in major congential malformation risk (<a href="./references#CD010236-bbs2-0107" title="TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , Sabers A et al. Dose-dependent risk of malformation with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17.">Tomson 2011</a>) and further investigations regarding LTG dose and neurodevelopmental outcome are required. </p> </section> <section id="CD010236-sec-0167"> <h4 class="title">Phenytoin (PHT)</h4> <p>Despite its extensive historical use, few prospective studies have investigated PHT exposure and child neurodevelopmental outcome in isolation from other AEDs. It is noted that a number of older cohort studies did investigate the neurodevelopmental functioning of children exposed to PHT, however, due to their retrospective nature they were not included here (for example.<a href="./references#CD010236-bbs2-0061" title="AdabN , Tudur SmithC , VintenJ , WilliamsonPR , WinterbottomJB . Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004848]">Adab 2004</a>). A meta‐analysis of PHT children in comparison to control children was limited by methodological heterogeneity, however the pooled estimate from two studies found a non‐significant difference for PHT exposed children compared with general population controls. This is consistent with other studies that have been reviewed narratively (<a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>; <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a>). In terms of specific abilities, two studies reported poorer motor development (<a href="./references#CD010236-bbs2-0001" title="ArulmozhiT , DhanarajM , RangarajR , VengatesanA . Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India2006;54(1):42-6. ">Arulmozhi 2006</a>; <a href="./references#CD010236-bbs2-0028" title="WideK , HenningE , EomsonT , WinbladhB . Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica2002;91:409-14. WideK , WinbladhB , TomsonT , Sars-ZimmerK , BerggrenE . Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology2000;42:87-92. ">Wide 2002</a>) and one reported poorer language abilities (<a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>), but the quality of the study designs was limited. Two studies investigated the dose of PHT and child neurodevelopment (<a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0022" title="GladstoneD , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology1992;6:257-61. RovetJ , ColeS , NulmanI , ScolnikD , AltmannD , KorenG . Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology1995;1(2):150-7. ScolnikD , NulmanI , RovetJ , GladstoneD , Czuchta D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA1994;271(10):767-70. ">Rovet 1995</a>) and both failed to demonstrate an association. </p> <p>In comparison to other AEDs, children exposed to PHT have been demonstrated as a group to have comparable mean DQ and IQ scores when compared to CBZ and significantly higher DQ and IQ levels compared to children exposed to VPA; with MDs ranging from seven to nine DQ or IQ points. </p> </section> <section id="CD010236-sec-0168"> <h4 class="title">Phenobarbital (PB)</h4> <p>Very few studies reported neurodevelopmental outcomes in children prenatally exposed to PB. Both studies investigating the DQ failed to find an association between exposure to PB and outcome (<a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a>; <a href="./references#CD010236-bbs2-0026" title="ThomasS , AjaykumarB , SinghuK , NairM , GeorgeB , SarmaP . Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior2008;13:229-36. ">Thomas 2008</a>). The numbers of exposed children were not reported in one study (<a href="./references#CD010236-bbs2-0015" title="LeavittA , YerbyM , RobinsonN , SellsC , EricksonD . Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology1992;42(5):141-3. ">Leavitt 1992</a>). Only the study by <a href="./references#CD010236-bbs2-0025" title="ThomasS , SukumaranS , LukoseN , GeorgeA , SarmaP . Intellectual and language functions in children of mothers with epilepsy. Epilepsia2007;48(12):2234-40. ">Thomas 2007</a> assessed ability in school aged children, measured by IQ, and reported no association between outcome and exposure; however the number of exposed children was small (n = 14). No identified studies investigated an association between dose of PB and child neurodevelopmental outcome. </p> <p>The evidence pertaining to PB is extremely limited. The absence of evidence should not be regarded as evidence of safety, and women should be counselled regarding the paucity of evidence for this drug. </p> </section> <section id="CD010236-sec-0169"> <h4 class="title">Levetiracetam (LEV)</h4> <p>There are limited data pertaining to the other monotherapy AEDs. A single study was identified which investigated the neurodevelopment of children exposed to LEV in utero (<a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>). This study assessed children at two years of age, with reassessment of part of the cohort at between three and four years of age. At both time points this study failed to find a difference between the neurodevelopment of children exposed to LEV and control children, and found that the LEV exposed children were superior in neurodevelopment in comparison to children exposed to VPA. Replication is required. A significant dose dependent effect was noted in the <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a> study for LEV but the association was weak. </p> <p>LEV is in widespread use by women in their childbearing years (<a href="./references#CD010236-bbs2-0095" title="MeadorKJ , PenovichP , BakerGA , PennellPB , BromfieldE , PackA . Antiepileptic drug use in women of childbearing age. Epilepsy and Behavior2009;15(3):339-43.">Meador 2009b</a>) due to the evidence pertaining to malformation risk, which, based on evidence to date, does not appear to be increased from the background rate (<a href="./references#CD010236-bbs2-0085" title="Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM . Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9.">Hernandez‐Diaz 2012</a>; <a href="./references#CD010236-bbs2-0092" title="MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , Parsons L et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5.">Mawhinney 2013</a>). The use of LEV in women of childbearing age and during pregnancy is not supported from a neurodevelopmental teratological safety point of view due to the lack of evidence. Research is needed to address this lack of evidence and women should be informed about the lack of evidence regarding neurodevelopmental risk and safety. </p> </section> <section id="CD010236-sec-0170"> <h4 class="title">Topiramate (TPM)</h4> <p>Only one identified study investigated the abilities of children exposed to TPM in utero. <a href="./references#CD010236-bbs2-0020" title="RihtmanT , ParushS , OrnoyA . Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology2012;34(3):308-11. ">Rihtman 2012</a> reported a significant difference between the children exposed to TPM in comparison to control children but extreme caution is required due to the small number of TPM exposed children (n = 9) and because of the heterogeneous indications for which the mothers were taking TPM. </p> <p>In the study by <a href="./references#CD010236-bbs2-0095" title="MeadorKJ , PenovichP , BakerGA , PennellPB , BromfieldE , PackA . Antiepileptic drug use in women of childbearing age. Epilepsy and Behavior2009;15(3):339-43.">Meador 2009b</a>, TPM was a relatively commonly used medication in women of childbearing age. Therefore, more research is needed to provide evidence on which counselling of women and their families can be based. Currently, there is not enough evidence to suggest neurodevelopmental safety or an increased risk of harm. </p> </section> <section id="CD010236-sec-0171"> <h4 class="title">Monotherapy and polytherapy</h4> <p>Historically there was a frequent analysis of monotherapy data as a single unitary group. The variation between treatment types, reported above, indicates that such practice should not be continued as it will lead to unreliable conclusions. As well as differences in risk levels across exposure types, groups of monotherapy and polytherapy cases will vary from cohort to cohort due to the documented differences in prescribing across countries (for example <a href="./references#CD010236-bbs2-0095" title="MeadorKJ , PenovichP , BakerGA , PennellPB , BromfieldE , PackA . Antiepileptic drug use in women of childbearing age. Epilepsy and Behavior2009;15(3):339-43.">Meador 2009b</a>), meaning that the characteristics of the two groups are unlikely to be the same. A number of older retrospective papers reported that monotherapy outcomes were better than for polytherapy, however data reviewed from the cohorts of <a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a> and <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a> highlight that the important driver in this conclusion may be the presence of absence of VPA. More data are required. </p> <p>Due to the above noted variability in monotherapy and polytherapy groups across studies systematic review and meta‐analysis was not undertaken as were likely to contain large variation and high bias. </p> </section> <section id="CD010236-sec-0172"> <h4 class="title">Other antiepileptic drugs (AEDs)</h4> <p>No studies were identified which investigated the neurodevelopment of children born to women with epilepsy and exposed to any other AED in monotherapy. Whilst there is unavoidably a latency between the onset of a medication use and adequate data, a number of these drugs have been utilised for a decade or more (for example TPM, zonisamide, ethosuximide and gabapentin), suggesting that prescribing for women with epilepsy is not currently based on evidence of neurodevelopmental safety. Prescribers are without the evidence on which to base their counselling of women. </p> </section> </section> <section id="CD010236-sec-0173"> <h3 class="title" id="CD010236-sec-0173">Overall completeness and applicability of evidence</h3> <p>The complexity of this area has brought a number of challenges for completing this review within the Cochrane framework. Heterogeneity across study methodologies and varied reporting methods have greatly limited the number of studies included in the meta‐analyses. The dynamic nature of child neurodevelopment means that different assessments are required to assess ability at different ages and for different outcomes. Therefore, the results section and meta‐analyses needed to be divided to give consideration to the type of assessment that was completed and the cognitive outcome in question. </p> <p>This systematic review is to our knowledge the most comprehensive review completed to date in this area. The creation and advance publication of the review protocol, the clear inclusion criteria, the extensive searches, the acquisition of unpublished data, and the assessment of risk of bias and quality in the non‐randomised evidence are strengths of this review. Under the Cochrane guidelines this review will be updated every two years, or following the publication of a significant amount of new data, to ensure it remains up to date. </p> <p>This review is limited by heterogeneity across study methods and in terms of study quality, although more recent studies tended to demonstrate higher quality methods. The largest limitation placed on this review relates to the lack of evidence pertaining to the newer AEDs. No evidence was found for AEDs such as tiagabine, gabapentin, zonisamide, oxcarbazepine and ethosuximide. A further limitation is that due to limited data and heterogeneity. The potential impact of confounding variables could not be explored and therefore the results need to be interpreted with a degree of caution. However, the majority of included studies did investigate the impact of confounding variables and several found a significant association with prenatal exposure to VPA even after controlling for confounders (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0008" title="GailyE , Kantola-SorsaE , Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology2004;62:28-32. Kantola-SorsaE , GailyE , IsoahoM , KorkmanM . Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society2007;13:642-52. ">Gaily 2004</a>; <a href="./references#CD010236-bbs2-0016" title="NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology2011;76:719-26. NadebaumC , AndersonV , VajdaF , ReutensD , BartonS , WoodA . The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society2011;17:133-42. ">Nadebaum 2011</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>) therefore producing results consistent with the findings of this review. The dose of the AED is likely to be a key variable in the level of risk. At this time, this review is not able to analysis data stratified by dose. </p> <p>It should be considered that in a few of the comparisons the number of children that were included was low (for example comparisons including LTG). Determining power is influenced by the level of discrepancy present between the groups. For example, 45 children in each group would be required to detect a difference of 1.5 SDs between two groups with 80% power at a 95% CI, , however larger levels of difference could be detected reliably with smaller groups. Those comparisons with a low number of children may be at risk of imprecision and therefore the results may be subject to change in light of new data. It should also be considered that smaller levels of difference may not be detectable in the group sizes included in this review, and that some non‐significant findings may change in light of new data. </p> <p>This review is also limited by its failure to include study methodologies which utilise large national electronic data sets taken from hospital and pharmacy records. Since the review protocol was written and published there has been a proliferation of studies using this methodology (for example <a href="./references#CD010236-bbs2-0074" title="ChristensenJ , GronborgTK , SorensenMJ , SchendelD , ParnerET , PedersenLH , VestergaardM . Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA2013;309(16):1696-703.">Christensen 2013</a>) and future updates of this review will include these data types. </p> </section> <section id="CD010236-sec-0174"> <h3 class="title" id="CD010236-sec-0174">Quality of the evidence</h3> <p>Randomised controlled trials are thought to be unethical in this area due to the permanence of potential adverse effects for the foetus. Gold standard evidence for this area would therefore comprise data coming from a prospective, blinded cohort study using standardised measures to assess neurodevelopment and utilising statistical methods to limit the influence of confounding variables. The methodological quality for each study is displayed in <a href="#CD010236-tbl-0003">Table 3</a>. By their nature, all studies were rated as high risk on the randomisation sequence and allocation concealment domains as they were non‐randomised trials. The included studies varied in their approach to controlling confounding variables, a key issue in non‐randomised studies. The majority of studies scored well for blinding of the outcome assessors; however blinding was unclear in five studies and did not occur in six. By the nature of longitudinal follow‐up studies, participant attrition is likely; however the majority of studies reported this clearly, providing reasons for the losses. Selective reporting was difficult to rate for most studies due to the absence of the study protocols. Other bias was a category created to reflect bias in other domains such as the neuropsychological test measure or principles, or failure to report specific AED treatments separately; this led to high ratings of bias for 11 studies. </p> <p>More recent studies tend to be prospective, blinded, include a reliable approach to control for confounders and have improved reporting, indicating methodological improvement over time. For recommendations on the conduct of future research see <a href="#CD010236-sec-0178">Implications for research</a>. </p> </section> <section id="CD010236-sec-0175"> <h3 class="title" id="CD010236-sec-0175">Potential biases in the review process</h3> <p>The review author RB was a study author on four of the included data sets (<a href="./references#CD010236-bbs2-0002" title="BromleyR , MawerG , LoveJ , KellyJ , PurdyL , McEwan L et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia2010;51(10):2058-65. BromleyR . Personal communication with R. Bromley. 2013. ">Bromley 2010</a>; <a href="./references#CD010236-bbs2-0003" title="BromleyR , MawerG , Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry2013;84(6):637-43. BromleyR . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology2008;71:1923-5. ">Bromley 2013</a>; <a href="./references#CD010236-bbs2-0017" title="CohenM , MeadorK , Browning N et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior2011;22:240-6. McVearryK , GaillardW , VanMeterJ , MeadorK . A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior2009;16:609-16. MeadorK , BakerG , Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine2009;360(16):1597-605. MeadorK , BakerG , Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology2013;12:244-52. MeadorK , BakerG , Browning N et al. Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain2011;134:396-404. MeadorK , BakerG , Browning N et al. Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior2011;21:147-52. MeadorK , BrowningN , Cohen M et al. In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006. ">NEAD Study</a>; <a href="./references#CD010236-bbs2-0023" title="ShallcrossR , BromleyR , IrwinB , BonnettL , MorrowJ , BakerG . Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology2011;76:383-9. ShallcrossR , BromleyRL , Cheyne CP et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology2014;82:213-21. ShallcrossR . Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool2011. ">Shallcross 2011</a>). This potential bias was reduced by delegating data extraction and risk of bias assessments to two other review authors. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010236-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010236-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD010236-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ versus controls (women without epilepsy), Outcome 1: Development (Griffiths)" data-id="CD010236-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: CBZ versus controls (women without epilepsy), Outcome 1: Development (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ versus controls (women without epilepsy), Outcome 2: Development (Bayley)" data-id="CD010236-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: CBZ versus controls (women without epilepsy), Outcome 2: Development (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ versus controls (women without epilepsy), Outcome 3: IQ" data-id="CD010236-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: CBZ versus controls (women without epilepsy), Outcome 3: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ versus controls (women without epilepsy), Outcome 4: IQ &lt;2SD" data-id="CD010236-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: CBZ versus controls (women without epilepsy), Outcome 4: IQ &lt;2SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ versus controls (women without epilepsy), Outcome 5: VIQ" data-id="CD010236-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: CBZ versus controls (women without epilepsy), Outcome 5: VIQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ versus controls (women without epilepsy), Outcome 6: PIQ" data-id="CD010236-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: CBZ versus controls (women without epilepsy), Outcome 6: PIQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 1: Development (Griffiths)" data-id="CD010236-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 1: Development (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 2: Development (Bayley)" data-id="CD010236-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 2: Development (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 3: IQ" data-id="CD010236-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 3: IQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 4: VPA below vs CBZ below IQ &gt; 1SD" data-id="CD010236-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 4: VPA below vs CBZ below IQ &gt; 1SD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 5: IQ &gt; 2SD" data-id="CD010236-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 5: IQ &gt; 2SD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 6: VIQ" data-id="CD010236-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 6: VIQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 7: PIQ" data-id="CD010236-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: CBZ versus controls (women with epilepsy, no AED treatment), Outcome 7: PIQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: VPA versus controls (women without epilepsy), Outcome 1: Development (Griffiths)" data-id="CD010236-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: VPA versus controls (women without epilepsy), Outcome 1: Development (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: VPA versus controls (women without epilepsy), Outcome 2: Development (Bayley)" data-id="CD010236-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: VPA versus controls (women without epilepsy), Outcome 2: Development (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: VPA versus controls (women without epilepsy), Outcome 3: IQ" data-id="CD010236-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: VPA versus controls (women without epilepsy), Outcome 3: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: VPA versus controls (women without epilepsy), Outcome 4: IQ &lt;2SD" data-id="CD010236-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: VPA versus controls (women without epilepsy), Outcome 4: IQ &lt;2SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: VPA versus controls (women without epilepsy), Outcome 5: IQ &lt;1SD" data-id="CD010236-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: VPA versus controls (women without epilepsy), Outcome 5: IQ &lt;1SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: VPA versus controls (women without epilepsy), Outcome 6: VIQ" data-id="CD010236-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: VPA versus controls (women without epilepsy), Outcome 6: VIQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: VPA versus controls (women without epilepsy), Outcome 7: PIQ" data-id="CD010236-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: VPA versus controls (women without epilepsy), Outcome 7: PIQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 1: Development (Griffiths)" data-id="CD010236-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 1: Development (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 2: Development (Bayley)" data-id="CD010236-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 2: Development (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 3: IQ" data-id="CD010236-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 3: IQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 4: IQ &lt; 1SD" data-id="CD010236-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 4: IQ &lt; 1SD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 5: IQ &lt;2SD" data-id="CD010236-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 5: IQ &lt;2SD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 6: VIQ" data-id="CD010236-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 6: VIQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 7: PIQ" data-id="CD010236-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: VPA versus controls (women with epilepsy, no AED treatment), Outcome 7: PIQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: PHT versus controls (women without epilepsy), Outcome 1: Development (Bayley)" data-id="CD010236-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: PHT versus controls (women without epilepsy), Outcome 1: Development (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: PHT versus controls (women without epilepsy), Outcome 2: IQ" data-id="CD010236-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: PHT versus controls (women without epilepsy), Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: PHT versus controls (women with epilepsy, no AED treatment), Outcome 1: Developmental (Bayley)" data-id="CD010236-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: PHT versus controls (women with epilepsy, no AED treatment), Outcome 1: Developmental (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: PHT versus controls (women with epilepsy, no AED treatment), Outcome 2: IQ" data-id="CD010236-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: PHT versus controls (women with epilepsy, no AED treatment), Outcome 2: IQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: PB versus controls (women without epilepsy), Outcome 1: IQ" data-id="CD010236-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: PB versus controls (women without epilepsy), Outcome 1: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: PB versus controls (women with epilepsy, no AED treatment), Outcome 1: Developmental (Bayley)" data-id="CD010236-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: PB versus controls (women with epilepsy, no AED treatment), Outcome 1: Developmental (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: PB versus controls (women with epilepsy, no AED treatment), Outcome 2: IQ" data-id="CD010236-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: PB versus controls (women with epilepsy, no AED treatment), Outcome 2: IQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: LTG versus controls (women without epilepsy), Outcome 1: Developmental (Griffiths)" data-id="CD010236-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: LTG versus controls (women without epilepsy), Outcome 1: Developmental (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: LTG versus controls (women without epilepsy), Outcome 2: IQ" data-id="CD010236-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: LTG versus controls (women without epilepsy), Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: LTG versus controls (women with epilepsy, no AED treatment), Outcome 1: Developmental (Griffiths)" data-id="CD010236-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: LTG versus controls (women with epilepsy, no AED treatment), Outcome 1: Developmental (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: LTG versus controls (women with epilepsy, no AED treatment), Outcome 2: IQ" data-id="CD010236-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: LTG versus controls (women with epilepsy, no AED treatment), Outcome 2: IQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: LEV versus control (women without epilepsy), Outcome 1: Developmental (Griffiths)" data-id="CD010236-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: LEV versus control (women without epilepsy), Outcome 1: Developmental (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: CBZ versus LTG, Outcome 1: Development (Bayley)" data-id="CD010236-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: CBZ versus LTG, Outcome 1: Development (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: CBZ versus LTG, Outcome 2: IQ" data-id="CD010236-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: CBZ versus LTG, Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: CBZ versus LTG, Outcome 3: IQ&gt;1SD" data-id="CD010236-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: CBZ versus LTG, Outcome 3: IQ&gt;1SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: CBZ versus PHT, Outcome 1: Development (Bayley)" data-id="CD010236-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: CBZ versus PHT, Outcome 1: Development (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: CBZ versus PHT, Outcome 2: IQ" data-id="CD010236-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: CBZ versus PHT, Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: CBZ versus PHT, Outcome 3: DQ&gt;1SD" data-id="CD010236-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: CBZ versus PHT, Outcome 3: DQ&gt;1SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: VPA versus LTG, Outcome 1: Development (Bayley)" data-id="CD010236-fig-0048" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: VPA versus LTG, Outcome 1: Development (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: VPA versus LTG, Outcome 2: IQ" data-id="CD010236-fig-0049" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: VPA versus LTG, Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: VPA versus LTG, Outcome 3: IQ&gt;1SD" data-id="CD010236-fig-0050" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: VPA versus LTG, Outcome 3: IQ&gt;1SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: LEV versus VPA, Outcome 1: Development (Griffiths)" data-id="CD010236-fig-0051" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: LEV versus VPA, Outcome 1: Development (Griffiths)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: PHT versus VPA, Outcome 1: Development (Bayley)" data-id="CD010236-fig-0052" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: PHT versus VPA, Outcome 1: Development (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: PHT versus VPA, Outcome 2: IQ" data-id="CD010236-fig-0053" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: PHT versus VPA, Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: PHT versus VPA, Outcome 3: DQ&gt;1SD" data-id="CD010236-fig-0054" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: PHT versus VPA, Outcome 3: DQ&gt;1SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ versus VPA, Outcome 1: Development (Bayley)" data-id="CD010236-fig-0055" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: CBZ versus VPA, Outcome 1: Development (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ versus VPA, Outcome 2: IQ" data-id="CD010236-fig-0056" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: CBZ versus VPA, Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-017.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ versus VPA, Outcome 3: VIQ" data-id="CD010236-fig-0057" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-017.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17: CBZ versus VPA, Outcome 3: VIQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-017.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ versus VPA, Outcome 4: PIQ" data-id="CD010236-fig-0058" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-017.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17: CBZ versus VPA, Outcome 4: PIQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-017.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ versus VPA, Outcome 5: DQ&gt;1SD" data-id="CD010236-fig-0059" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-017.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.5</div> <div class="figure-caption"> <p>Comparison 17: CBZ versus VPA, Outcome 5: DQ&gt;1SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-017.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ versus VPA, Outcome 6: DQ&gt;2SD" data-id="CD010236-fig-0060" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-017.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.6</div> <div class="figure-caption"> <p>Comparison 17: CBZ versus VPA, Outcome 6: DQ&gt;2SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-017.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ versus VPA, Outcome 7: IQ&gt;2SD" data-id="CD010236-fig-0061" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-017.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.7</div> <div class="figure-caption"> <p>Comparison 17: CBZ versus VPA, Outcome 7: IQ&gt;2SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-017.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ versus VPA, Outcome 8: IQ&gt;1SD" data-id="CD010236-fig-0062" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-017.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.8</div> <div class="figure-caption"> <p>Comparison 17: CBZ versus VPA, Outcome 8: IQ&gt;1SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-017.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: PHT versus LTG, Outcome 1: Developmental (Bayley)" data-id="CD010236-fig-0063" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: PHT versus LTG, Outcome 1: Developmental (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-018.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: PHT versus LTG, Outcome 2: IQ" data-id="CD010236-fig-0064" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-018.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-018.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18: PHT versus LTG, Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-018.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-019.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: CBZ versus PB, Outcome 1: Developmental (Bayley)" data-id="CD010236-fig-0065" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-019.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-019.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: CBZ versus PB, Outcome 1: Developmental (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-019.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-019.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: CBZ versus PB, Outcome 2: IQ" data-id="CD010236-fig-0066" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-019.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-019.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19: CBZ versus PB, Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-019.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-019.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: CBZ versus PB, Outcome 3: DQ &gt;1SD" data-id="CD010236-fig-0067" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-019.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-019.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19: CBZ versus PB, Outcome 3: DQ &gt;1SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-019.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-020.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: VPA versus PB, Outcome 1: Developmental (Bayley)" data-id="CD010236-fig-0068" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-020.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-020.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: VPA versus PB, Outcome 1: Developmental (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-020.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-020.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: VPA versus PB, Outcome 2: IQ" data-id="CD010236-fig-0069" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-020.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-020.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20: VPA versus PB, Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-020.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: PHT versus PB, Outcome 1: Developmental (Bayley)" data-id="CD010236-fig-0070" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: PHT versus PB, Outcome 1: Developmental (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-021.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: PHT versus PB, Outcome 2: IQ" data-id="CD010236-fig-0071" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-021.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-021.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21: PHT versus PB, Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-021.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-021.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: PHT versus PB, Outcome 3: DQ &gt;1SD" data-id="CD010236-fig-0072" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-021.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-021.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21: PHT versus PB, Outcome 3: DQ &gt;1SD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-021.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-022.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Monotherapy versus controls (women without epilepsy), Outcome 1: Developmental (Griffiths)" data-id="CD010236-fig-0073" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-022.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-022.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22: Monotherapy versus controls (women without epilepsy), Outcome 1: Developmental (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-022.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-022.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Monotherapy versus controls (women without epilepsy), Outcome 2: Developmental (Bayley)" data-id="CD010236-fig-0074" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-022.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-022.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22: Monotherapy versus controls (women without epilepsy), Outcome 2: Developmental (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-022.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-022.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Monotherapy versus controls (women without epilepsy), Outcome 3: IQ" data-id="CD010236-fig-0075" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-022.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-022.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22: Monotherapy versus controls (women without epilepsy), Outcome 3: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-022.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-023.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Monotherapy versus controls (women with epilepsy, no AED treatment), Outcome 1: Development (Griffiths)" data-id="CD010236-fig-0076" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-023.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-023.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23: Monotherapy versus controls (women with epilepsy, no AED treatment), Outcome 1: Development (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-023.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-023.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Monotherapy versus controls (women with epilepsy, no AED treatment), Outcome 2: Developmental (Bayley)" data-id="CD010236-fig-0077" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-023.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-023.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23: Monotherapy versus controls (women with epilepsy, no AED treatment), Outcome 2: Developmental (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-023.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-023.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Monotherapy versus controls (women with epilepsy, no AED treatment), Outcome 3: IQ" data-id="CD010236-fig-0078" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-023.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-023.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.3</div> <div class="figure-caption"> <p>Comparison 23: Monotherapy versus controls (women with epilepsy, no AED treatment), Outcome 3: IQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-023.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-024.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: Polytherapy versus controls (women without epilepsy), Outcome 1: Developmental (Griffiths)" data-id="CD010236-fig-0079" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-024.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-024.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24: Polytherapy versus controls (women without epilepsy), Outcome 1: Developmental (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-024.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-024.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: Polytherapy versus controls (women without epilepsy), Outcome 2: Developmental (Bayley)" data-id="CD010236-fig-0080" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-024.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-024.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.2</div> <div class="figure-caption"> <p>Comparison 24: Polytherapy versus controls (women without epilepsy), Outcome 2: Developmental (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-024.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-024.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: Polytherapy versus controls (women without epilepsy), Outcome 3: IQ" data-id="CD010236-fig-0081" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-024.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-024.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.3</div> <div class="figure-caption"> <p>Comparison 24: Polytherapy versus controls (women without epilepsy), Outcome 3: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-024.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-025.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: Polytherapy versus controls (women with epilepsy, no AED treatment), Outcome 1: Developmental (Griffiths)" data-id="CD010236-fig-0082" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-025.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-025.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25: Polytherapy versus controls (women with epilepsy, no AED treatment), Outcome 1: Developmental (Griffiths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-025.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-025.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: Polytherapy versus controls (women with epilepsy, no AED treatment), Outcome 2: Developmental (Bayley)" data-id="CD010236-fig-0083" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-025.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-025.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.2</div> <div class="figure-caption"> <p>Comparison 25: Polytherapy versus controls (women with epilepsy, no AED treatment), Outcome 2: Developmental (Bayley) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-025.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-025.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: Polytherapy versus controls (women with epilepsy, no AED treatment), Outcome 3: IQ" data-id="CD010236-fig-0084" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-025.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-025.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.3</div> <div class="figure-caption"> <p>Comparison 25: Polytherapy versus controls (women with epilepsy, no AED treatment), Outcome 3: IQ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-025.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-026.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: Monotherapy versus polytherapy, Outcome 1: Developmental (Griffiths)" data-id="CD010236-fig-0085" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-026.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-026.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26: Monotherapy versus polytherapy, Outcome 1: Developmental (Griffiths)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-026.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-026.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: Monotherapy versus polytherapy, Outcome 2: Developmental (Bayley)" data-id="CD010236-fig-0086" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-026.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-026.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.2</div> <div class="figure-caption"> <p>Comparison 26: Monotherapy versus polytherapy, Outcome 2: Developmental (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-026.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-026.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: Monotherapy versus polytherapy, Outcome 3: IQ" data-id="CD010236-fig-0087" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-026.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-026.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.3</div> <div class="figure-caption"> <p>Comparison 26: Monotherapy versus polytherapy, Outcome 3: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-026.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-027.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 27: VPA monotherapy versus VPA polytherapy, Outcome 1: Developmental (Bayley)" data-id="CD010236-fig-0088" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-027.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-027.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27: VPA monotherapy versus VPA polytherapy, Outcome 1: Developmental (Bayley)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-027.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-027.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 27: VPA monotherapy versus VPA polytherapy, Outcome 2: IQ" data-id="CD010236-fig-0089" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-027.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-027.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.2</div> <div class="figure-caption"> <p>Comparison 27: VPA monotherapy versus VPA polytherapy, Outcome 2: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-027.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010236-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/urn:x-wiley:14651858:media:CD010236:CD010236-CMP-028.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: VPA polytherapy versus non‐VPA polytherapy, Outcome 1: IQ" data-id="CD010236-fig-0090" src="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-028.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_t/tCD010236-CMP-028.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28: VPA polytherapy versus non‐VPA polytherapy, Outcome 1: IQ</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/media/CDSR/CD010236/image_n/nCD010236-CMP-028.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD010236-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias scale parameters</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>1</b> </p> <p><b>Low risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>4</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>5</b> </p> <p><b>High risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Confounding</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All important<sup>1</sup> confounders considered<sup>2</sup> and suitable method of adjustment<sup>3</sup> employed. Outcome unlikely to be affected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most important<sup>4</sup> confounders considered and suitable method of adjustment employed. Outcome unlikely to be affected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some confounders<sup>5</sup> considered and full or partial adjustment employed<sup>6</sup>. Possible implication on outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some confounders considered and no adjustment employed. Likely to affect outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No important confounders considered and no adjustment employed. Likely to affect outcome</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Blinding</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assessors blinded to participant’s drug regime and participants blinded to drug regime. Outcome unlikely to be affected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assessors blinded to participants drug regime. Outcome unlikely to be affected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Partial blinding<sup>7</sup> involved in study. Possible implication on outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Partial or no blinding involved in study. Outcome likely to be affected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No blinding involved in study.  Outcome likely to be affected</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Incomplete outcome data</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No missing data and/or</p> <p>appropriate analysis<sup>8</sup> used to deal with missing data. Unlikely to affect outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Smaller amount (&lt;25%) of missing data with reasons given, balanced across groups. Unlikely to affect outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Larger amount of missing data (&gt;25%) with or without reasons given, balanced across groups. Possible implication on outcome  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Larger amount (&gt;25%) of missing data, imbalance across groups. Outcome likely to be affected </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information provided regarding missing data. Likely to affect outcome</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Selective outcome reporting</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A priori outcomes measured, analysed and reported in main report. Protocol available. Unlikely to affect outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A priori outcomes measured, analysed and reported in main report<sup>9</sup>. Protocol not available. Unlikely to affect outcomes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited information regarding a priori outcomes and measures. Possible implication on outcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes measured but not analysed or reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes measured  but not analysed or reported and clinical judgement infers the presence of an unreported measured outcome<sup>10</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other bias</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No bias identified  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bias identified. Unlikely to affect outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bias identified. Possible implication on outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bias identified. Likely to affect outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bias identified. Extremely likely to affect outcome</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Important confounders include maternal IQ, socio‐economic status, epilepsy type, seizure exposure, child age at assessment, child gender, child gestational age at birth or birth weight, polytherapy. </p> <p><sup>2</sup> Reported demographic information and other confounders. </p> <p><sup>3</sup> Matching scores, multiple regression, analysis of co‐variance, stratification. </p> <p><sup>4</sup> At least five out of eight important confounders including maternal IQ and socio‐economic status, gestational age at birth. </p> <p><sup>5</sup> At least two out of eight important confounders. </p> <p><sup>6</sup> Full adjustment of confounding variables e.g. see footnote 2 or partial adjustment such as researchers select limited number of variables to adjust for. </p> <p><sup>7</sup> Assessors of outcome are only blinded to certain groups e.g. blinded to intervention group but not controls. </p> <p><sup>8</sup> Intention‐to‐treat analysis. </p> <p><sup>9</sup> An a priori statement is made in methods section of main report regarding measurement and analysis of outcome. </p> <p><sup>10</sup> For example, failure to report full scale IQ when all other indices are reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias scale parameters</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010236-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis results for below average performance outcome</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AED</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control/Another AED</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main result: risk ratio</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity (i): risk difference (MH)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity (ii): OR (M‐H)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity (iii): OR (Peto)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ&lt;1SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Controls (women with epilepsy, no AED treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.33 (2.05, 52.01)</p> <p>P=0.0046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.20, 0.54)</p> <p>P&lt;0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.49 (2.86, 95.27)</p> <p>P=0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.68 (2.92, 25.80)</p> <p>P=0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ&gt;1SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.28 (0.63, 8.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (‐0.03, 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.43 (0.60, 9.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.35 (0.64, 8.56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ&gt;1SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.87 (1.50, 15.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16 (0.06, 0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.35 (1.73, 23.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.94 (1.79, 13.66)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ&gt;2SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26 (0.05, 1.19)</p> <p>P=0.083</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.04 (‐0.10, 0.01)</p> <p>P=0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.05, 1.21)</p> <p>P=0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19 (0.04, 0.96)</p> <p>P=0.04</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis results for below average performance outcome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010236-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Matrix of study quality characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Representative Population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Controls From Same Community</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective/Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exposure Ascertainment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliable Diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recruitment Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different Interventions Compared</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes Investigated Over TIme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standardised Measure Used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data on Specific</p> <p>Monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dose Investigated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Siblings Accounted</p> <p>For</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arulmozhi 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bromley 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bromley 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cummings 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D'Souza 1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eriksson 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FINNISH Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hirano 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gaily 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GERMAN Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gladstone 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hanson 1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospectve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jones 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leavitt 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nadebaum 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NEAD Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ornoy 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regesta 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rihtman 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rihtman 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scolnik 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shallcross 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sobczyk 1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomas 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomas 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veiby 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wide 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Matrix of study quality characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010236-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Fixed and random effects analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No. studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Effect measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fixed‐effect result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Heterogeneity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Random‐effects result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Conclusion change?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AED</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control/Another AED</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi<sup>2*</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women without epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bayley</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.58 (‐10.83 to ‐0.34), P=0.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.35 (‐14.04 to 5.34), P=0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Changed to non‐significant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women without epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VIQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.81 (‐4.94 to 1.33) P=0.026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.84 (‐8.01 to 4.34), P=0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No change</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women with epilepsy, no AED treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bayley</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7.22 (‐12.76 to ‐1.67), P=0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.60 (‐15.40 to 4.20), P=0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Changed to non‐significant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women without epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.94 (‐11.96 to ‐5.92), P&lt;0.00001</p> <p>‐11.42 (‐14.68 to ‐8.15), P&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88%</p> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.003</p> <p>P=0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.28 (‐15.54 to 4.97), P=0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Changed to non‐significant</p> <p>Changed to significant with the removal of Thomas 2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women without epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PIQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10.48 (‐13.94 to ‐7.02), P&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.11 (‐19.66 to ‐4.55), P=0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No change</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.25 (4.78 to 13.72), P&lt;0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.38 (‐4.84 to 17.58), P=0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Changed to non‐significant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA mono</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA polytherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.96 (‐2.68 to 6.61), P=0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P=0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.67 (‐5.46 to 12.80), P=0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No change</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>*Chi<sup>2</sup> is significant at 0.1 </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Fixed and random effects analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/full#CD010236-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CBZ versus controls (women without epilepsy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Development (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐6.44, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Development (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.58 [‐10.83, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.58 [‐10.83, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐3.08, 3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐6.46, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [‐2.49, 5.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 IQ &lt;2SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 VIQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.81 [‐4.94, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.81 [‐4.94, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 PIQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [‐1.55, 4.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [‐1.55, 4.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CBZ versus controls (women without epilepsy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CBZ versus controls (women with epilepsy, no AED treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Development (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.00 [‐11.35, ‐0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Development (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.22 [‐12.76, ‐1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.22 [‐12.76, ‐1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [‐2.13, 5.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [‐5.08, 7.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐2.87, 7.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 VPA below vs CBZ below IQ &gt; 1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.26, 95.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 IQ &gt; 2SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.02, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 VIQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐3.98, 4.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐7.28, 5.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [‐4.47, 6.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 PIQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.65 [‐0.60, 7.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [‐2.72, 10.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.42 [‐2.07, 8.91]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CBZ versus controls (women with epilepsy, no AED treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">VPA versus controls (women without epilepsy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Development (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.00 [‐12.79, ‐3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Development (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.30 [‐23.51, ‐3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.94 [‐11.96, ‐5.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.22 [‐15.84, ‐8.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.48 [‐6.94, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 IQ &lt;2SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.33, 22.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 IQ &lt;1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.88 [6.27, 45.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 VIQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.39 [‐14.68, ‐8.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.39 [‐15.02, ‐7.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.40 [‐19.21, ‐3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 PIQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.48 [‐13.94, ‐7.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.94 [‐12.79, ‐5.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.80 [‐24.61, ‐8.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">VPA versus controls (women without epilepsy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">VPA versus controls (women with epilepsy, no AED treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Development (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.00 [‐17.73, ‐6.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Development (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.72 [‐14.31, ‐3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.72 [‐14.31, ‐3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.17 [‐12.80, ‐3.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.30 [‐15.34, ‐3.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.58 [‐13.77, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 IQ &lt; 1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.33 [2.05, 52.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.00 [1.38, 72.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.00 [0.67, 180.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 IQ &lt;2SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.17, 17.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 VIQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.81 [‐13.32, ‐4.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.45 [‐13.02, ‐1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.42 [‐19.13, ‐3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 PIQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.20 [‐12.44, ‐1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.30 [‐13.71, ‐0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.01 [‐16.13, 2.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">VPA versus controls (women with epilepsy, no AED treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">PHT versus controls (women without epilepsy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Development (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐7.54, 7.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐7.54, 7.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.80 [‐4.10, 13.70]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">PHT versus controls (women without epilepsy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">PHT versus controls (women with epilepsy, no AED treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐18.26, 14.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.00 [‐12.60, 34.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">PHT versus controls (women with epilepsy, no AED treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">PB versus controls (women without epilepsy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.80 [‐12.90, ‐0.70]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">PB versus controls (women without epilepsy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">PB versus controls (women with epilepsy, no AED treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐14.33, 10.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐23.30, 22.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">PB versus controls (women with epilepsy, no AED treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">LTG versus controls (women without epilepsy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Developmental (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐5.75, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐8.32, 0.32]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">LTG versus controls (women without epilepsy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">LTG versus controls (women with epilepsy, no AED treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Developmental (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.00 [‐10.70, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐7.48, 5.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">LTG versus controls (women with epilepsy, no AED treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">LEV versus control (women without epilepsy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Developmental (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [‐2.81, 4.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">LEV versus control (women without epilepsy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">CBZ versus LTG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Development (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐9.29, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐5.44, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐5.44, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 IQ&gt;1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [0.63, 8.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [0.63, 8.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">CBZ versus LTG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">CBZ versus PHT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Development (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [‐2.41, 8.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [‐2.41, 8.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐7.91, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐7.86, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.90 [‐20.20, 8.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 DQ&gt;1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.52, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.52, 1.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">CBZ versus PHT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">VPA versus LTG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Development (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.00 [‐20.31, ‐3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.80 [‐14.42, ‐7.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.80 [‐14.42, ‐7.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 IQ&gt;1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.87 [1.50, 15.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.87 [1.50, 15.78]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">VPA versus LTG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">LEV versus VPA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Development (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.03 [6.24, 17.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">LEV versus VPA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">PHT versus VPA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Development (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.04 [0.44, 13.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.04 [0.44, 13.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.25 [4.78, 13.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.00 [6.15, 15.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐12.26, 10.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 DQ&gt;1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.91, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.91, 2.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">PHT versus VPA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">CBZ versus VPA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Development (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.16 [‐0.21, 8.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.16 [‐0.21, 8.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.69 [5.51, 11.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.19 [5.49, 12.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.29 [1.06, 13.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.3 VIQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.44 [4.21, 12.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.4 PIQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.48 [6.02, 14.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.5 DQ&gt;1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.62, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.62, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.6 DQ&gt;2SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.38, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.38, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.7 IQ&gt;2SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.05, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.7.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.04, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.7.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.8 IQ&gt;1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.19, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.8.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.17, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.8.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.09, 1.70]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">CBZ versus VPA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">PHT versus LTG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.00 [‐14.48, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐3.87, 5.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">PHT versus LTG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">CBZ versus PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [‐5.61, 11.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [‐7.04, 18.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.3 DQ &gt;1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.62, 1.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">CBZ versus PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">VPA versus PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐13.45, 6.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.1 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.30 [2.73, 21.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">VPA versus PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">PHT versus PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐14.03, 14.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.60 [1.18, 22.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.3 DQ &gt;1SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">PHT versus PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Monotherapy versus controls (women without epilepsy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.1 Developmental (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐6.86, ‐1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.2 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐7.82, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.3 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐4.12, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.70 [‐11.53, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐3.18, 3.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Monotherapy versus controls (women without epilepsy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Monotherapy versus controls (women with epilepsy, no AED treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.1 Development (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.00 [‐12.16, ‐3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.2 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐12.80, 9.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.3 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐4.19, 6.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐13.22, 9.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [‐3.92, 8.72]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Monotherapy versus controls (women with epilepsy, no AED treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Polytherapy versus controls (women without epilepsy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.1 Developmental (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.00 [‐13.27, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.2 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.50 [‐12.32, ‐2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.3 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.57 [‐11.77, ‐5.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.24 [‐12.39, ‐4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.06 [‐14.07, ‐4.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Polytherapy versus controls (women without epilepsy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Polytherapy versus controls (women with epilepsy, no AED treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.1 Developmental (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.00 [‐17.92, ‐2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.2 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.50 [‐20.31, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.3 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.70 [‐10.31, ‐1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.42 [‐11.42, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.10 [‐13.33, 1.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Polytherapy versus controls (women with epilepsy, no AED treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Monotherapy versus polytherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.1 Developmental (Griffiths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [‐4.08, 8.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.2 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.80 [3.44, 14.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.80 [3.44, 14.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.3 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.84 [4.35, 13.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.41 [2.04, 16.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.50 [2.85, 14.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Monotherapy versus polytherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">VPA monotherapy versus VPA polytherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27.1 Developmental (Bayley) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.28 [‐10.68, 35.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27.2 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [‐2.68, 6.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐9.88, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.20 [0.64, 13.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">VPA monotherapy versus VPA polytherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010236-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">VPA polytherapy versus non‐VPA polytherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.1 IQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.74 [‐15.70, ‐1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1.1 Prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.00 [‐14.65, 4.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1.2 Registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.80 [‐22.86, ‐2.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">VPA polytherapy versus non‐VPA polytherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010236.pub2/references#CD010236-tbl-0032">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010236.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010236-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010236-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010236-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010236-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD010236-note-0007">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD010236-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD010236-note-0005">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD010236-note-0004">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010236-note-0003">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010236\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010236\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010236\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010236\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010236\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010236.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010236.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010236.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010236.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010236.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717114936"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010236.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717114940"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010236.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db003d894936e',t:'MTc0MDcxNzExNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 